var title_f21_50_22304="Breathing forces on pharynx";
var content_f21_50_22304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal section of the upper airway, showing collapsing and dilating forces exerted on the pharynx during normal breathing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Martin, RJ, Miller, MJ, Carlo, WA, J Pediatr 1986; 109:733.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22304=[""].join("\n");
var outline_f21_50_22304=null;
var title_f21_50_22305="Indirect inguinal hernia sac TEP dissection";
var content_f21_50_22305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Indirect inguinal hernia sac TEP dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure&nbsp;shows an indirect hernia viewed from within the extraperitoneal space.&nbsp;After gently pulling the hernia sac from the inguinal canal&nbsp;into the abdomen, the end of the hernia sac can be identified and&nbsp;bluntly dissected from the cord structures.",
"    <div class=\"footnotes\">",
"     TEP: total extraperitoneal hernia repair.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones, DB, Maithel, SK, Schneider, BE. Atlas of minimally invasive surgery. Cin&eacute;-Med, Woodbury, CT 2006. Copyright &copy; 2006 Cin&eacute;-Med, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22305=[""].join("\n");
var outline_f21_50_22305=null;
var title_f21_50_22306="Artist impression";
var content_f21_50_22306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Artist impression of the volar anatomical structures of the longitudinal view of second metacarpophalangeal joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5p1qR/wC2b752/wBe/f8A2jVLzH/vt+dWtb/5DN9/13f/ANCNU6AHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAJI5H3r87dR3r7959TX5/x/wCsX6iv0AoA+Ctb/wCQzff9d3/9CNU6ua3/AMhm+/67v/6Eap0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB1J+H/AIpXRk1R9GnSyeNZgzsqsY2OA+wndtJ/ixj3rPvPDOq2XiiTw7eQRW+rRy+S8UtxEiq+M4MhbYPruxXrupePfCl94Q8rXbi01zVorWGCwuU0prW+t2UjiaYNtdFAIwAd3fGTW9rPxO8Eah4x0rU7S5ksrW016S8vYmtncahGyALOTtyCuCuw9uRz1APmx1KOyNjKkg4OR+YpK968IfFDRdJsvCGmS3hTSkg1WLWofsm4SiV5WgU/LlhlkPHTvXgtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALH/rF+or9AK/P+P/AFi/UV+gFAHwVrZH9s33I/17/wDoRqlkeor2PVPjIYdSu4/+FfeAX2Ssu59JyWwTyTu61W/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5LkeooyPUV61/wALoP8A0Tz4f/8Agp/+yo/4XQf+iefD/wD8FP8A9lQB5PGR5i8jqK/QCvlhPjQSyj/hXnw/6/8AQJ/+yr68/tj/AKh9h/36/wDr0Afnrrf/ACGb7/ru/wD6Eap1c1v/AJDN9/13f/0I1ToAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr0T4XfDj/AITXStY1Jrm8aPTTGpstNtlubuXfn5gjOg2jHXJPYCvO66nwX4uTwxuY6Hp2oTCQTRTzvPFLEw7B4pEJX1U5BoAs3vw/1Q3iDSkluLKfWBolvJcx/ZZWuSFIR4mOUPzAHPAPet+7+EGpt4b0a706e3l1a5S/NxYSXEaPutpnjZYVzmThGY49PpRZfGjW0u7m51TS9H1SaTV01qNrmJx9nuFVVBTY442ooAOemeTSD4x6klrAY9F0pdStft32TUD5pktvtcjvLtXfsJ/eEAlTgfjQBhw/DXxBJa6bIf7PiudS8hrWylvYkuZEmkWOOTyyc7SzDn05IxzWh4J+E2t+Jdahs5ZbbT7ZtSm0qS5kkVtlxFGXZQm4FuPT39KgPxLu3j0m4m0bSJdc0tbWO11Z0k85Ut3V4wV3+WT8gUttyVyPetg/GrVIr6yutO0LRbBrbVn1grAku2WZ4zG+/LnqCemMcY6UAYXh/wCGOveIZbyHR5tIu7m2kaLyYtQidpSqhiY8EhhgjBzgnIB4NC/C7xK3h9tXEVj5A07+1hD9ti89rXnMoi3btoxycfrxW34R+Mt94Vhig0rQNKjtre8kvLaES3AWIuoUqcS/vBgcGTcRk47Yx0+JepL5WLOz/d+G38Mj73MDbsydfv8AzH29qAC4+E/i2HTYbsWEUru9ujWsVwjTwmcgQ+YmcruJXGfUZxST/CzxMmq2FhBDZXct608cUltdxyR+ZAheWNmBwrKAeD17ZrVvfjR4gu7a0aS3thqlsbcrfCa4+byWVkJh8zydxKLk7ORn61Enxf1W21rSb7S9J0iwh0+5uLz7HEkjRTzTqUlZ97s3KkgAEADpQBkaB8NfEmuWVhe2VtbrY3lvPdpcTXCIixQyeW7Nk5GHIGOp7VX8O+C59W+Ith4TkvrKKa4uVga6jnSWIAjcSrA4Y46LnJbC9a6W3+MN3bSaSLTw/pdpb6ZDPBbw2c91b7FllEjEOkocHIwfmwQTkenPXHj7U7r4mJ43uYLNtTW7ju/JRCkO5MADGc4woyc5PUnPNAG/c/Ce91TxFq1h4NurW/jsZmgWOe9g8+ZlQM21UYgjnAOeoI6ggYPjPwLceF9A8ParLqNhdR6varcrFFMhki3buNoYkj5fvYxnjqK6Lwf8Z9X8MRKlvpenXHl382oRtI8ybXlGGBCOquMdN4bHauS8Q+LZdd8N6HpV5p9msukRfZ4b2MuJWh3MwRhu2cFjyFB4HNAHNUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAsf+sX6iv0Ar8/4/9Yv1FfoBQB8Fa3/yGb7/AK7v/wChGqdXNb/5DN9/13f/ANCNU6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFj/1i/UV+gFfn/H/rF+or9AKAPgrW/wDkM33/AF3f/wBCNU6ua3/yGb7/AK7v/wChGqdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACx/6xfqK/QCvz/j/ANYv1FfoBQB8Fa3/AMhm+/67v/6Eap1c1v8A5DN9/wBd3/8AQjVOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBY/9Yv1FfoBX5/x/wCsX6iv0AoA+Ctb/wCQzff9d3/9CNU6ua3/AMhm+/67v/6Eap0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFJQAtFWrXTb68jMlpZXU6A4LRQs4z6ZArcs/AHjC9ERtfC2uSJLjY4sZNrZ75xjHvQBzNFei2PwS+I17IUi8LXiEDOZ3jiH5swrRT4HeILMZ8Uax4a8NN1WPU9SRXcdyAm7P50AeU0V6t/wrjwVbHzNS+KujiAcH7JZSzvn2UHke9KPD/whtG8ufxl4h1N1+YvZaYIlcegD8g9smgDyiivY4E+FUUQl0/wf461hH4zcSrGq47qY+v41YjuvAkCmax+Eut3LD5St/qUqRqO5Jxx+PFAHidGR6ivb4/HFtZcaJ8PPAWnsPlia8nS6cL7kvlj79avp8SPiCrBLWfQbS3HCQW2hybYx2Cgw9PxoA8Ts9C1e9nSGy0rULiZ/upFbOzH6ACuqtfhB8QbmZI4/CWqBn6GSMRr+LMQB+NdveeOviNJA6ah401GG3bqYrJbUj6O4jx+BJ9q5W71GeaF01DxhrFxA/DRy6yu1vrsMp/8dx7igC5F8BPHhQG6stPs5P8Anlc6hCr/AFwGNP8A+FJagvyz+MfA0Eo4eKTWAGQ+h+XrXLyR+Gi3+kXKTSd3kup3J/EQgfpUX2nwqOPs8X/gJOf/AG6H8hQB1n/Cn7e151f4h+CbVW+4Yb4zlj3yABij/hVfh/8A6Kl4T/77euWjv/DkRPkWSyZ67bFmx/33O36YqT+1ND/6Bp/8Fyf/AB2gDpf+FV+H/wDoqXhP/vt6P+Fb+CrQ/wDE2+K2jJu+59ispbr67tp4rmv7U0P/AKBp/wDBcn/x2rMd0roGt/DV/LCfuOlhbYYeozA5/Nj9aAN3/hBPht/0VqH/AMEc/wDjQfBnwvtf3t18UJbqIdYrXRZVkP0LHFYv2h/+hW1H/wAALX/5FqaG71MLi08NaosfoEji5+iQqP0oA0/7C+D3/Q6+If8AwWUf2F8Hv+h18Q/+CyqH2zXP+hb1b/vsf/GqPtmuf9C3q3/fY/8AjVAF/wDsL4Pf9Dr4h/8ABZR/YXwe/wCh18Q/+CyqH2zXP+hb1b/vsf8Axqj7Zrn/AELerf8AfY/+NUAXx4X+E94fLtPiFqdlJ18y80lmTHphcHNL/wAIJ8Nv+itQ/wDgjn/xrP8Atmuf9C3q3/fY/wDjVRT3WottF74Z1Rl7Zjil5+jwMB+FAGp/wrbwbdfNpXxV0N4xwxvbWS2bPsCeR70f8Kr8P/8ARUvCf/fb1jfaH/6FbUf/AAAtf/kWq8+oabE+2/0We3l/uS6fETj/AID5Y/8AHfxoA6L/AIUvNJ89r478CSQNyjtquwsOxI28Uf8AChPGjf6n+xZgfulNTiO/0xz3rlZL7w1I2Z7NUbsGsXX/ANAuFH6Ui/8ACKy/OPJjPpm4i/T95/6F+VAHQn4D/EoZ/wCKYlOPS6g/+LrDvfhd46s4HmuPCesrGn3itszY/LNSmXRJsCPU5I9v92/nT/0KA/pW3Za7q0UyTaX431yKQcJt1ZJQPwkeMn6FR+NAHm09heW6Fri0uIlBwWeJlA/MVWyPUV73F8RPiSp3x+KpbyEDGy50pJUP1MSuv/j2aZc/ELxBDHvm8OfDxmJ5efR3h3H13SBVz7ZoA8Hpa9tbxvaXPN/8OPAF48n+ve2njhZs9cEP8pPt0pssvw/mAe8+FfiOzeThhZ38jonuuRz680AeKUV6xLpfwcmJf+2fGOmZ48i4tI5GQ+5XrTf+FdeCLr97pvxU0kW56C8spYZAfdSf1oA8por1Zvgbr90N3h/WvDGuofufYdTTLH+7hsc+1QXPwF+JVvA8r+GnZVGSI7qF2P0AfJoA8worptW+H/i/SN/9o+GdYgVMbnNo5QZ6fMAR+tYV3p17Zor3lnc26ngGWJkB/MUAVqKTI9aWgAooooAWP/WL9RX6AV+f8f8ArF+or9AKAPgrW/8AkM33/Xd//QjVOvYNT+B/iP8AtK7fUNV8MaY7ys6xXmqorlSThsAHiqn/AAqjRovnuvid4NSNeZPKuGkcDvhQPmPtQB5VRXqp8NfCaw/4/vHurai0f+sjsNKKeYf9hn4H41Pb23wehXzrS18d6yc7RAywxrn3ZRn/APXQB5HSZr21NV8JWo36f8GZxKeM6nqUxQj2DADP0pyeOo7CQf2B8PfA+k3R6y3c8dzLGfVVLbh9MGgDxJVZh8qsfoM1s6P4S8R60m/R9B1W+TGd1vaSOMfUCvX/APhaHxEhgeWx1XRNLtU5kFjpBeP/AHmIhYA/UisO7+I/ivxBO3m/EPVFI522ix2Sj85IwfoM0AYEHwb+Ic8SSJ4T1IK4yA6qh/EEgj8a11+A3jOID+1DoulFuUF7qcSl/ptJrPuL8mR5r/xXqk8pOZHfV+WPqRGJD+W761kFPC6MS8sc5bnLy3E38o4sfrQB1P8AwpHVLf8Aean4o8H2Nov355NUDBfwAyTSf8IF8PbMbtT+Kdq6ngCx0uWU59+elcqbzwxCdqWscg65W0kf9WuF/lSnxNp0J22+nPt68R2sf6GFv50AdVHpPwg00kza/wCJ/EjnkRafYi2C/Uycn8PWtOM/DyMiKH4XeKrqMfdnutQkhZ/qFG0fhXEW3iq+vnMVpDGjAZ/0nU5I1x+MiDPsPypktxcBd0l/4YgGeWWBZT9MCNifrj8aAO8fxH4ctTmH4RaJauv+qOo6uQD6Eq5G/wB6mt/iBfw7ZNA8JfD7RtQJwtza26zSp/uhS2T9Aa87TUnhzjxPbW+f+gfYsgP+9hE/rUUuqRTMYpvEWvXe7gxwxbVf2GZP/ZaAPT7j4hfEmXbJceLJ7RQMEW2mJCn5yLGPzIrFuvFfiedpjqHj7XWWbOVGowQLz1ACTsMe2BXFw6UkuJIPDOtXQPSW5mKxt9cRj/0KpX0+WHB/4RrTLfPe8vyoP03Sr/WgC9f3VncoIdS8R310EO4LPq0jgH6LA6/k35VQa58NRSB1jS5lPTbFLMf/AB90H6N9KUCVFwF8J2wH/LMmOYj/AIES+fzNNOpvErb/ABNBCp7aZZMjN7E7I/w5NAF6C8EiFtP8N388XdorGBQD+MEn8/wqzJqGvIoK6VLbDs11qLwr9Mh4+fbP4VgmWzvT5klx4k1Fhx5uFXHt95/51NHo5BzH4S1Q5HW8uGVD9MInP4mgC7LeanI5advDySHqJ70TN+LNIxP51VmuZw4abU/Ddsw5/d2yzsPcMI3wfbcP601rOSI7f7A0KHH8FzqAEg+oM6n9KVRLEDiPwrY98F0uD/vA5kP4fpQAyXWMcSeLNUfI+7Z25UH2OXTn8DUIWynxGieJLp26RfKN/t0b+RqyNUkjUhvFMUOe2n2TID9fkj5/zmoDqkE48p9e8SXQbgw+WBv9v9c38jQA+PRwhJj8K6pkDrf3BWIe5Ijj/wDQqkW2liO7+y/DNt/tyXolH0w0zD9Kgjsba4cC30fX71xzsmcKg9yQmcfiPrVh9NlhG7/hGNPg7b7u+Kp9OZVGfxoAQzyoSv8Aafhe3x/yzWyWUD/gQhbP/fRp41eUDH/CX49ls3x+Hy01RKi7QvhO3A/5ZsY5SP8AgRL5/wC+jTft0o4/t7w+PYaaT/7b0AEuskEb/F2pn/rzt2X88un9aZ/ba/8AQ2+I/wDv0f8A5IqRdUkiznxTbwZ/58LJkB/3sIn9ad/bL/8AQ53v/gM/+NAEP9tr/wBDb4j/AO/R/wDkiozPZTEySXfiS4duTLhRv9/vH+Zq1/bL/wDQ53v/AIDP/jUD6zHuO/xR4hZs8tHFhT9MzD+QoAj36f8A89PEv5L/AI05dOt7v95FoviS/Xp5u8L+HET/AM6X+2of+hn8S/8Afof/AB+mmSzvD5sk/iTUD087Cr+HV/50AO/sWP8A6FbxJ/39/wDuej+xY/8AoVvEn/f3/wC56b5Fh/z6+JfzX/4mjyLD/n18S/mv/wATQA7+xY/+hW8Sf9/f/uej+xY/+hW8Sf8Af3/7npvkWH/Pr4l/Nf8A4mjyLD/n18S/mv8A8TQA7+xY/wDoVvEn/f3/AO56RrG2s/mm0nxJpwbgNvDbvbmNP5mk8iw/59fEv5r/APE0Ce0sTuiu/EumluN+A272+8n8zQAm/T/+eniX8l/xp6anBbDy4df8SWS9fK8vP48Sr/Kj+2of+hn8S/8Afof/AB+pYdZ+U+X4u1WNfSeBi36O386AFi1liCU8X34H/T3bMzfhhn4/H8KGvpJW3f8ACQ6NP/t3en7pPzMLfzoOpySHI8T2M/8AtX1gzuPoTE/H4j6UqzTS/ML7wrcZ/jktkjP5NGp/SgBFlllOBfeFrvHZ7ZYdv4mNM/maDZyztzouhXme9nebXb/dVZev/AKHSWTANv4UvMdllSDb+IePP5mj+zHmQs3heGYH+PTrwvn/AHcM4J/A0ARzaSkTGSfw1rdqF5MlvMWVPfmM/wDoQqNbu0tjvg1PxJYt08zaDn24df50r21tYtuksPEmlyL8wIYNs/2uVQ/y+tPi1lN37vxXrkZx1nhJX9JW5/CgB0esFs7PFuo/9vlszflh3/pUkFxPlvJ1HwzcHvm3W3I/Expn8zTW1SSXp4otp8f8/wDZM+P93Mb4/ShlllAzB4UvPZZUgK+/DR5/X8KANSHUdeYALYx3SgcCz1R5CPfb5rgD8BUNzeMg3ap4dv4kzzJJaQyAt9fJUn6lz+NUX0hnUb/CVyw9bC6Zyf0k4/zmq4a1087lfxJpLj5S2A2P9nrH/P8ACgCx9q8NSynzLdLeUHJLW8sRB9MpKw/JB+FTwHRIp1uLbVpYJQdytHqM0ZX6f6MSPzP1quNVaRAE8UmQdQmpWbOB+kgz/nNPDzMN32rwnLnne0EalvcgoCPyFAHW6V4r8R2AjGjeO9ajVM4ja/huV5/2ZJE/kT7Ct228f/EqDcT4omu1Yf6u70jzEP5Rk/lmvM1sZLgn/in9Ju8d7G95+pCynHtwKifR0jUu/hbxFCo5MgkJ2+/MI/nQB6ZP8RNaZni1bw18Pb6HqYZ7DyCT2JD7WH4gVVHjXT7o+Vf/AAv8CTwnpHY3UUEpPbDLISfoBzXnaajBakQxa54isQp4haMME+uJBx/wGrB1d2G3/hL53zxtmtXKH2Yc8fgfpQB3zat4VuFKX/wZeKEc7rLUphJn8ulR/afAH/RIfEv/AIMbj/CuCS6csAus+HJG7I2n7Af+BGAAfmKn866/5+vCn/fEf/xNAHcw6h4Mt3D6f8HdTkmJAxf6lPsA9Rkda+rvPg/6Ayf9/DXws1xOrp5mpeGYBnrHarLn8FibH6V9tb/+m1v/AN+v/saAPivV28LwarehxDI/nOT8s8vO48ZzEPwwfrUNvqOju5FhpUk8mOVh09MgevzvKP8Ax0fWrOrX8sGqXqjxFplsPOc7LWxPqe6xAbvx/Gs6TVopgFn8TeIbpR/AsZGPfmU0AbMN5qYQNZ+HdSjT+CRgkCAf7yRIV/BxUdxqGtFsTxadAcdLvVmLY9cNPyPbBrJj0+3umEsWieIdQZ+RK7hRJ7nEZP8A48am/suSLhfC9vCOv/EwvWRvrgunH4UADXEkZBbV/DlvnvBZByfrthNNfVwsZSTxXf7e8Vlbsif8BBZAPyFOPmx4y3hOy9wsdxu9sYkx+Qo/tKSFMHxPawKP4bCyKlf9whEA/MUAUbtrW8tpJlbX9QZFwJ5cBE9iPn4/4EK5+uiv9RhubeTzNd12+k24XzEwn0bMhOK52gAor27S/GGpR/s93lysmnfb7bVItMhc2FsXFr9n+7ymT0++ct710Ws/DrwHE2iQadZTz2c2padEmqx3I8u7hlkRZQ5848/McbEUrjnjmgD5vor6H07wV4B1m6sm/s0aalt4hvdIeIai5+3rFAZItzOf3ZZwq5XHX1II0NZ0DSdUtvC9nquj2sV7Y+H7yWz0Bb5lSS5FzxEZN5c/KWbbv3HGMjBFAHzRRXuep+GfA+hr401J9LTU00pdLaPThqLhIZZ9/nw+Yhy4UgDPUYxnrXnnxf0PTvDfxJ13SdEyNNt5gIAX37VZFbG7uASRzzQBx9bWi6h9ls5I21zULBWbJgtUJD++d6jNYtbuhXr2tnIF1saeu7JRLdnkPurAcf8AfQoAtJbW1+wkj0/xHqrv0kLBRJ+Suf1NTro7ocp4Rukz/wA/906D/gPEfP4moGuLa/YxyX/iPVXf/lmFC+Z+bOePoafDo8TMfJ8La9Me4llIx9MRCgCQ20sR2nR/DkGP4bi+UuPrumz+lBu5bfk61olmPWwswZPwKxjB/wCBD60p0ySPgeGLOID+G8vmWQfUeYn/AKCKQvLBhvO8Madj+OJUuHP0wJCCPwoAil1eFm/feJtfnb+9HHgfTmUUkemW87fudA8RXbdcM+M+/EZqZ9ZZDh/F1+p9LG2dE/Ebk5/D8ar/AOiX58sHxJqhHzGP5Vx/tfx/y/GgCyukyIML4TVR6Xl46yfiNyf+gig2ssBwdG8P2nf/AEq9DMPcBpTke2D+NMi0UFMxeEdZlTs0kzAn8owKf/ZkkPTwvb2+Of8AiY3rKw98F0yPwNACfbJYP+Y3oNtnnFrY7s++Vi6/iKbJrWUIk8X6zIvdEhYE/TMgFOLSxdZ/Ctl3wsaXBPvkLJj8xSnVZVXLeK4lA729k6uP907F/mKAKwmtdRIhW48R6u3UQEBfxzuf+VWF0ZkOU8IX6H1vbl0j/PanP4/hUUupRXgEM2v+IdSDcC3VCu4+mTI38jRFo8LPiHwxr8zf3ZZcD9IgaAJTbSRZQ6P4bhI/gnv13j65mzS75f8An98JL7fZYzj8fLo/syRPlHheyjA/hu79lkH1Hmp/6CKBHKOPsXhMexuo8j/yJQAfa5YT/wAhrw7bZ/597ENn67YTR/aUv/Qy6R/4Lm/+MUhaSM8yeE7PPYRx3G7/AMdkx+lHnP8A9BTwp/4L0/8AjFAC/wBpS/8AQy6R/wCC5v8A4xR/bLLwfGF+hH8NvbusY/3RuXA/4CPpSec//QU8Kf8AgvT/AOMU5dSlQbR4m06IDjZFYNsH0xFjFACf223/AEOWr/8Afh//AI5UEurws5M3ibxBM396OPA/WUVZ/tSb/oa7P/wAf/41TG1lkOH8X6gp9LK3ZI/y3Jz+FAFf+1bT/oYPEn/fC/8Ax6j+1bT/AKGDxJ/3wv8A8eqf+2/+px1//v03/wAeo/tv/qcdf/79N/8AHqAIP7VtP+hg8Sf98L/8eo/tW0/6GDxJ/wB8L/8AHqn/ALb/AOpx1/8A79N/8eo/tv8A6nHX/wDv03/x6gCD+1bT/oYPEn/fC/8Ax6nxaxEjHyfFGvQHuZIs5/KU1J/bf/U46/8A9+m/+PUqawznCeLrxsf8/wDbO6/hzJz+AoAX+22/6HLV/wDvw/8A8coGqyScr4qgkH96+sneT89j8fjTv7Um/wChrs//AAAf/wCNUw3ckx3HW/D8/bfc2A3f+PQk0AL9plm+b+1/DdxjjdPZBSPYboRSFZH5Nt4Tuv8App56QZ/4DvT/ANBpV82Tkf8ACJ3n+2fLt8e2P3efrg/Wj7FNKS39haBP/tw3+1fyWYCgBBZyzHA0LQbjHa1vxkfXbMabLpAwXm8K6kgHWWynZ4x9CVcf+PU/+ypJDhvCscuO1hes7D/e+eTj8BUEunwWjGWbQ/EGnMnJljfcI/flAf8Ax4UANW6tbBhFHqHiLSmHIiZQwHvwyf8AoNWf7YeThfFs8vtfWrvH+Xz8/h+NRRaskfyQeJ9at1J4juIiyf8AAsSHj/gJqVr+Wb5T4i0i4HXbc2B2/X5oSM0AH2qWY/8AIZ8O3OP+fixC4+m6EUCzlnPGh6DdY/59b4Aj3O2akBkkziTwneY9Ujt9v6R5/Wl/sqSX73hWKb/sH3jOf+BfNJgfgKAIZdJijw0/hnXbYH+KKUsD9Mx9PxNJFqcFu3lw+INfsWUbdkke4J/s8SD+Qppt7SwO97LxHpRPG8ENu9uVT+ZqaLVyQEi8V6goA4jvrdnRR6YDPz/wGgB326W4PGv6Rdjri/svm+rFoyCf+BGgxyNz9h8KTZ/5afa0j3e+3zVx9No+lAllnYn7Z4ZvyecTQrAx9yxRDn23GlFhK/zf8I/ocmed6agQp9wBPjFADW0l5Vy/hSSQdd2nXTP+J/1nHp0/GoPstnb/AL37B4ktSnPnblPl+/3F/mKkm0hFAafwvrMA6hraYsp/OM8fj+NRi/tIyCmseI4WXoxUYX8pBQBNFrI2BYvFmrIvaO4gZl/4Fh2BH4H6U86hK3y/8JFoz5/hfT2APscwYoGqSSJ8vimKRW4xfWbMx9mO1xj8TSebIeBqHhSTP8H2JE3e27yRj65H1oAUtKwx5/hKfP8Ayz8mOLd/wLauP++hSeVJ/wBAzwn/AOB6f/H6UwyyDb/Z3haXP8Ed2gY/QiUGj+zpf+hb0f8A8GLf/H6AFjWSORSIvCdnkj5vMS43e2N0mPyFfbmT/ftf++B/hXxGlpLDIp/sXw9bZPWe+DA/TdMa+3MH+5a/99D/ABoA+LNZmki1a8zqHhqz/fOdqWqzN9487hE/P/AhVSTWGUDf4uvcf9Odsyt+OWTj8at6qsseqX2I/C1oPOc4d0mbqeckufw/Sqi6lJEcnxNp8HvY2DI/0JEScfiaAK++0v2KmXxJqcsn8PC+afzc/wA6mi0bCny/CWpOP711cMuPyROP85qOTU4rgmGbxBr96GODFFFtV/pmQ/8AoNEemwXPzwaB4ivlHHmNJtAPocRH+YoAmW3lhP8AyDPDNrnvLeCXP4NK2PyFH2qSBs/2v4esyva2sw7p/ussRz+DUPp0kOD/AMIzp1vnve3xUH6ZlXmjMsKZD+FbIL2CpOyfjiQt+tAFfUNVMltLG/ijULgsuPKhgZIn9my6/wDoJrmK6yW/3wPDceJ4EjcYaOysmVGHuNic/h+NZ0FtojsRHJrF2R/DFbJHj3zvf+QoAxaK128P6nNKWstK1L7KxzG80JHHbLYC0N4b1ROJ4YLcnp9ouoos/TcwzQBkUVrjQZQP31/pULD+FrxGP/jhIoGnaYgxPrsG7/pjbSuPzYL/ACoAyKK2YLfRXfbHNq922PuRWqR/jne38qYvhzWnY7dJv0U8hpIWQY+pAFAGTW3oVw8FsxXU9NssPn99a+bL9Vby2I/76FRt4b1OP/XxQW5PQT3UUWfpuYZq9YWs+nwMr3Xh1GzuLTtHcOn02hs/QZoAll1WOUmKfxLrd0D1itoSqN9MyD/0GoxbWl6cRWPiTUivJXcF2e/3H/pU7asyR7ZPFcygdY9PtWRf+A/6sfyqBry1vcLLqfiTUgvIXaF2e/8ArH/pQBYi0Y7Pk8Iaiy/3ri4YN+OFUfoKQQy24J+w+GrD/ppLcC4P4KZJP0Wo00qKdfMh8OeIrtD0lMmM/lEf51K1hJbkN/wj+mWX/TS/vCR9QrOM/TB+lACpqUkIK/8ACT2EHfbZ2LKp9ziNefwqB9TguPkn1/xFfKOfLWPbj35lb+VTNcywnH9q+GrbPO2KyEgPvlYW/nTZdZwo8zxbqbj+7a27KR+brx/nFAEQ063uh5seieJL5T/y33gbvw8pv51LFo+FJj8J6iwH8V5cMoH1wicf5zUJks7s+bJN4kvmP/LfCjd+GW/nT4tNguTvt9A8Q3wBxvkk2qD6HEZ4/EfhQBKsMsII+w+F7Tv+8uVmP1+aR/y/SkF3JGd39u+H4sfxQacA6/QiAH9aV7CSAj/indJtu/8Apt9g/UBpVyPwNKzzIu77T4Thx/GsKOV/AISfyNADZtW3Jtm8VXsyNwY7O2ZGb2JJUY/P6VAIbO8PlxW3iTUG6+TkL+Odr/yqwmoS7tq+I7RS3AGmWDLK3txHH/6FWrH4f1zUXjga38d6hvOVhNg6ZPrkuw/SgDKi0Y7Pk8Iai6+s1wwb8cKv8qT7DKP+YBoA9m1I5H1/0iuqtvhF4nu4/Nj8C+JJVJxvuLyKBz9UZMitZPgj4rKgt4M09CR92TWlDD2Pz9aAOAWCaEkDTvC9rn/nrdrLn6bpWx+lPxN/zz8If99x/wCNd6fg1r9qc32keE9KRvutqWssQ59F2SdqT/hU2of8/Hw3/wDBxN/8XQBweJv+efhD/vuP/GozPKpK/wBq+F4SP+WYsVkC+24QNn65Negf8Km1D/n4+G//AIOJv/i6X/hW8tmMap4n+GenIeIladZc+vJBP5k0AeffaZP+g14Z/wDBaP8A5HpyalLENv8AwlFjB322liyp+kajP4V3/wDwglh/0Pvww/8AHP8A4mk/4QzTrY+ZdfEvwBbWo+99jtY7h8+ybMn86AOD/teX/obx/wCAb/8AxNH9ry/9DeP/AADf/wCJrvP+Ef8ACn/RWfD/AP4Tg/8AiaP+Ef8ACn/RWfD/AP4Tg/8AiaAOD/teX/obx/4Bv/8AE0f2vL/0N4/8A3/+JrvP+Ef8Kf8ARWfD/wD4Tg/+Jo/4R/wp/wBFZ8P/APhOD/4mgDg/7Xl/6G8f+Ab/APxNNfUZJsD/AISbTrjHa8sCwH0zE1d9/wAIvoVz+70z4q+EpJ+uLvR0tUx/vlCM+1A8C27H9/8AEb4azDsHEQx+SCgDz/7TJ/0GvDP/AILR/wDI9ORpZBuE3hS6/wBto0hP02lU/lXoH/Ct7u5+bSPE3wzvohwzLNGm0+mCtIfhRqj8z3vw2kf+9/abR/ohUfpQB5+1tLMcnS/DNzjjdHeiID2wsyj9KVdJkkG4+E0m/wBuzvGaP8wz8/jXfj4K+K5fnXwtoNzEf9XNa6xtjdexGZCT+lZsvwb8WfM0nw+1RcdrfU4tv4BgxP50AcfNo3TzPCWrR+n2adiT9cxt/Soc2unNtz4k0mVOQOG8v3/5Znn8OtdJH8N9fDHHgbxnbY7xr5mf/IS1RfT9U02AsZfGOl26Hn7RYuYkPuwcf+g0AUF1dpEITxXM4PG3ULRnz9f9YMfn9KVZZZDgX/ha7/6ZtaLCPruMSfln8KG1CSZsf8JDpd1njF/ZHefYsY2wP+BClZJZBgweFLrvsWRISPfcGT8s/hQAjQSzHnTfDF1j/nldrFt/75lXP602bRsgeZ4S1VPQ2twWz9co/FOXT5Js/wDFN6ZcY/58r8tj67ZW/pUMmnQWuDcaH4jsQ3Qq+4N7cxr/ADNACJeW1mf3Op+JNNb7p+UN/wAB4dP89qnOpSTIFHie1nHXbqFkX/E5Rxu/P61HDq6qdsXijWoMDG24hLAewxI3P4CpFu5Z241fw/d55xdWYRj7lmiGT/wI/jQAGOWdR/o/he/75SVbdj74DRkfTA+lOGkSMNx8ISPn+KC7cxn3U5PH4n600Wctwx/4kei3vfdZXm1j77Vk4H/ARTG0UFiT4R17P/TGYlPwPknj8T9aAImtLaxO6bTfEWllujKwYN9MonT6mpV1oZAXxbroPYTQkoPr++PH4GohcW2n8R3niTSmPBBUNnHb7ydPxqydXdl2jxfK+f4Z7Ryh/wB4Ybj8DQAhu5Jmz/bmg3Of+fqwAd/YsYePru/EU4rMwx5HhJ88bVljUt7ZDDH5imh5pVz9o8K3We7RJEz+3KoR9ePrSfZJGwP7D8OvnjbFqILH2GLg8/gaAAafK5C/8I7o8mf4LbUS0h/3R57c/gaf/Yz/APQm3f8A4Ev/AIUj6Q5UhvCE2P8AphdOX/AfN/I1F/Yi/wDQo+I/+/p/+MUATDS5InUjwtbwc9b69ZFP0y6c/ia+29h/54W//fz/AOyr4ig0YrINnhHVM5H/AB+XDKPwwifzNfb3lH/n0/8AHzQB8WaxayRave/8SfQLfMznN1egt9484aXOPbFVftMsJDf2r4atu26CzVj9PliJq1q+mSR6relfDNvGPOc7r+9ZG+8ecb04/D8aqHzY+SPCdn/t5juM+2P3mPrgfWgBJNYwhWXxZfle8dnbsif8BBZAB+AqD/RNQ+cjxJqpHyiT5Vx/s/x/z/CrH9pyQrg+J7SAL/DYWTKy/wC4QiD9RUMmpW87fv8AX/EV4x4G1MZ9uZDQBMmjsnKeErxc97+5dAf93iPn8TR5EsJx/ZvhuzK957tZHT6qZGJ/75NRQ6RE5PkeGNeuD1PmS4x+UVS/2fLAMjw5p1uF7316Qy/7ymRR/wCOigBftksPH9t6Bbd9tvY7s++VhIz+NRzayjACbxXrcwHQQwkY/OQU8tJH/wAtvCln32rElxn33bZMfTI+lT215eXDFbfxLcyMByNLsZNw/wB7ATj8TQBRS0tbxg8em+I9SeT5t5YAS+/CMf1NTppDpnZ4RuVz/wA/906f98/6v+tazeGNbv4PMbTPHepxS88WDqkvvuO/j8DWxp/wa8UXgZrfwHrTAYz9s1CGA/hlVzQByLWssLFTovh63PXbc3w3D3+abOPwpftcsPy/214fts/wQWO8fmsJGfxruk+CvjCJv33grT7K2HLXGoauNq/UpIOP+A1K3w9t7LB1Dxv8NbCI8KLfZeMW753KSPzxQB55LrCsoE3ivWZV/uQQkflmQcVGmn207AQ6H4iu3PO1nAz78Rk16O2meFNKXdrXxYEufuxaBYHeR7uAAB7VRnvPg/5f2e91H4h6kAcmVWgVHPqFbkfjQBxqaO6Z2eErhc/8/wDdOh/4D/q/60G3lgOP7K8OWZH/AD8Xiu6e5VpST9Np+ldP/wAJD8Irf5ofA+u3TJ90XGqbRJ6btvT8Kd/wsnwbYfv9B+FmjwXw+7JfXst5Gv8A2zbAJ/GgDlv7Qkg4PiLTLXHbT7Ih1/3WWNR/48KsJLeXbRKmu+JrwyHEYtrRyST6ZkGfwroP+F7eKIPl0vTfDWmQnkw2elRqhPqc55qpc/HT4jTiRF8RyW8TggRwW0MYQei4TI/OgCGDwPrWp3DhfDXje+nAy0sluYiR9GVv/QjW3pfwf8TXMLTL4NWwTOA2t6kIwcdSFGw/XOa4y9+Jfje+jEdz4s1tkByALx15/Aiud1TVdQ1aYS6rf3d9KBgPczNKw/FiaAPY/wDhW0tp8974p+GWn2o4YrcLcHd9HUn9cUf2F4bs/lv/AIwaZbzpy66VpTMCvoJIwM8dvWvEMD0paAPaXuvhjbOXvPHHjvVC/AFnEISmO53nn8KqXWpfB8MJ5f8AhPtXkxs8q7nhQAeu4HP4e9eQ0UAerf8ACcfDfTwBpHwxW4kT5Vm1LVJJN49WjA25+lO/4XLHCPLsvh34EjgXiNZNM8x1HbLFuT715PRQB6rJ8efGiofsX9jWEvRZbXTYldB6AkGsG6+LPj66heKXxbq2x+uybYfwIwR+FcRRQBrXnibXr2czXmuapcSkY3y3cjHH1JrKdmkdndmZ2OSzHJJ96SigBMD0owPQUtFACYHoKv6DpF7r2s2el6VAZ767lEUMakDcx9z0HqT0pfD+j3viDW7HSdLiM17eSrDEnqSep9AOpPYAmu4v9e0nwH8UtMvfBcCXMOglIZZ3ckahKuRNJ3ChtzKuOgAPNAGbrXw61Kwv7aw0zUNJ8QajNM0Bs9Gna4mjdVLMGXaDgANyMj5TzxWTL4M8TxajPp7+HdX+3QKrywCzkLorHCsQBwCeAe5rsbPxd4C03xTDqun+FtTljkadriO9u4phGZEKgRoY9rBS2f3m7PQ1reJfjDbahbajHptnqFrLPoNto8UxljR0aK4aQufLVQAVbGFA/KgDko/hd4ljGiS6lYXVlaavHI8E5s55dpVHcKyRozBiIyQMfd+b7oJFaX4d6+66INKtJdVn1XT/AO0o4bKJ5Hii3lDvGOOQOenIrrfDfxV0/To/Bk99Y6lNf+H4rq2crcKYp45kmAbBGQ4Mq98YB9eGaR8TNEhttJh1LQ5rhrHRBpaTjynaOQTGTzESRWQ5yB8ykjqKAOEsvBnia+v76xsvD2rXF7Y4+1QRWkjSQ56BlAyCew70208HeJbyDUJrXQNVmi092ju2S0c+Q6/eV+PlI7g8jvXuek/EXw74x1rWLnXLhNG046vp+rRCW88uZmggWIqQsTCRPk3YGDnGPUY6fGvT7a/vxHZ3aiDWL/ULC9tYrUyPHcSMxVvPhkMZwcblxwcEHAoA8HooooAQgGjA9BS0UAJgVoR63q0e3y9Uv12427bhxj6c1QooA6UeP/GIxjxZ4gwOn/Exl/8Aiq3LP4z/ABDtJkkj8VX7leNs22RT9QwINefUUAerj46eIpfl1LR/C2owH70NzpSFWPqcEUn/AAtDwy3Mnws8MlzySruBn2HavKaKAPV/+E3+Gd0P9O+FvlSyf62S01iVApPUohGB7DpVi1vvg+S0ltdfEDSJZRgpDJC6R/j95gOteP5HrRkE8UAe3rp3g26G+2+MEqRHhINT0eSZlPvnKj6gUf8ACt5bzEln4s+GmpWp6STTrbOT7hFDfrivH10bVGxt0y+JPTFu5z+lao8BeLyAR4T18g9/7Om/+JoA9A1D4O+LIo2lPgmG+gA3GbSNSDA/QFm/ILmseb4ba5b27TTeCvGMSKMsEAYL9P3eT+VYVj4T8fafIr2GgeKbV1O5Wgs7hCD6jA61t2//AAuC2nSaFPHiyKcg7bs4/A8UAZlx9s0pmiuNW8T6WyAbo720dQB2H3/6Cq/9oSuNv/CQ6JLn+GTTyA31Jgx+tegad4z+OVlGsTWniO8gGf3d7o5mDfUtHk/nVS5+L/jVVc+IfDWiahbR/ej1DRAFQ9DyAMHtQBxXlSSn/jx8L3ZbjdHcpEz/AEUSLg/8BFOOlSkYPhSAg/8APK9cv/wEbzz+B+ldL/ws/wAKXP7vUvhZ4beA8kWkslu+fZxkge1KfGfwwu/3d38MJLSLr5tprMrPn0wwAxQByj6MkaFpPCniCFB1kEhO384cVF9isv8AoFeJf++l/wDjddnDrXwellUN4c8W6YV+YXFnfpJID6YbjHvVz+2vhD/z9fEz/wACLf8AxoA4SDTLeaVRB4e8RXRB5DPjb+URr7h8n/p0n/M/4V8qT618IAUb7D471Zs4EN9eRIi/7QKnOa+tfP0n/nyn/wC/tAHyxL8F/Fd5eXk9v4GuCjTOQ97q0UZPPXaNvy/5zQvwj1m3O+T/AIQCzjH+slm1RpAg7khnYcewryXxFqF5e6zeSXd3czuJXUGWVmIG48cnpWVgelAHt/8Awi3hzT23aj8TvCtr5X+sXS9JW4ZP+ubhdzfXNJJ/wr61Pm3PxS8S6hF0Ntp2nPbMfcljt9vWvEa1PDugap4k1H7BodlLe3hUuIo8biAQM8/UUAekT678IY8MNC8Zau3Ty7/UEjQf7QKHOai/4Tn4d6aN+h/DKGa46htV1GSdFP8AudCPrXl15bTWV3Pa3UbRXEEjRSRt1VlOCD9CKm1HTrjTjbC68nNxAlxH5U6S/IwyM7SdreqnDDuBQB6X/wALnmtvl0nwR4JsYTyyDTN+4+uS1Q3Px18clRHpl7Y6Nbg5EOm2MUSD8wT+tedW2m3tzp15f29rNJZWZQXE6qSkRckJuPbJBA+lVKAO1n+K3j6eZ5H8X60Gc5IS5ZFH0VcAfhXNahrur6iytqGq390y5wZrl3xn0yaz6KAJJJ5pF2ySyOvozkiosD0pa0rDQ9R1DR9V1Szt/MsNLWJryXeo8oSPsTgnJyxxwDjvQBm0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVJa2893OsNrDLPMxwscSF2P0ArvtA+DHj7W4xLb+Hbm1gPPm3zLbqB6/OQf0oA89or1n/hUel6W8Y8W/EPwxppY8xWkjXkg57hcY471FG/wh8PyTRyQ+IvFsyk7ZNy2Nu3twd/vn9KAPKqMj1Ferj4m+FtO+XQPhf4dRR8u7U3e9Yr2zuxz70f8AC8dbb5JfDvhCS3PDQnSl2sv93r0xQB5RW34M8P3PivxXpehWTBJ76dYQ5GQgP3mI7gDJ/Cu8/wCFl+E9Q4134X6Axbhn02aS0IHbAGRn3r2f9nO1+H/iDxdfa34T8Oalpl5pUYzJcXPmRL5oZeBnIJAf8KAPM9W8Gar8E/C+rajqiK/iHVHfS9PubbLxW8BXMswfA2u4OxQcMBuNeHV9l/Gb4l+FfF2g6j4S0XxrYabcSP5dzPcWsjwyqDyiyhSBz/EM5xwcV4DqXwT8WRxGfQRp3iSzwT52j3azYHUZU4bJHbBoA8yoqe/srrTruS01C2mtbqM4eKZCjqfcHmoKACiiigAooooAKKKKACiiigAooooASvQ/Avwd8aeNIobjTNLNvp0vK3t43lRFf7w/iYf7oNafwA+HieM/EUmpau8UPhzSCJ7x5h8smOQmTxjjJz2+tL8Zvi3qfjDWZrLR7q40/wANW/7m3tIJCiyKONzAYzn06AUAdTd/BrwJ4ThT/hPviJDFebfntdOjDspBwcfeY/iop7eJfgJoR2af4U1XW5F5EsxbazDpkPIOD/u/h2r587570tAH0F/wvrwvpnHhv4X6LbY+dXlMYKv2OFj+ncUf8NQ6/wBvDPh/P+7J/wDFV8+0UAe5N+0948OQsGhqD0xavx/4/WUf2i/iQTn+17Ue32GL/wCJryKigD13/hor4k/9Bi2/8AYv/iaP+GiviT/0GLb/AMAYv/ia8iooA9d/4aK+JP8A0GLb/wAAYv8A4mti2/ae8bqyC7s9Duoh99GtnXf+If8ApXhVFAH0F/w0k17/AMh/wH4f1AL/AKv+HZ6/eV/6Un/CYfA/xP8ALrng6+0C5k+9PY/cTtkBCPr9z86+fqKAPoe0+Dnw38TQeb4S+JUcbsGIgvgm/wDFSUYD8K5nXP2dfH2nh5LC0stXtwSVks7lcsvY7XwefQZrx3A9K19D8S65oMyS6Lq9/Yurbh5E7IM+4BwfxoAn1zwj4i8O3AXXNE1GxwwG6aBgp57NjB/A19yV8xaP+0b8QbSdPtl7Y6lDwDFc2iAfmm019d/8JNdf88Lf8j/jQB+dWrf8hW8/67P/AOhGqtWtW/5Ct5/12f8A9CNVaACu1+Ed3ouk+MtP1vX9VNjFpdzFdLEts8zXG0klV28KeByeOfauKooA990f4n+GRpMjXElxbQNNqkuoaP8AZQ66sbksYC7jgGPco56beOtUj8R9FsNJuJNGuzBqy+FdN063kFscrdxODLglcAgZ+bv2NeH0UAfQGufFDR9QtPHttaazLZPrVrYSwzLZnbLPHFtuVIA4L8DdjHGciuK+FvinT9E8Oa3YHV5vDutXc0EkOrxWxmIiTdvh+X5lySDwOcYPFeaUUAfQknxE8J/8K51fRTrF1eyXemXKCG7tZQTetKWV1VT5ManORhSwzywxg6/xO8YaFo+r6tpV7qUd9595pFxb2JsfNg04RJE8sp5AkLrlSqkEg4JHb5kooA+kfEPxJ8Fa1qFxDearfFb7R76wkuhDLPb2skzxMjRxyfvAMRkFQdo4x3NYOv8AjrwiPDOq6ZYXEl6j6JothGrWrQ/aHtZ90wYchcqM9T14JrwyigD2340/EDQfFfhoWmjXMDxfbEuLW1ezlSa0TYVMe4uY1UcDagwTzxiuNsLb4b6hZ28dzqPibRr7y1Esr28V5BvwMkBSjgZzxz9a4SigD0EfD3TNQwfD3jvwzdg9I72SSwkJ9MSqF/8AHvpmq1/8J/G9pCZ08P3N9b54m05lvEPvmItXD1ZsL+806cT6fdXFrMOkkEhRh+IOaAPXp/2ePFsvgvTNe0pUu57mATT6a6+VcQ5zgANw3GDjg84wa8i1PT7zSr6Wz1O0ntLuI7ZIZ4yjqfcHkV9RW/7VOn2Om2ttB4Zv7p4YVjMlxfKGdlXGSdrE5xya43x98etK8c2f2TWPh5YXBxthklvWaWI/7LqisPoDj1zQB4LRXqHhf4L+JfEMbajPbJ4e0IsW+1aq/lhEz7gE/XABrRm0f4SeE5v+Jlrup+LbmM/8e2mx+TCWHZpD1U+qmgDyGCGW4lWKCN5ZW4CIpYn8BXoug/BPx3q9v9pfR/7MsxjM+pSrbqB64Y7sY9q05fjZeaRF9l+Hvh7R/C1pt274ohcXDf70rjn8RXnniPxPrniW6a41/Vby/lJz+/lLKPovQD2AoA9FPg34a+GmLeJ/HEmtXMfLWOhW5IY4+75zfL+PFYPjHxV4NvNFbS/CvgiPTgCCuoXN20tySOue2D6civP6u6Ppd9rWpQafpNrNd3s7bY4YlyzGgDufD/xj8VeG/DsGj+HjpumxxJsNzDZJ58nJOWYg5PPXFcpr3ivxB4gkd9b1rUb4t1E9wzL1zgLnAHsBXs+kfs5i0sIL7x14v07QY2QPJAcb0/2SzsBn6Zq/JD+z74PYFpNQ8UXUf8Ks8ik59tkZ/WgD5uAyQByTwAK67wz8N/GPiaLzdE8O6hcwc/vSnlocdcM5AP516tcfH7Q9EgMPgH4faTprdfPuUUnrnlUAJ/76rkdY/aA+IupAqNbWyQggraW0adf9ogkfgaANDSf2bviHfIGntNP08FQcXV2M/TCBua22/Zh1zYRH4n0B58cR7nGW9M4/pXjereL/ABJrDltU1/Vbs7t2Jbt2APqBnA/CsNWKuHUkODkMDzn1zQB7Hqv7OHxDsQxhsrC/CrnNtdrz7APtOafHpXxL8IeAdR8Mad4U1i0W/mM2pXkEBkeSPAVYlZMgLwSccncRwM5830rxl4m0gqdM8Q6tahW3BYruQLn125xXWaT8c/iNppTy/Es9winOy6ijlz9Sy5x+NAHA6lpWoaXJ5ep2F3Zvx8txC0Z59mAo0jVNQ0a9S80i9ubG6T7s1tKY2H4ivabb9pbxJcwLaeJtC0HWrEgeZFLAVMmD1OSVz/wGtIeKfgj43vBHr3hq68L3DZxdWnyx5P8Ae8vjr0ymKAOJtPi9dasyW3xH0jT/ABXYYC75oVguoh/sTIAfwPX1rWf4Z+FvHFtLc/CjXZJNQRTI2hariOfH/TN+jY/H61peJP2fHvLR9Q+GXiGx8TWfU24mQTIOw3A7SfrtPtXjGp6bq/hnVzb6jbXmmalA2QsitFIh7EH+ooAZrmjaloOoyWGtWNxY3kf3op0Kt9eeo9xxVCvYtB+Ken+JNLi8P/FuzfVbFQVt9XjH+mWnvn+Mfr65rn/HvwzutDsF17w7dDX/AAnNzFqNup/d8/dlXqh9zx/KgDz2iiigAooooAKKKKACrOl2FzqupWun6fEZru5kWKKMfxMTgVWr379l3w7Z2L6t8QfEA2aVosTCFmH3pMfMR6kDge7UAS/G+5X4ceAdF+G+jMFknhF3qsyn5pXJ+6fYkZ+gFfPldD8QPE9z4y8X6lrl4TvupSyIf4EHCqPoMCueoAKKKKACiiigAor6t+IFppkvwiu4ngs7aMeHtPngupooPLNwuC0cRGJPOccE5Ix25NczqPw+8ErdWECW0MOntq2lWthqCagZG1mCYgXDMu4hNuc5ULjp1oA+eKK+gLfwd8PtWutLMtoNEtIfE11oty/9oM4uYo4TJGzFzhNz7UyMDk/hxPxq8PaPoV1pB0bSrjS5ZopBcwO+6MsrDDxgyyOAQe7YJHHegDzWiiigAooooAKKKKAFj/1i/UV+gFfn/H/rF+or9AKAPgjVv+Qref8AXZ//AEI1Vq1q3/IVvP8Ars//AKEaq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFABLAKCSTgAd62fCXhjVvFusRaZoVo9zcvyxA+SJe7u3RVHqa9Ql1Hwt8IYmh8PyWnibxuPlk1CSMPaae2ORCD958/wAXT+VAGF4c+FpTTI9a+IGrReFtFcboknXdd3I/6Zw9ce5H4GtaT4n+G/CMS2/wu8Lw290mR/bWrKs9y3uq9E/l7V5Xrmr6hrupzajrF5NeXszbnllbJP8AgPYV3fxh8BHwXpngqcQmM6npCyz56/aAd0g/ASRj8KAOS8UeL/EPiqcS+IdYvdQIJKrNKSiZ/ur0H4CsOiigAoor1H4K/CLU/iHqKXVwsln4bhf9/eHjfjqkeep9+g/SgDH+F3wx174i6mYNJiEFlH/r76ZT5UY9B/eb2H44r2TxN4r8K/AzS5vDvgCGHUPFzDZeanOgfyj3BPqOyDgd8mpPix8Z9M8I6Ongz4VCGGK3QwTXsS/LF2IjP8Ter8+3rXzBLI8sjSSMzuxLMzHJJPc0AXNb1fUdd1GW/wBZvZ728lOWlncux9ueg9qo0UUAFFFdx8D7W3vfi14YtryCK4t5LsK8UqB1YYPBB4NAHD0V9S+OfB2hazrnhOLVLGPT7gjUlaxe3hsLvUHQloFPl/KEOAitgMfctkchdeAvC1jeardX+l3SPZeG49WuNGF6Q1rcmYIYmfBYAqQ21vmG76UAeE0lfSlh8LvBk+rahcQ2F9dg2un3cOjRTvJLFFPHukZdvzyYIAHYZyQRivBPGWn22k+LNX0+x88WltdSRQicASBAxwHxxuA4PvQBj0UUUAX9C1nUtA1GO/0W+uLG8jPyywOVP0OOo9jXtujfGnRvF9rHpHxi0K31G3A2x6paxbZ4fcgc/iv5GvA6KAPbvGHwLkm0mTxF8M9Ui8R6C2XEKH/SIx6Y/iI9OD7V5z4M8beI/Al/MdGungDnbc2dwm+GXsVeM/l2PvTfAfjnX/Auqi+8O3rQkn95A3zRTD0de/16+9e9pqHgT9oC0EGpJF4b8dKu2GQN8twccc4AcZ7H5h2yKAPOL3w5ovxLsptV8Cww6Z4kjBkvPD5cBZQBkyWvqOuU7du1eUTwyQTSQzxvFLGSro4wVI6giup8XeFPE3w28SpDqUc9hewvvtryBiFfH8Ubj/8AX613sF3o3xj0+Oz1DyNM+IyDEN4cJDqoA4WQ9FkPY9/x4APFqKva5pF/oOq3Om6vayWl9btskikGCD/Ue9UaACiiigCS1glu7mG2to2knmcRxovVmJwAPxr3j47XUfgnwJ4b+G+mMQUiW91FgeXkbkA+nJJx7isL9mbQrG78bSa/rVzbwadocLXRWR1zI4BxhTycDJ474rg/iL4kl8XeNdW1qYn/AEqYtGD/AAoOFH4DFAHOUUUUAFFFFABXRweCdfm8ODXVso00xo3lSSW5ijeREJDMkbMHcAg8qp6Vzlej6b8UZbD4cT+FF0lJ0lt5LfzLm4aWJN7ZMiRMCEcdipAzzjNAGD/wr/xR/aV/p/8AZEv2yxuLe0uY/MTMcs52wqfmwdx44/HFdNofwd1iWz1678TNJokGk2y3EibI5pX3OyABPMUDlGySe3AORWrc/G8TX93qCeFrSHUb6906/vZ47uT9/JaSB1+U5Cg4xx0ySd3GOMbxxIdP8cWv2FMeKJo5nbzD/o+y487A4+bJ47UAQXvw+8TWenW18+mrLb3E0dshtrmK4YSyfcRljZmRj2DAc8Val+GHi6K9S1fTIhKUkdiL23KQiMqH81w+2MgugIcg5YCuw1T463txYwxafosNjJDd2l5Gq3LvbxPB/DHDgBEbuAc+54xnaV8V7XRtWvrzRvDMdmmppKuoqmoSl5mdlcNG/WPaynA5+8Qc8YAPPNf0bUPD2r3Gl6zava30BAkiYg4yAQcgkEEEEEHBBrPrd8beIW8UeIZtUeKaIyIiBZrl7h8KoXl25PT2A7CsKgAooooAKKKKAFj/ANYv1FfoBX5/x/6xfqK/QCgD4I1b/kK3n/XZ/wD0I1Vq1q3/ACFbz/rs/wD6Eaq0AFFFFABRRRQAUUUUAFFFFABRRRQAVteDPDl34s8TWOi6fgTXL4Lt92NByzn2Ayaxa6b4c+LZvBXieLVY7WO8hMbwXFtIcCaJxhlz2+tAHb+P/GOn+F9IbwR8OpjHYxgx6pqiIqy6hICQRvBz5fp/hXkNevX3gbwX4vuo7jwD4usdNnuPmbSddZoWiYk/Kku3a3sOfrXOeJfhJ458Oy7b3w7ezxHlZ7JPtMbD1ymcfjigDH+HOgnxP480HRtu6O7vI0lH/TPOXP4KGNfW/wC2BoA1H4WxalEg8zSbuOQkDpG/7sj/AL6ZD+FfI3hu58SeGNZh1XQ4b6z1CAMI5ltixTcpU8MpHQkfjXtnj7U/il4p0TwtpWmR6rf22r6FG1/GtouySYzSgl2K4Q7QncdqAPnOljRpHVI1Z3Y4VVGST6AV7NB8FIvD1ja6h8TfEVn4cgfczWakTXLgfwoFJBJ9ecV6b8HLPwyWm1bwdoQ0rw/YKTc+J9bZWuJcHlYl+4noW/TNAHnvw2+AmoX9suv+PpV0Hw3CnnyrM22aVBzgj+AH359BVX4u/GRtasV8L+B4TpHhS2XyAsXytcqOmcfdXjp370v7Qvxfn8capJpGiXDL4Ztmwu3Km6Yfxt7eg/GvFqAEFLRRQAUUUUAPgikuJo4YI3llkYIiICWZicAADqc9q6i/+HfiuwkEd1o0yyeXLKVV0cqsa7pNwVjtKggkHBFc7pd19h1OzuyjP9nmSXakhjJ2sDgMOVPHUcivXrz43Q3OtWN5J4Yjmjjguba7ae6U3N1HOm0qZkiTAHUZVj70AefaZ4C8VaqsLaboV7dCa3W6j8pNxaJnKBwB23Aj8K6PUPhHrVj4a0K+kJbVNYZ/I08RgbUVXYs8pYKp2oWx6d+1Wta+K1teeG7rRbDw8bK1k0iPSY/9OMpjVLgzbzlAWJzjHHr7VT0b4lwWMnhL7V4fhvYtBsriz2yTjMplZmEi5QhGUtxkN0/IAwv+Fe+K/wC230n+xbj7aluLtl3LsEJOBJ5mdm3PG7OM8U9fhx4ua3vZxoV2YrMuJT8uTsGX2DOXwCCSucV2Ot/GOHWp7iDUPD802j3WkW+lXMDaifPk8mZ5UlE3l8HL8gqQcfhRpfxjh07Q7bSrXQbm3trBphp5ttTKPFHLklJGMbGTknldnBx0oA8hooooAKKKKAChWKsGUkMDkEHBBoooA9y+H/xittS0pfCXxYh/tjQJfljvpAWntTjAJI5OP733h7isH4s/CW/8ELDruhXJ1TwvPtkt9QhI3RZ5Xdjp7MOD7HivK69i+B/xaHhYP4b8Vp9v8IXuY5IpBv8As+7qQO6+o/Ee4BLZT23xj8NfYtQlVPiHp0WLOY4X+1IVH+rYngyAZwe/v28curea0uZbe6ieG4iYpJG42srDqCK9b+MvwyufBOpw+I/CDTXHha4K3FpfW77vszHkAsORz0b+tN8a2UXxD8FJ450mNRrViFg1+3jUjc38NwB6N3Pr+NAHkVFFFACYBpaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAWP/AFi/UV+gFfn/AB/6xfqK/QCgD4I1b/kK3n/XZ/8A0I1Vq1q3/IVvP+uz/wDoRqrQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlbmgeLfEPh2R5ND1vULBnAD+ROyhgOmRnBrEooA9JHxy+JAAH/CU3P/AH4h/wDiK2/i/wCPPFVxYeCS2v6jGbrQY7ufyJjF5krTTKWbZjJwij8K8br3y0+HV98QtV+HVqqyQ6TD4bge8u8YWNBcXGVB6bj2/OgDivg/4BufiDr5l1S4eHQrAedf3kznaEHJQE9Ceec8DJrf+OfxTtdftofCXg2FLPwjp5Cr5a7ftLLwDjso7Dv1PtsfHb4gaBaeH4PAfw68uHR7dit7LAo2zleg3dW5BJPevAaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD274EfFW20a1k8GeM4xdeFdQzEGbJ+zluoP+wT+IPP0n1fSr34EfEBmnRtT8H6zE8Tqg4uLds5Q543rnjn+deE19JfC7Ubb4ufDC98Aa9PnXtNjM+lXDn5mCj5Rn2+6c9iDyRQB87akbVtQuW05ZVszIxhWbG8LngHHGar1Y1GyuNOvp7O9heC5gcxyRupUqQcEEGq9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACx/6xfqK/QCvz/j/wBYv1FfoBQB8Eat/wAhW8/67P8A+hGqtWtW/wCQref9dn/9CNVaACiiigD0TUPAuiaF4a0u68TeJJrPWdW08alZ2cFgZo1ibPleZJuGC+0jgHHes+/+GfiWx05Lua3tj81us0CXKNNbefjyTKgOUD5GM+vOKnb4jz3Xhqy0rV9A0TVJ7C1NlZ393E5nghOQF4cK23J25BxVnUfixq19ZyRvp+mx3l01odQvY1k829FrjyQ4LlVxtXO1RnAoAS6+Dvi63mtoRb2E0819/Zpjgv4ZDDcbSwSTax2EgE8/jjIqvP8ACnxTHeaTbxQWNz/aQm8qa2vYpYk8rmUPIrbV2Dk5P5nitXTPizrtrqOp6vBpVpIJtaTWpjskKRy7XVUyDwp3Hrzx1rP8P/FXW9Bg0iPT4LMDT57qYbwx84XAAdGwwOOOCCCPWgCOb4VeJYLyaO4XT4bOG1jvX1CS8jW1EMjFEbzCcZLAqF65HStW1+EN6LHQLy41GwuBqWpPp7WtneQNLlXVMxEvtcnOeOgwTwarXPxXu7l72C60TT7nR76COC5sLm5u5hJ5bs6P5rTGQMGZsYYDBxjvUem/FK5sIdNji0HRwumao2qWG0SqLZmZS0agPgodgHzZOM85oAzx8OPEE/lzWdqrWcwvJI5XnQbUtTiUvzhSOPrnjNN1L4beJNN8MPrt3bW62sUUVxNCLhDPDFKQI3eMHIDZHuMjIFWLT4maxa+EfEXh+GG1FtrNw87ylSZIN5UyJGc8KwRQQfT1qfXvipq2veFxpGpWlvJL9mjtDdrPcKWjTG3MQk8ot8oG7Z+vNAHn1FFFABRRToY3mlSKJGeR2CqqjJYngAUAavhLw7qPirxBZ6Po8DTXdy4UYBIQd3bHRR1NfRPx58VXPw48GaB8PfD9x+8bTlFzeL95otzptHpllfNUc2XwE+HyYSKb4ha5AcsG5soj/LH6sPQYry/4vTS3Fr4DmndpJZPDcLM7HJYm5uMk0Aee9aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAq/oGs6h4f1e21TR7l7W/tyWilUAlSQR346E1QooAs6lf3ep3017qNzNdXczF5JpnLM5Pck1WoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAWP8A1i/UV+gFfn/H/rF+or9AKAPgjVv+Qref9dn/APQjVWrWrf8AIVvP+uz/APoRqrQAUUUUAFXNFuI7TWbC5niimhhuI5HjlyUdQwJDYIOCODgg1TooA+j/AIgLoF9qvj2aU6KkFzd6S1mLHVAqXkLTyiSR8SMobHByBsAVtozk2NS0LwCvijSSljoLW7xXTLpqXcCTR4CiJpJPtRhmGSSFLxs3zE5xgfNFFAH0NqXhDwVqFzPDp+oeFjdWmu2T3LJdi1jNiYQJUUNKysd/XYzc9MdKtaNoPw32ayiWul32NY1CC5je/iieC2DkW7QvLOgCBcNuUOT0NfN9FABRRRQAUUUUAFe9/APwtY+HdEvfib4wiUafYKf7MhkbaZ5uRkA9eeB17ntXmHws8G3PjvxrYaLAHELtvuZVH+qiH3j/AEHua7v9o3xrYanqFh4S8LuF8O6EghURk7JZQME+4HQH6+tAHm3jnxTf+MvE99reqOTPcvlUzxGv8Kj2A4rc+KM8U2n+AxDLHIY/DkKOFYHa32i4OD6Hkce9ReCfhzq/jHw1r+r6PJbv/ZCqz2rFvNnyrMRGAOSFRjjvjin33ww8SReIJ9J061GpTQW1vdSyQHbGizIGQFnwAx3YA7kHGaAOHoro4PA/ie40/Ub6HQ79rTTpJYryTyiBbtEu6QP/AHdoIJzWvH8JPHknk7PDF/iVxGpIUDJXcMkngEdCcAnjOeKAOForqNP8AeKNRtbuez0eeRbR5Y5k3KJFaP8A1iiMncSvfANReMPC8nhtPD5a5FydX0uHU1CoV8sSM6hOpyRs6+9AHOUV19z8NfF9s8Mc2h3CzS7tsW5DICqFyGQHcp2qxwQDgGq+meAPFOqeT9g0S7m862W8TaBzCzFVk5PCkg8n0NAHMUV10Hw28YTarf6amg3f22xZEuI22rsZhlFBJwxYcgAkntmqFp4N8RXf2P7PpF25vGnWD5cbjCMyjnoV75xQBgUV0+teDdR0+wS+hguprNdPtdQuJng8sQrOcJ3O5SeA3f0FT6f8NvGGo6jdWFnoF5JdWrRLOnyjyjIu+PcScDcCCPqKAORore8SeDvEPhm1s7nX9JurCG7LCFplxuK9QR1B5HBwawaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBY/9Yv1FfoBX5/x/wCsX6iv0AoA+CNW/wCQref9dn/9CNVatat/yFbz/rs//oRqrQAUUUUAFFFFABRRRQAUUUUAFFFFABR+tFey/s5/D5Nf1mXxRrwEfhvRMzytIOJZFG7b0wQOp/AUAdCQvwW+D2Cqr418UxncCRvtbfHoOnBP4k+lfPJJJJJJJ6k11vxT8YXPjjxrf6vOxEDOY7aPtFEPuqPwrkqAO08GfEC98I+H72x0uArezX9rfxXfm4EZhLfKUx8wbdg8jjI5zXV6z8ZLbW9d1241PwyH0vVTZyGyhvjG8UlsMIVkEfKnnK7fTBB5ryCigDvPGPxGufFPh6/0+8sI4p7zXZNbeaOT5V3xLGIgmOwXO7PPp3rc1L4w/bdT1W7/ALD2fbtQ0y+2fa87PsaKuzOznftznjbnoa8nooA9r0P44W+l317eL4XAubnUL6+ZoL4ReaLndhJv3RMmzd8pyBx93PNed+LvFf8AwkR8NH7F9n/sbS4NN/1xbzvLd238Abc78Y5xjrXMUUAe1S/GOPVvEvhSc2K6Y2napHdTardy/a7gRY2PHuSJXaPaWJB3seOeKyvGnxOt9Q1rxvFp1iH0nVraHTNP2v5S2ttA6mMhNvQhM7eMbvwryqigD2CX4zQ3l3u1Pw39otIrmyv7eJL8xtHc20IiDM4T5kYDJXAx2PeszTvi7qFt4c8WafcafDNea3cz3UV2shT7E9xxPsXByGXgcjHXmvMqKAPVE+K9rPp8um6r4bF5pk+h2OjzQi+aNma1O5JQ4TgE8lMf8CqbVfjEL/VdXvV0ERC/1DTL8Ri83eX9jRV2Z2c79vXt6GvJaKAO58bePv8AhJ9GubD+zfsvna5d615nn79vn4/d42j7uPvd/QVw1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAsf+sX6iv0Ar8/4/wDWL9RX6AUAfBGrf8hW8/67P/6Eaq1a1b/kK3n/AF2f/wBCNVaACiiigAooooAKKKKACiiigAooooAu6Hpd1resWWmWCGS6u5VhjX3Jxn6DrX0X8etWtPh18PNJ+Gnh5yJpIhNfyq2GIJyQcd2bn6AetY/7O+g2nhjQtV+J/iRdlnYRvHp6N/y1k6Ejv1+UfU14l4o1y88Sa/favqcrS3V3KZGJ7Z6AewHFAGZRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACx/wCsX6iv0Ar8/wCP/WL9RX6AUAfBGrf8hW8/67P/AOhGqtWtW/5Ct5/12f8A9CNVaACiiigAooooAKKKKACiiigAp0JQSoZVLxhgWUHBIzyAe1NooA9S+LXxJsfFHh7w7oHhe0utL0LTrcCSzkYEGXpnIPzADoT6mvLaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFj/1i/UV+gFfn/H/rF+or9AKAPgnWBt1a9HpO/wD6EaqVc1v/AJDN9/13f/0I1ToAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAWP8A1i/UV+gFfn/H/rF+or9AKAPgrW/+Qzff9d3/APQjVOt3WY0/te++Rf8AXv2/2jVPy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGdRWj5af3F/Kjy0/uL+VAGfH/rF+or9AK+EUjTevyL19K+8cD0FAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22306=[""].join("\n");
var outline_f21_50_22306=null;
var title_f21_50_22307="Centruroides antivenom: Drug information";
var content_f21_50_22307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Centruroides antivenom: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16547?source=see_link\">",
"    see \"Centruroides antivenom: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/44/39619?source=see_link\">",
"    see \"Centruroides antivenom: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13215077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anascorp&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13168364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antivenin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13168394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Scorpion envenomation:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy as soon as possible after scorpion sting. Initial: 3 vials (containing &le;360 mg total protein and &ge;450 LD50 [mouse] neutralizing units); may administer additional vials in 1-vial increments every 30-60 minutes as needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13168393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/44/39619?source=see_link\">",
"      see \"Centruroides antivenom: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Scorpion envenomation:",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13168395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13168396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13168512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anascorp&reg;: &le;120 mg total protein and &ge;150 LD50 (mouse) neutralizing units [contains cresol, sucrose 4.3-38.3 mg/vial]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13168397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer over 10 minutes; monitor for return of symptoms of envenomation and repeat as needed. Medications (eg, epinephrine, corticosteroids, diphenhydramine) and equipment for resuscitation should be readily available in case of hypersensitivity reactions. Avoid I.M. since the time to peak blood concentration may be prolonged with this route of administration (Turri, 2011; Vasquez, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13168384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13168365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of scorpion envenomation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13168373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (4%), fatigue (2%), headache (2%), lethargy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (3%), pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (5%), nausea (2%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Rhinorrhea (2%), cough (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Aspiration, ataxia, chest tightness, eye edema, hypersensitivity, hypoxia, palpitation, pneumonia, respiratory distress, serum sickness (delayed)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13168369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13168370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concern related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acute hypersensitivity reactions: Derived from equine (horse) immune globulin F(ab&rsquo;)",
"     <sub>",
"      2",
"     </sub>",
"     fragments; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to horse protein. Patients who have had previous treatment with",
"     <i>",
"      Centruroides",
"     </i>",
"     immune F(ab&rsquo;)",
"     <sub>",
"      2",
"     </sub>",
"     or other equine-derived antivenom/antitoxin may be at a higher risk for hypersensitivity reactions. In patients who develop an anaphylactic reaction, discontinue the infusion and administer emergency care.  Immediate treatment (eg, epinephrine 1:1000, corticosteroids, diphenhydramine) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Delayed serum sickness: Delayed serum sickness may occur, usually within 2 weeks; monitor patients with follow-up visits for signs and symptoms (eg, arthralgia, fever, myalgia, rash).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form related issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cresol: Product may contain small amounts of cresol resulting from the manufacturing process; local reactions and myalgias may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Disease transmission: Product of equine (horse) plasma; may potentially contain infectious agents (eg, viruses) which could transmit disease.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13225889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13168366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13168367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13168368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13168399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of envenomation (eg, opsoclonus, involuntary muscle movement, slurred speech, paresthesias, respiratory distress, salivation, frothy sputum, vomiting); signs and symptoms of hypersensitivity reactions; follow-up visits for signs and symptoms of serum sickness (eg, arthralgia, fever, myalgia, rash)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13168385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains venom-specific F(ab&rsquo;)",
"     <sub>",
"      2",
"     </sub>",
"     fragments of IgG which bind and neutralize venom toxins; thereby helping to remove the toxin from the target tissue and eliminate it from the body.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13168387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Time to resolution of symptoms: Adults: 1.91 &plusmn; 1.4 hours; Children: 1.28 &plusmn; 0.8 hours; &gt;95% of all patients will experience resolution of symptoms within 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 13.6 L &plusmn; 5.4 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 159 &plusmn; 57 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer LV, Theodorou AA, Berg RA, et al, \"Antivenom for Critically Ill Children With Neurotoxicity From Scorpion Stings,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(20):2090-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/50/22307/abstract-text/19439743/pubmed\" id=\"19439743\" target=\"_blank\">",
"        19439743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tuuri RE and Reynolds S, &ldquo;Scorpion Envenomation and Antivenom Therapy,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2011, 27(7):667-675.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/50/22307/abstract-text/21730810/pubmed\" id=\"21730810\" target=\"_blank\">",
"        21730810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vasquez H, Chavez-Haro A, Garcia-Ubbelohde W, et al, &ldquo;Pharmacokinetics of a F(ab&rsquo;)2 Scorpion Antivenom Administered Intramuscularly in Healthy Human Volunteers,&rdquo;",
"      <i>",
"       Int Immunopharmacol",
"      </i>",
"      , 2010, 10(11):1318-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/50/22307/abstract-text/20849955/pubmed\" id=\"20849955\" target=\"_blank\">",
"        20849955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16767 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22307=[""].join("\n");
var outline_f21_50_22307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13215077\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168364\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168394\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168393\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168395\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168396\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168512\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168397\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168384\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168365\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168373\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168369\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168370\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299002\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225889\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168366\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168367\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168368\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168399\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168385\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168387\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16547?source=related_link\">",
"      Centruroides antivenom: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/44/39619?source=related_link\">",
"      Centruroides antivenom: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_50_22308="Morcellation by wedge resection";
var content_f21_50_22308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Morcellation by wedge resection during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22308=[""].join("\n");
var outline_f21_50_22308=null;
var title_f21_50_22309="Daunorubicin: Patient drug information";
var content_f21_50_22309=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Daunorubicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     see \"Daunorubicin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31029?source=see_link\">",
"     see \"Daunorubicin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cerubidine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cerubidine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney or liver disease you may need a lower dose. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701897",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to daunorubicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had daunorubicin, doxorubicin, epirubicin, idarubicin, or mitoxantrone before, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Color of urine is orange or red for 1 to 2 days after getting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11335 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22309=[""].join("\n");
var outline_f21_50_22309=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157117\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157118\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029656\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029658\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029657\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029662\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029663\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029665\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029660\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029667\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=related_link\">",
"      Daunorubicin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31029?source=related_link\">",
"      Daunorubicin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_50_22310="Peyronies disease deformity";
var content_f21_50_22310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peyronies disease deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peyronie's disease is an acquired, localized fibrotic disorder of the tunica albuginea causing penile deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Porth, CM. Pathophysiology Concepts of Altered Health States, Seventh Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22310=[""].join("\n");
var outline_f21_50_22310=null;
var title_f21_50_22311="Acute colonic pseudo-obstruction (Ogilvie's syndrome)";
var content_f21_50_22311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22311/contributors\">",
"     Michael Camilleri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22311/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22311/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22311/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/50/22311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute colonic distension can occur as a result of three processes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Toxic megacolon (eg, as a complication of inflammatory bowel disease or Clostridium difficile infection)",
"     </li>",
"     <li>",
"      Mechanical obstruction",
"     </li>",
"     <li>",
"      Acute colonic pseudo-obstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute colonic pseudo-obstruction (Ogilvie's syndrome) is a disorder characterized by gross dilatation of the cecum and right hemicolon (although occasionally extending to the rectum) in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Chronic intestinal pseudo-obstruction is a separate disorder that is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute colonic pseudo-obstruction is associated with an underlying disease in 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 400 cases, the most common associations were: trauma (nonoperative) 11 percent, infection (pneumonia, sepsis most common) 10 percent, cardiac (myocardial infarction, heart failure) 10 percent, obstetric or gynecologic disease 10 percent,",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    surgery 9 percent, neurological (Parkinson disease, spinal cord injury, multiple sclerosis, Alzheimer disease) 9 percent, orthopedic surgery 7 percent, miscellaneous medical conditions (metabolic, cancer, respiratory failure, renal failure) 32 percent, and miscellaneous surgical conditions (urologic, thoracic, neurosurgery) 12 percent (",
"    <a class=\"graphic graphic_table graphicRef66068 \" href=\"UTD.htm?9/20/9547\">",
"     table 1",
"    </a>",
"    ). There may also be an association with opiate administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/2\">",
"     2",
"    </a>",
"    ]. Several cases in the literature are associated with Cesarean section (even without bowel injury), normal vaginal delivery, and spinal anesthesia used during childbirth or surgery.",
"   </p>",
"   <p>",
"    Cardiac surgery is one of the more common associations with acute pseudo-obstruction. However, acute pseudo-obstruction is a rare complication of cardiac surgery, occurring during the postoperative period in only 3 of 5438 patients (0.06 percent) in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasingly recognized association of acute colonic pseudo-obstruction is chemotherapy, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and other medications (eg, all transretinoic acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) used in the treatment of a variety of malignancies, including hematological malignancies such as acute myeloid and lymphoblastic leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Several individual cases and series have been reported in children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism by which colonic dilation occurs in patients with acute colonic pseudo-obstruction is unknown. The clinical association with retroperitoneal pathology or trauma, spinal anesthesia, and pharmacological agents suggests an impairment of the autonomic nervous system. Interruption of the parasympathetic fibers from S2 to S4 leaves an atonic distal colon and a functional proximal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. However, there is no proposed mechanism to explain colonic dilation in those patients without obvious involvement of the parasympathetic nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute colonic pseudo-obstruction is more common in men and in patients over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"     1",
"    </a>",
"    ]. Nausea, vomiting, abdominal pain, constipation, and, paradoxically, diarrhea are the primary manifestations although they occur with great variability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Abdominal distention is always present and can cause labored breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, the abdomen is tympanitic, although bowel sounds are present in almost 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"     1",
"    </a>",
"    ]. Peritoneal signs are absent in the early stages of the disease; if they develop, they suggest impending perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109746724\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109746731\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no pathognomonic laboratory findings in patients with acute pseudo-obstruction. Laboratory evaluation may reveal leukocytosis and metabolic abnormalities. If present, leukocytosis is due to the patient's underlying disease or impending perforation, not to uncomplicated pseudo-obstruction.",
"   </p>",
"   <p>",
"    Metabolic abnormalities, especially hypokalemia, hypocalcemia, and hypomagnesemia, are common, occurring in more than 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/2\">",
"     2",
"    </a>",
"    ] and representing the sole manifestation in about 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypokalemia may be due to a secretory diarrhea with abnormally high potassium content [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In one patient, immunohistochemistry revealed marked upregulation of apical BK potassium channels throughout the surface-crypt axes of the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/8\">",
"     8",
"    </a>",
"    ]. Colonic BK channels play a significant role in intestinal potassium secretion in a variety of disease processes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109746738\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain and upright abdominal radiographs show a dilated colon, often from the cecum to the splenic flexure, and occasionally to the rectum; haustral markings are normal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78963 \" href=\"UTD.htm?5/23/5503\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A CT scan or gentle Hypaque (water soluble) enema is essential for confirming the diagnosis and excluding mechanical obstruction and toxic megacolon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link&amp;anchor=H8#H8\">",
"     \"Toxic megacolon\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute colonic pseudo-obstruction can be made only after excluding the presence of toxic megacolon or mechanical obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mechanical obstruction frequently complain of crampy abdominal pain; however, lack of pain, especially in the elderly or postoperative patient receiving opiates, does not exclude that diagnosis. Similar to acute pseudo-obstruction, there are no pathognomonic physical or laboratory findings of mechanical obstruction. A \"cut-off sign\" (lack of gas in the distal colon or rectum) or small bowel air-fluid levels on plain abdominal x-rays suggest mechanical obstruction, but can also be seen in patients with Ogilvie's syndrome.",
"     </li>",
"     <li>",
"      Patients with toxic megacolon typically appear very ill with fever, tachycardia, and abdominal tenderness. They frequently have a history of bloody diarrhea or other signs or symptoms of chronic inflammatory bowel disease. Abdominal upright and plain films may show \"thumbprinting\" due to the presence of submucosal edema, or thickening of the colonic wall (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59217 \" href=\"UTD.htm?10/11/10416\">",
"       image 2",
"      </a>",
"      ). Active colitis will be apparent on flexible sigmoidoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objectives of treatment are relief of discomfort and avoidance of perforation or ischemia, which are associated with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"     1",
"    </a>",
"    ]. There are few controlled trials comparing treatments of acute colonic pseudo-obstruction. An approach to the management of acute colonic pseudo-obstruction is presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef67491 \" href=\"UTD.htm?34/15/35070\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Supportive care and removal of precipitants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care with removal of precipitants is the first step in the management of patients with acute colonic pseudo-obstruction. Conservative therapy can be continued for 24 to 48 hours provided that there is no pain or extreme (&gt;12 cm) colonic distension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serial physical examinations and plain abdominal radiographs (every 12 to 24 hours) to measure the colonic diameter and determine which patients need colonoscopic decompression or surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treat underlying reversible diseases, such as infection or congestive heart failure",
"     </li>",
"     <li>",
"      Maintain the patient on intravenous fluids; oral intake should be avoided",
"     </li>",
"     <li>",
"      Correct electrolyte imbalances (particularly hypomagnesemia, hypocalcemia, and hypokalemia)",
"     </li>",
"     <li>",
"      Insert a nasogastric tube and attach to intermittent suction",
"     </li>",
"     <li>",
"      Insert a rectal tube and attach to gravity drainage",
"     </li>",
"     <li>",
"      Discontinue unnecessary medications, especially opiates, sedatives,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      , and those with anticholinergic side effects.",
"      <br/>",
"      <br/>",
"      Patients should be placed in a prone position with the hips elevated on a pillow or the knee chest position with the hips held high. These positions should be alternated with right and left lateral decubitus positions each hour.",
"     </li>",
"     <li>",
"      Gentle enemas can be administered to patients with Ogilvie's syndrome, although they were associated with perforation in 5 percent of patients in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pharmacologic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neostigmine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    , an acetylcholinesterase inhibitor, may be effective in producing rapid colonic decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]. Neostigmine efficacy is also documented in acute colonic pseudo-obstruction associated with pediatric hematological malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard dose in adults is 2.0 mg IV with cardiovascular monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/17\">",
"       17",
"      </a>",
"      ]. The dose is adjusted in the presence of chronic renal insufficiency, especially if the serum creatinine is &gt;3",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Decompression in response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      has been achieved in 80 to 100 percent of patients.",
"     </li>",
"     <li>",
"      Time to clinical response is short. In a controlled trial of 21 patients with acute colonic pseudo-obstruction treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      , the median time to response was four minutes (range 3 to 30) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/16\">",
"       16",
"      </a>",
"      ]. Prompt decompression was observed in 11 patients (91 percent) who received neostigmine compared to none receiving placebo. Postoperative patients tend to have a favorable response to neostigmine, while patients with electrolyte imbalance or those using antimotility agents have been associated with a poor response [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Side effects may vary. In the above trial [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/16\">",
"       16",
"      </a>",
"      ], the most frequent adverse effect was mild to moderate crampy abdominal pain, which was transient. Excessive salivation and vomiting were also noted in a few patients. Symptomatic bradycardia requiring",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      was observed in two patients. Bronchospasm and hypotension have been reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       Neostigmine",
"      </a>",
"      should therefore be used with caution in patients with known bronchial asthma, recent myocardial infarction, and concurrent therapy with beta-blockers. Those who have underlying bradyarrhythmias or who are receiving beta adrenergic antagonists may be at increased risk. The use of neostigmine in pregnancy, although reported, has not been well studied [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      should be available at the bedside, patients should be kept supine on a bedpan and should receive continuous electrocardiographic monitoring with vital signs for 30 minutes, and continuous clinical assessment for 15 to 30 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Clinical experience suggests that lower doses (1.5 mg) may also be effective and may possibly decrease abdominal cramping, nausea, and vomiting, which can be severe. A study in patients with a spinal cord injury suggested that the risk of some side effects (particularly bradycardia and bronchoconstriction) might be reduced by co-administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      (an anticholinergic agent that has limited activity on the muscarinic receptors of the colon) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reported recurrence rate after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      ranges from 5 to 33 percent. Anecdotal experience suggests that recurrence may also be treated with repeat administration of neostigmine with the usual precautions (especially cardiovascular monitoring); it is our practice not to repeat dosing within 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of a polyethylene glycol electrolyte balanced solution after initial resolution of colonic dilation has been recommended by some experts because it may reduce recurrence rates. Such an approach has not been extensively studied but was more effective than placebo in at least one controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    binds to motilin receptors in the intestine and stimulates smooth muscle contraction. There are anecdotal reports of patients treated successfully with erythromycin either intravenously (250 mg in 250 mL of normal saline every eight hours for three days) or orally (250 mg four times daily for 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18653852\">",
"    <span class=\"h3\">",
"     Methylnaltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been one case report of successful decompression following subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    (12 mg) in a patient on opioids following surgery, after initial decompression with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    failed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/29\">",
"     29",
"    </a>",
"    ]. However, large prospective studies are needed to determine the role of methylnaltrexone in the treatment of patients with Ogilvie's syndrome associated with opioid use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompression in patients with Ogilvie's syndrome may consist of endoscopic decompression with or without placement of a decompression tube, or percutaneous tube cecostomy. The latter procedure is more invasive, involving a combined endoscopic and radiographic approach, and is usually reserved for those who fail initial endoscopic decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of decompression in patient management remains controversial. Success rates for endoscopic decompression in uncontrolled series vary from 69 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/2,31,32\">",
"       2,31,32",
"      </a>",
"      ]. However, in a retrospective study of 25 patients with cancer, pseudo-obstruction, and a cecal diameter ranging from 9 to 18 cm, 23 resolved without colonoscopy, usually within 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, the complication and death rates associated with colonoscopy for treatment of Ogilvie's syndrome are 3 and 1 percent, respectively, figures which are much higher than in patients without pseudo-obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no colonic diameter which mandates decompression; the rate of dilation is probably more important than the absolute diameter of the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/13,32\">",
"       13,32",
"      </a>",
"      ]. Nevertheless, an attempt at colonoscopic decompression is indicated when supportive measures have failed and the colonic diameter has progressed to 11 to 13 cm or there is evidence of clinical deterioration.",
"     </li>",
"     <li>",
"      Recurrence requiring repeated colonoscopic decompression occurs in approximately 40 percent of patients after initial successful decompression [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109746916\">",
"    <span class=\"h3\">",
"     Colonoscopic decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual pre-colonoscopic bowel preparation with a balanced electrolyte solution should not be administered prior to colonoscopy. Water enemas can be administered gently via a rectal tube, but there is often little stool passed following such enemas because of the dilatation and lack of propulsion in the colon. Although controlled trials are lacking, the placement of a decompression tube with the aid of a guidewire at the time of colonoscopy may reduce the need for repeated colonoscopic decompression. The guidewire is passed through the channel of the colonoscope after reaching the distal transverse colon. Gas should be aspirated from the colon and the wire left in place as the colonoscope is gently removed. A decompression tube (customized with several extra side holes, if necessary) can be passed over the guidewire and left in the transverse colon. To minimize air inflation, the whole colon should not be examined and the guidewire should not be delivered into the cecum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Percutaneous tube cecostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is more invasive, and involves placing a tube using a combined endoscopic and radiologic approach (fluoroscopic guidance). It is usually reserved for those who fail initial endoscopic decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Percutaneous endoscopic colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous endoscopic colostomy (PEC) comprises the endoscopically guided insertion of a plastic tube into the left colon or cecum, allowing decompression and irrigation.",
"   </p>",
"   <p>",
"    PEC on the left side of the colon is a minimally invasive endoscopic technique increasingly used to treat lower gastrointestinal conditions. In a retrospective audit over five years among 31 patients presenting for PEC, insertion was possible in 27 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/33\">",
"     33",
"    </a>",
"    ]. Indications included recurrent sigmoid volvulus (n = 8), colonic pseudo-obstruction (n = 5), and neurological constipation (n = 6). In 81 percent, symptoms were markedly improved after insertion. However, 77 percent of patients had episodes of infection that led to tube removal in 44 percent; fatal fecal peritonitis occurred in 2 of 27 patients. Thus, PEC in the left colon should only be considered in carefully selected cases in settings where the appropriate expertise is available.",
"   </p>",
"   <p>",
"    Percutaneous endoscopic cecostomy can be effective for treatment for both acute colonic pseudo-obstruction and neurogenic bowel when other more conservative measures have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/34\">",
"     34",
"    </a>",
"    ]. However, given the concurrence of comorbid diseases, these patients need to be monitored carefully for local infection or bleeding, which may result from associated medical therapy such as anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/34\">",
"     34",
"    </a>",
"    ], particularly in patients who are being treated in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tube placement, usually in the right colon, using a combined endoscopic and radiologic approach (fluoroscopic guidance) is another technique described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is rarely required. It is reserved for patients who fail medical and endoscopic management, and for those who develop signs of peritonitis or perforation. The type of operation will depend upon the findings at surgery. A surgically placed cecostomy tube or a right hemicolectomy with primary anastomosis can be performed in patients whose bowel has not perforated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22311/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the rare patients who have perforated, a total colectomy, ileostomy, and Hartmann procedure are performed in order to retain the option of future ileorectal anastomosis. The Hartmann procedure involves resection of the diseased colon, an end-colostomy, and creation of a rectal stump; this is followed by colostomy closure three months later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute colonic pseudo-obstruction (Ogilvie's syndrome) is a disorder characterized by gross dilatation of the cecum and right hemicolon (although occasionally extending to the rectum) in the absence of an anatomic lesion that obstructs the flow of intestinal contents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute colonic pseudo-obstruction is associated with an underlying disease in 95 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nausea, vomiting, abdominal pain, constipation, and, paradoxically, diarrhea are the primary manifestations although they occur with great variability. Abdominal distention is always present. Plain and upright abdominal radiographs show a dilated colon. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute colonic pseudo-obstruction can be made only after excluding the presence of toxic megacolon or mechanical obstruction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our recommendations for treatment are consistent with a guideline for the management of acute colonic pseudo-obstruction that has been issued by the American Society for Gastrointestinal Endoscopy (ASGE) (",
"      <a class=\"graphic graphic_algorithm graphicRef67491 \" href=\"UTD.htm?34/15/35070\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest initial conservative therapy after mechanical causes of obstruction have been excluded for patients without significant abdominal pain or signs of peritonitis and those who have one or more potential factors that are reversible. Patients should have serial physical examinations and plain abdominal radiographs (every 12 to 24 hours). Conservative therapy can be continued for approximately 24 to 48 hours, provided that there is no excessive pain or extreme colonic dilatation (&gt;12 cm). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Supportive care and removal of precipitants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest pharmacologic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      in patients at risk for perforation (based upon the rate and size of colonic dilation as described above) and those who failed conservative therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The standard dose is 2.0 mg IV with monitoring as described above. However, side effects might be reduced by using a lower dose (1.5 mg IV) or by co-administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      (0.4 mg IV). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neostigmine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest colonoscopic decompression in patients who fail or who have contraindications to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest a trial of subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"       methylnaltrexone",
"      </a>",
"      , prior to percutaneous or surgical decompression, in patients whose acute colonic pseudo-obstruction may be precipitated by opiates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest percutaneous endoscopic colostomy or surgical decompression (with cecostomy or colectomy) for patients who fail endoscopic and pharmacologic therapy and for those in whom exploration, lavage, or drainage of the peritoneal cavity is indicated for other reasons (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients treated with percutaneous cecostomy need to be monitored carefully for local infection or bleeding, which may result from associated medical therapy such as anticoagulants, particularly in patients who are being treated in the intensive care unit. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Decompression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/1\">",
"      Vanek VW, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. Dis Colon Rectum 1986; 29:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/2\">",
"      Jetmore AB, Timmcke AE, Gathright JB Jr, et al. Ogilvie's syndrome: colonoscopic decompression and analysis of predisposing factors. Dis Colon Rectum 1992; 35:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/3\">",
"      Johnston G, Vitikainen K, Knight R, et al. Changing perspective on gastrointestinal complications in patients undergoing cardiac surgery. Am J Surg 1992; 163:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/4\">",
"      Delmer A, Cymbalista F, Bauduer F, et al. Acute colonic pseudo-obstruction (Ogilvie's syndrome) during induction treatment with chemotherapy and all-trans-retinoic acid for acute promyelocytic leukemia. Am J Hematol 1995; 49:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/5\">",
"      Xie H, Peereboom DM. Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma. J Clin Oncol 2012; 30:e192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/6\">",
"      Lee JW, Bang KW, Jang PS, et al. Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies. Korean J Hematol 2010; 45:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/7\">",
"      Ogilvie WH. William Heneage Ogilvie 1887-1971. Large-intestine colic due to sympathetic deprivation. A new clinical syndrome. Dis Colon Rectum 1987; 30:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/8\">",
"      Simon M, Duong JP, Mallet V, et al. Over-expression of colonic K+ channels associated with severe potassium secretory diarrhoea after haemorrhagic shock. Nephrol Dial Transplant 2008; 23:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/9\">",
"      Blondon H, B&eacute;chade D, Desram&eacute; J, Algayres JP. Secretory diarrhoea with high faecal potassium concentrations: a new mechanism of diarrhoea associated with colonic pseudo-obstruction? Report of five patients. Gastroenterol Clin Biol 2008; 32:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/10\">",
"      van Dinter TG Jr, Fuerst FC, Richardson CT, et al. Stimulated active potassium secretion in a patient with colonic pseudo-obstruction: a new mechanism of secretory diarrhea. Gastroenterology 2005; 129:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/11\">",
"      Sandle GI, Hunter M. Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM 2010; 103:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/12\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Acute colonic pseudo-obstruction. Gastrointest Endosc 2002; 56:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/13\">",
"      Johnson CD, Rice RP, Kelvin FM, et al. The radiologic evaluation of gross cecal distension: emphasis on cecal ileus. AJR Am J Roentgenol 1985; 145:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/14\">",
"      Stephenson BM, Morgan AR, Salaman JR, Wheeler MH. Ogilvie's syndrome: a new approach to an old problem. Dis Colon Rectum 1995; 38:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/15\">",
"      Tur&eacute;gano-Fuentes F, Mu&ntilde;oz-Jim&eacute;nez F, Del Valle-Hern&aacute;ndez E, et al. Early resolution of Ogilvie's syndrome with intravenous neostigmine: a simple, effective treatment. Dis Colon Rectum 1997; 40:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/16\">",
"      Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999; 341:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/17\">",
"      Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2005; 22:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/18\">",
"      Hutchinson R, Griffiths C. Acute colonic pseudo-obstruction: a pharmacological approach. Ann R Coll Surg Engl 1992; 74:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/19\">",
"      Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum 2000; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/20\">",
"      Paran H, Silverberg D, Mayo A, et al. Treatment of acute colonic pseudo-obstruction with neostigmine. J Am Coll Surg 2000; 190:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/21\">",
"      Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg 2001; 67:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/22\">",
"      Loftus CG, Harewood GC, Baron TH. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol 2002; 97:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/23\">",
"      Mehta R, John A, Nair P, et al. Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo-obstruction: a prospective study. J Gastroenterol Hepatol 2006; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/24\">",
"      Rausch ME, Troiano NH, Rosen T. Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy. J Perinatol 2007; 27:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/25\">",
"      Korsten MA, Rosman AS, Ng A, et al. Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury. Am J Gastroenterol 2005; 100:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/26\">",
"      Sgouros SN, Vlachogiannakos J, Vassiliadis K, et al. Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial. Gut 2006; 55:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/27\">",
"      Bonacini M, Smith OJ, Pritchard T. Erythromycin as therapy for acute colonic pseudo-obstruction (Ogilvie's syndrome). J Clin Gastroenterol 1991; 13:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/28\">",
"      Armstrong DN, Ballantyne GH, Modlin IM. Erythromycin for reflex ileus in Ogilvie's syndrome. Lancet 1991; 337:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/29\">",
"      Weinstock LB, Chang AC. Methylnaltrexone for treatment of acute colonic pseudo-obstruction. J Clin Gastroenterol 2011; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/30\">",
"      vanSonnenberg E, Varney RR, Casola G, et al. Percutaneous cecostomy for Ogilvie syndrome: laboratory observations and clinical experience. Radiology 1990; 175:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/31\">",
"      Rex DK. Acute colonic pseudo-obstruction (Ogilvie's syndrome). Gastroenterologist 1994; 2:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/32\">",
"      Sloyer AF, Panella VS, Demas BE, et al. Ogilvie's syndrome. Successful management without colonoscopy. Dig Dis Sci 1988; 33:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/33\">",
"      Cowlam S, Watson C, Elltringham M, et al. Percutaneous endoscopic colostomy of the left side of the colon. Gastrointest Endosc 2007; 65:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/34\">",
"      Ramage JI Jr, Baron TH. Percutaneous endoscopic cecostomy: a case series. Gastrointest Endosc 2003; 57:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/35\">",
"      Saunders MD, Kimmey MB. Colonic pseudo-obstruction: the dilated colon in the ICU. Semin Gastrointest Dis 2003; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/36\">",
"      Saunders MD. Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol 2007; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22311/abstract/37\">",
"      De Giorgio R, Knowles CH. Acute colonic pseudo-obstruction. Br J Surg 2009; 96:229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2531 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22311=[""].join("\n");
var outline_f21_50_22311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109746724\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109746731\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109746738\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Supportive care and removal of precipitants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neostigmine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Erythromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18653852\">",
"      - Methylnaltrexone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109746916\">",
"      - Colonoscopic decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Percutaneous tube cecostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Percutaneous endoscopic colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2531|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/15/35070\" title=\"algorithm 1\">",
"      Rx pseudoobstruction ASGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2531|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/23/5503\" title=\"diagnostic image 1\">",
"      Acute colonic pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/11/10416\" title=\"diagnostic image 2\">",
"      Toxic megacolon in C diff",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/20/9547\" title=\"table 1\">",
"      Ogilvies syndrome associations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_50_22312="Pituitary and adrenal gland dysfunction in HIV-infected patients";
var content_f21_50_22312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pituitary and adrenal gland dysfunction in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22312/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22312/contributors\">",
"     Melissa Weinberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22312/contributors\">",
"     Morris Schambelan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22312/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22312/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/50/22312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early AIDS epidemic, the diverse endocrine manifestations of HIV infection were more often a consequence of opportunistic infections (OIs), neoplasms, or concomitant systemic illness. The widespread use of potent antiretroviral therapy (ART) has led to a decline in the incidence of glandular infiltration by OIs and neoplasms and has generated increased attention toward the metabolic complications of HIV therapy, including insulin resistance, dyslipidemia, and alterations in body fat distribution.",
"   </p>",
"   <p>",
"    This topic review will address the assessment and management of pituitary and adrenal disorders in patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    Issues related to insulin resistance, bone and calcium disorders, and thyroid dysfunction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38388?source=see_link\">",
"     \"Thyroid gland dysfunction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the diagnosis and treatment of a specific endocrinopathy in a patient with HIV infection does not differ from that in an immunocompetent individual. There are, however, some special considerations. HIV infection may cause changes in pituitary and adrenal function that are adaptive and do not require treatment. Furthermore, many of the signs and symptoms of pituitary and adrenal dysfunction are nonspecific and can overlap with other non-endocrine disorders that are common in HIV-infected patients. Finally, many medications that are used to treat HIV infection and its complications can induce endocrine dysfunction (",
"    <a class=\"graphic graphic_table graphicRef83250 \" href=\"UTD.htm?32/32/33292\">",
"     table 1",
"    </a>",
"    ), including affecting pituitary and adrenal hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLANDULAR INFECTION AND INFILTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection by a diverse array of organisms, as well as HIV-associated malignancies (ie, Kaposi's sarcoma and lymphoma), have been detected in the pituitary and adrenal glands (",
"    <a class=\"graphic graphic_table graphicRef72716 \" href=\"UTD.htm?17/62/18413\">",
"     table 2",
"    </a>",
"    ). Such occurrences were far more common prior to the widespread introduction of potent ART, although they may still be observed in patients not receiving ART or who have antiretroviral drug resistant infection.",
"   </p>",
"   <p>",
"    Tissue is generally required for a definitive diagnosis. When technically feasible, fine needle aspiration (FNA) biopsy of the adrenal gland provides a less invasive alternative to open biopsy. Pheochromocytoma must always be excluded before FNA biopsy of the adrenal gland is performed. Standard functional testing should also be performed since clinically significant endocrine dysfunction may accompany glandular infection or infiltration of the pituitary or adrenal glands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PITUITARY GLAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pituitary gland secretes and releases hormones that directly affect the functions of the thyroid gland, the adrenal gland, and the gonads, as well as influencing growth, milk production, and water balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=see_link\">",
"     \"Hypothalamic-pituitary axis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific effects of HIV infection on pituitary function are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alterations in pituitary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior pituitary functional reserve is usually maintained, as evidenced by studies administering hypothalamic releasing hormones (ie, gonadotropin-, thyrotropin-, and corticotrophin-releasing hormones) to HIV-infected patients at various stages of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Poststimulation peak levels of growth hormone (GH), prolactin, thyroid-stimulating hormone (TSH), and corticotropin (ACTH) may even be modestly increased, suggesting enhanced pituitary responsiveness due to subclinical target organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the normal response to gonadotropin-releasing hormone (GnRH), which excludes significant follicle-stimulating hormone (FSH) or luteinizing hormone (LH) deficiency, hypogonadotropic hypogonadism is commonly observed in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/5\">",
"     5",
"    </a>",
"    ] as a consequence of hypothalamic dysfunction. This abnormality is likely due to a variety of factors, including the presence of chronic systemic illness, which suppresses the hypothalamic-pituitary-gonadal axis.",
"   </p>",
"   <p>",
"    Published reports have demonstrated conflicting results as to whether or not prolactin levels are increased compared to HIV-seronegative controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/1,6-9\">",
"     1,6-9",
"    </a>",
"    ]. In a large study of 192 clinically stable HIV-infected men, 21 percent were found to have hyperprolactinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/10\">",
"     10",
"    </a>",
"    ]. Although there was no HIV-seronegative control group in this study, this prevalence is greater than would be expected in the general population. The cause for elevations in prolactin is unknown, but is hypothesized to be related to immunologic dysregulation. Other researchers have suggested that these higher serum prolactin levels are due to increases in macroprolactin, a glycosylated isoform of prolactin that is not biologically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the anterior pituitary gland, posterior pituitary function is often abnormal in patients with advanced AIDS. In a study of 103 hospitalized AIDS patients, 36 were found to have serum sodium less than 130",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/12\">",
"     12",
"    </a>",
"    ]. Hyponatremia was attributed to the syndrome of inappropriate ADH secretion (SIADH) in 23 subjects. There was no definitive evidence, however, of a primary pituitary disorder since there were other confounding factors, including pulmonary infection (most notably Pneumocystis) and treatment with medications known to affect fluid and electrolyte metabolism (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The somatotropic axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection itself does not affect circadian growth hormone (GH) secretion, as evidenced by frequent sampling studies among men with asymptomatic HIV infection and clinically stable AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/13\">",
"     13",
"    </a>",
"    ]. The somatotropic axis, however, is influenced by nutritional status and body composition, leading to characteristic abnormalities in patients with AIDS wasting and the HIV-associated lipodystrophy syndrome (",
"    <a class=\"graphic graphic_table graphicRef75394 \" href=\"UTD.htm?9/10/9387\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIDS wasting appears to be associated with an acquired GH-resistant state, with decreased levels of insulin-like growth factor-1 (IGF-1) and IGF-1 binding protein-3 in the setting of increased GH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/14\">",
"     14",
"    </a>",
"    ]. In HIV-associated lipodystrophy, normal GH pulse frequency and IGF-1 levels are observed, but there are lower mean GH concentrations, basal GH concentrations, and GH pulse amplitude [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/15\">",
"     15",
"    </a>",
"    ]. Reduced GH levels are inversely correlated with visceral obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/15\">",
"     15",
"    </a>",
"    ], and abnormal response rates to GH stimulation testing with GHRH-arginine are common [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/16\">",
"     16",
"    </a>",
"    ]. Reduced GH levels are also found in generalized obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effects of antiretroviral therapy on pituitary gland function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body composition changes associated with ART may affect GH secretion and action, but the specific effects of individual medications on the somatotropic axis have not been determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Marked elevations in prolactin levels, accompanied by symptomatic galactorrhea, were reported in four patients treated with protease inhibitors (PIs), although three of these patients had received medications known to cause hyperprolactinemia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .) Use of opioids is also associated with hyperprolactinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to the anterior pituitary can occur suddenly or slowly, can be mild or severe, and can affect the secretion of one, several, or all of its hormones. As a result, the clinical presentation of anterior pituitary hormone deficiencies can vary significantly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment and treatment of pituitary gland dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of an HIV-infected patient with possible pituitary dysfunction is the same as in an uninfected patient. Regardless of etiology, hypopituitarism is treated with physiologic hormone replacement and requires both biochemical and clinical monitoring of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"     \"Treatment of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADRENAL GLAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major adrenal steroid hormones include the glucocorticoids (particularly cortisol), mineralocorticoids (particularly aldosterone) and androgens, which can also be aromatized to estrogens. Abnormalities in adrenal gland function can lead to electrolyte disturbances, hyper- or hypotension, and changes in sex hormones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of HIV infection on adrenal gland function is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alterations in adrenal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several characteristic alterations in adrenal steroid hormone metabolism have been observed in HIV-infected individuals. These shifts in hormone metabolism may simply signify an adaptive response to systemic illness and often do not require treatment.",
"   </p>",
"   <p>",
"    Elevated basal cortisol levels may be accompanied by diminished responsiveness to ACTH stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/18\">",
"     18",
"    </a>",
"    ]. This can lead to an incorrect interpretation of the standard ACTH stimulation test if a \"subnormal\" increase in cortisol levels is considered diagnostic without taking into account the absolute cortisol levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given that elevated cortisol levels may be present without higher levels of ACTH, non-pituitary factors (eg, cytokines) may be directly promoting adrenal steroidogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/19\">",
"     19",
"    </a>",
"    ]. Moreover, patients with advanced HIV disease often have an attenuated pituitary-adrenal response to corticotrophin-releasing hormone (CRH) infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased ACTH levels may be accompanied by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased cortisol levels suggesting hypothalamic activation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low or normal cortisol levels suggesting that the rises in ACTH may be compensatory in the setting of clinical or subclinical adrenal insufficiency",
"     </li>",
"     <li>",
"      Paradoxically elevated levels of cortisol despite Addisonian signs and symptoms suggesting peripheral glucocorticoid resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the signs and symptoms of glucocorticoid deficiency are relatively non-specific and often overlap with manifestations of AIDS, this diagnosis is frequently considered in patients with HIV infection. Prior to the availability of potent ART, pathologic changes in the adrenal gland were noted commonly at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Depending on the stage of HIV infection, the presence of suggestive clinical signs and symptoms, and the method of diagnostic testing used, the proportion of patients thought to have adrenal insufficiency varied considerably but, in many cases, exceeded 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/25\">",
"     25",
"    </a>",
"    ]. Frankly elevated ACTH levels were rarely observed, suggesting that, in those with a subnormal response to ACTH, a secondary (ie, hypothalamic-pituitary) etiology was more likely.",
"   </p>",
"   <p>",
"    Although the prevalence appears to be greater than in the general population, clinically significant adrenal insufficiency remains rare in HIV-infected patients. Overt hormone deficiencies are uncommon given the adrenal gland's high functional reserve; 80 to 90 percent destruction of the adrenal gland is usually required before adrenal failure is clinically apparent. Nevertheless, since untreated adrenal insufficiency has such potentially dire consequences, we recommend evaluation for glucocorticoid deficiency in a patient with AIDS, refractory hypotension, and critical illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyporeninemic hypoaldosteronism, which may present with hyperkalemia, hyponatremia, and metabolic acidosis was reported in the early AIDS epidemic in a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/26\">",
"     26",
"    </a>",
"    ]. As originally described in non-HIV infected patients with this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/27\">",
"     27",
"    </a>",
"    ], ACTH-stimulated cortisol levels were normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dehydroepiandrosterone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydroepiandrosterone (DHEA), an adrenal steroid hormone with weak androgenic activity, has been investigated for its proposed anti-aging and immunomodulatory effects in a variety of clinical settings, including HIV disease. DHEA gained attention in the HIV community when early reports in the 1990s indicated that DHEA inhibits HIV-1 replication and activation in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low DHEA levels and elevated cortisol to DHEA ratios are found in HIV infection, particularly in the setting of body composition changes due to either lipodystrophy or malnutrition. In several cross-sectional studies, low serum concentrations of DHEA have been significantly associated with low CD4 cell counts, weight loss, and progression to AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small trials have assessed the efficacy of DHEA replacement therapy for improvement of quality of life and treatment of nonmajor depression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small, double-blind placebo-controlled trial of orally-administered DHEA (50",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      32 patients with advanced HIV infection demonstrated improved quality of life without a significant change in CD4 count; HIV viral load or metabolism were not assessed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized placebo-controlled study of 40 subjects with viral suppression also showed a positive effect on overall quality of life assessed by validated questionnaires, but no benefit on immune function, metabolism, or body composition [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another placebo-controlled trial of 145 HIV-infected patients with nonmajor depression showed improvements in clinicians' ratings of depression, but these measurements were not blinded [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its wide availability and acceptability by HIV-infected patient populations, we do not recommend the routine use of DHEA until its efficacy has been proven in larger, randomized clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effects of medications on adrenal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART-associated lipohypertrophy (eg, dorsocervical fat pad enlargement and visceral adiposity) is not associated with overt hypercortisolism, despite phenotypic similarities to Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/37\">",
"     37",
"    </a>",
"    ]. Furthermore, these patients demonstrate normal diurnal cortisol variation and normal cortisol secretory dynamics after administration of ovine CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iatrogenic Cushing's syndrome can result from the coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    and nasal or inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    (given for allergic rhinitis or asthma) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/39\">",
"     39",
"    </a>",
"    ]. The effects of ritonavir on cytochrome P450 lead to prolongation of the half life of fluticasone. The resultant high plasma levels of fluticasone cause features of classic Cushing's syndrome and suppression of endogenous ACTH and cortisol levels, such that abrupt withdrawal may precipitate an Addisonian crisis. Iatrogenic Cushing&rsquo;s syndrome can also occur with the coadministration of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    or intraarticular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    and ritonavir, although much less commonly than with fluticasone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. The typical phenotype of Cushing's syndrome may not be recognized when pre-existing ART-associated lipodystrophy is present, given the similarities in clinical presentation, such as visceral adiposity and peripheral lipoatrophy.",
"   </p>",
"   <p>",
"    Adrenocortical function can be altered by other medications used in the treatment of HIV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      inhibits adrenal steroidogenesis and can lead to glucocorticoid deficiency in patients with impaired adrenal reserve",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      can lower circulating cortisol levels through enhanced clearance of cortisol",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       Megestrol acetate",
"      </a>",
"      , a synthetic progestin with intrinsic glucocorticoid-like activity, can suppress both the hypothalamic-pituitary-adrenal and the hypothalamic-pituitary-gonadal axes when administered chronically for appetite stimulation. Long-term exposure can lead to iatrogenic Cushing's syndrome and diabetes mellitus, and Addisonian crisis if the drug is withdrawn abruptly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"       \"Management of tissue wasting in patients with HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Opiate use, which may accompany HIV infection, can also be associated with suppression of the HPA axis; the subsequent cortisol response to ACTH stimulation may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Assessment and treatment of adrenal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other clinical situations complicated by acute or chronic illness, the optimal method of adrenal functional testing and the normal range for cortisol response are controversial.",
"   </p>",
"   <p>",
"    The standard ACTH stimulation test (administration of 250 mcg cosyntropin intramuscularly or intravenously, with cortisol levels checked at baseline, 30 and 60 minutes later) is the most widely available and most frequently performed test. Clinicians should note that since the standard stimulation test employs a supraphysiologic dose of ACTH, it is not sensitive in patients with partial or acute pituitary dysfunction. Insulin-induced hypoglycemia or the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test are sometimes necessary to confirm the diagnosis of suspected secondary adrenal insufficiency in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/45\">",
"     45",
"    </a>",
"    ], although these tests are challenging to perform in routine clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of clinically significant adrenal insufficiency in patients with HIV can be further complicated by hypoalbuminemia since total cortisol levels are typically measured. In a study of 66 critically ill patients, the 36 patients with albumin &lt;2.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and subnormal ACTH-stimulated total cortisol concentrations were subsequently found to have normal adrenal function and elevated free cortisol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the above caveats, a standard ACTH test should be performed initially. If this test is normal, but adrenal insufficiency is still suspected, we recommend consultation with an endocrinologist.",
"   </p>",
"   <p>",
"    If adrenal insufficiency is confirmed, a baseline ACTH level is useful to distinguish between a primary and secondary etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high ACTH level indicates primary adrenal insufficiency, which in an HIV-infected patient is most often due to an infiltrative process of the adrenal glands, such as tuberculosis, histoplasmosis, or CMV adrenalitis.",
"     </li>",
"     <li>",
"      A low or normal ACTH level usually implies central adrenal insufficiency. In the latter group, without a known exposure to an exogenous agent that can suppress the HPA axis (eg, corticosteroids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      ), MRI scan of the pituitary should be obtained to exclude an anatomic abnormality (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"       \"Diagnosis of adrenal insufficiency in adults\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the treatment of the HIV-infected patient with glucocorticoid insufficiency is the same as in the HIV-seronegative patient. Glucocorticoid replacement therapy should be initiated using the lowest possible doses (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    15 to 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    that relieve clinical symptoms. Patients with documented adrenal insufficiency require higher doses of glucocorticoids during periods of stress, such as acute illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    may be necessary in the setting of primary adrenal failure with concomitant mineralocorticoid deficiency (usually manifested biochemically by hyponatremia, hyperkalemia and metabolic acidosis).",
"   </p>",
"   <p>",
"    It is not clear whether patients who have elevated basal cortisol levels with a blunted response to standard ACTH stimulation testing require replacement therapy, since some will respond to prolonged (72-hour) ACTH infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22312/abstract/18\">",
"     18",
"    </a>",
"    ]. These challenging cases must be evaluated individually, taking into account the potential benefits on clinical symptoms and the risks of adverse effects. Some practitioners advocate treating these patients with glucocorticoids only during periods of stress, limiting steroid exposure as much as possible (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early AIDS epidemic, endocrine abnormalities were usually due to infiltrative diseases and systemic illness. In the era of potent ART, there has been a decline in opportunistic infections and malignancies, but an increased incidence of metabolic complications, some related to medications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection by a diverse array of organisms, as well as HIV-associated malignancies, has been reported in the pituitary and adrenal glands. Tissue is generally required for a definitive diagnosis, particularly in the patient with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glandular infection and infiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the diagnosis and treatment of pituitary and adrenal disorders in a patient with HIV infection does not differ from that in an immunocompetent individual. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pituitary gland",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior pituitary functional reserve is usually maintained, whereas posterior pituitary function may be abnormal in a patient with untreated advanced AIDS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Alterations in pituitary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The somatotropic axis is influenced by nutritional status and body composition, leading to characteristic abnormalities in patients with AIDS wasting and the HIV-associated lipodystrophy syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'The somatotropic axis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment and treatment of the HIV-infected patient with possible pituitary dysfunction is the same as in an HIV-seronegative patient. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Assessment and treatment of pituitary gland dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adrenal gland",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the prevalence of glucocorticoid deficiency appears to be greater than in the general population, clinically significant adrenal insufficiency remains rare, but should be considered in the patient with AIDS, hypotension, and critical illness. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Alterations in adrenal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low DHEA levels and elevated cortisol to DHEA ratios are found in HIV infection, particularly in the setting of body composition changes due to either lipodystrophy or malnutrition. However, we do NOT recommend routine DHEA replacement therapy due to lack of data supporting its efficacy and safety. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dehydroepiandrosterone replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain medications can lead to cortisol insufficiency or excess. Iatrogenic Cushing's syndrome can result from the coadministration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      and nasal or inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      , whereas medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      can lower circulating cortisol levels through enhanced clearance of cortisol. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Effects of medications on adrenal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A standard ACTH stimulation test should be ordered as the initial approach for evaluation of adrenal function. If adrenal insufficiency is confirmed, an ACTH level should be drawn to help differentiate between primary and secondary adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Assessment and treatment of adrenal dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of the HIV-infected patient with glucocorticoid deficiency is the same as in the HIV-seronegative patient. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Assessment and treatment of adrenal dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/1\">",
"      Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/2\">",
"      Raffi F, Brisseau JM, Planchon B, et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991; 5:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/3\">",
"      Hommes MJ, Romijn JA, Endert E, et al. Hypothyroid-like regulation of the pituitary-thyroid axis in stable human immunodeficiency virus infection. Metabolism 1993; 42:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/4\">",
"      Wilson LD, Truong MP, Barber AR, Aoki TT. Anterior pitutiary and pitutiary-dependent target organ function in men infected with the human immunodeficiency virus. Metabolism 1996; 45:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/5\">",
"      Poretsky L, Can S, Zumoff B. Testicular dysfunction in human immunodeficiency virus-infected men. Metabolism 1995; 44:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/6\">",
"      Graef AS, Gonzalez SS, Baca VR, et al. High serum prolactin levels in asymptomatic HIV-infected patients and in patients with acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1994; 72:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/7\">",
"      Croxson TS, Chapman WE, Miller LK, et al. Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men. J Clin Endocrinol Metab 1989; 68:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/8\">",
"      Chernow B, Schooley RT, Dracup K, et al. Serum prolactin concentrations in patients with the acquired immunodeficiency syndrome. Crit Care Med 1990; 18:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/9\">",
"      Gorman JM, Warne PA, Begg MD, et al. Serum prolactin levels in homosexual and bisexual men with HIV infection. Am J Psychiatry 1992; 149:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/10\">",
"      Collazos J, Ibarra S, Mart&iacute;nez E, Mayo J. Serum prolactin concentrations in patients infected with human immunodeficiency virus. HIV Clin Trials 2002; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/11\">",
"      Ram S, Acharya S, Fernando JJ, et al. Serum prolactin in human immunodeficiency virus infection. Clin Lab 2004; 50:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/12\">",
"      Agarwal A, Soni A, Ciechanowsky M, et al. Hyponatremia in patients with the acquired immunodeficiency syndrome. Nephron 1989; 53:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/13\">",
"      Heijligenberg R, Sauerwein HP, Brabant G, et al. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996; 81:4028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/14\">",
"      Frost RA, Fuhrer J, Steigbigel R, et al. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol (Oxf) 1996; 44:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/15\">",
"      Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/16\">",
"      Koutkia P, Canavan B, Breu J, Grinspoon S. Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 2005; 90:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/17\">",
"      Hutchinson J, Murphy M, Harries R, Skinner CJ. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet 2000; 356:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/18\">",
"      Membreno L, Irony I, Dere W, et al. Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1987; 65:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/19\">",
"      Villette JM, Bourin P, Doinel C, et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab 1990; 70:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/20\">",
"      Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab 1996; 81:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/21\">",
"      Verges B, Chavanet P, Desgres J, et al. Adrenal function in HIV infected patients. Acta Endocrinol (Copenh) 1989; 121:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/22\">",
"      Mayo J, Collazos J, Mart&iacute;nez E, Ibarra S. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med 2002; 162:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/23\">",
"      Bricaire F, Marche C, Zoubi D, et al. Adrenocortical lesions and AIDS. Lancet 1988; 1:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/24\">",
"      Welch K, Finkbeiner W, Alpers CE, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA 1984; 252:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/25\">",
"      Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci 2001; 321:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/26\">",
"      Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987; 82:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/27\">",
"      Schambelan M, Stockigt JR, Biglieri EG. Isolated hypoaldosteronism in adults. A renin-deficiency syndrome. N Engl J Med 1972; 287:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/28\">",
"      Henderson E, Yang JY, Schwartz A. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses 1992; 8:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/29\">",
"      Yang JY, Schwartz A, Henderson EE. Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA. AIDS Res Hum Retroviruses 1993; 9:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/30\">",
"      Yang JY, Schwartz A, Henderson EE. Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro. Biochem Biophys Res Commun 1994; 201:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/31\">",
"      Jacobson MA, Fusaro RE, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. J Infect Dis 1991; 164:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/32\">",
"      Mulder JW, Frissen PH, Krijnen P, et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. J Infect Dis 1992; 165:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/33\">",
"      Laudat A, Blum L, Gu&eacute;chot J, et al. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol 1995; 133:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/34\">",
"      Piketty C, Jayle D, Leplege A, et al. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin Endocrinol (Oxf) 2001; 55:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/35\">",
"      Abrams DI, Shade SB, Couey P, et al. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses 2007; 23:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/36\">",
"      Rabkin JG, McElhiney MC, Rabkin R, et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006; 163:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/37\">",
"      Lo JC, Mulligan K, Tai VW, et al. \"Buffalo hump\" in men with HIV-1 infection. Lancet 1998; 351:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/38\">",
"      Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/39\">",
"      Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/40\">",
"      Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma 2010; 47:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/41\">",
"      Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide. S Afr Med J 2010; 100:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/42\">",
"      Yombi JC, Maiter D, Belkhir L, et al. Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol 2008; 27 Suppl 2:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/43\">",
"      Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther 2009; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/44\">",
"      Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37 Suppl 2:S132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/45\">",
"      Grinspoon SK, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 1994; 79:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22312/abstract/46\">",
"      Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3720 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22312=[""].join("\n");
var outline_f21_50_22312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLANDULAR INFECTION AND INFILTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PITUITARY GLAND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alterations in pituitary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The somatotropic axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effects of antiretroviral therapy on pituitary gland function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment and treatment of pituitary gland dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADRENAL GLAND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alterations in adrenal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dehydroepiandrosterone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effects of medications on adrenal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Assessment and treatment of adrenal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pituitary gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3720|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/32/33292\" title=\"table 1\">",
"      HIV medications affecting pituitary or adrenal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/62/18413\" title=\"table 2\">",
"      OIs HIV endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/10/9387\" title=\"table 3\">",
"      Somatropic axis HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=related_link\">",
"      Hypothalamic-pituitary axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38388?source=related_link\">",
"      Thyroid gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=related_link\">",
"      Treatment of hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_50_22313="Clonidine and related imidazoline poisoning";
var content_f21_50_22313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clonidine and related imidazoline poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22313/contributors\">",
"     Kevin C Osterhoudt, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22313/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22313/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/50/22313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview summarizes the important clinical features and initial management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning (",
"    <a class=\"graphic graphic_table graphicRef63110 \" href=\"UTD.htm?42/27/43452\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    , an alpha-2 adrenergic agonist, is a biochemical derivative of imidazoline that was initially introduced as a topical nasal decongestant over 40 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, clonidine has been primarily utilized for its potent antihypertensive effect. Related imidazolines are found in topical eye and nose decongestants and in the antispasticity agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and related imidazoline intoxication will be reviewed here. The clinical approach to the poisoned patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, about 7000 calls regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    exposure are made annually to regional poison control centers, and serious clinical findings are common [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Clonidine poisoning may occur from exploratory ingestion by young children, transdermal exposure from a clonidine patch, malicious drug administration, suicidal ingestion, or therapeutic error.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    exposure is frequently symptomatic in children, deaths due to pediatric exploratory ingestion of clonidine are rare, with only one reported in a poison control center cohort of 10,060 exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is indicated for the treatment of hypertension in adults, but is also used for anesthetic premedication, spinal anesthesia, opioid detoxification, alcohol withdrawal, smoking cessation, and amelioration of postmenopausal hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. In children, it is used in the treatment of attention deficit disorder with hyperactivity, refractory conduct disorder, and Tourette's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In a mail survey of pediatricians, clonidine was also the second-most commonly prescribed (off-label) medication for treating sleep disturbances in children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Guanabenz and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=see_link\">",
"     guanfacine",
"    </a>",
"    are related alpha-2 adrenergic agonist medications used for hypertension. In addition, guanfacine is used for the treatment of behavioral disturbance in children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imidazoline derivatives, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34064?source=see_link\">",
"     tetrahydrozoline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/24/33152?source=see_link\">",
"     naphazoline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    , and xylometazoline, are found in commercial topical eye and nose decongestants.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=see_link\">",
"     Brimonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/28/36291?source=see_link\">",
"     apraclonidine",
"    </a>",
"    are prescribed for treatment of glaucoma.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     Tizanidine",
"    </a>",
"    is a muscle relaxant used for the treatment of spasticity. Ingestion or systemic absorption of small amounts of these agents can produce toxicity syndromes strikingly similar to that produced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is supplied as 0.1, 0.2, and 0.3 mg tablets and in transdermal patch delivery systems containing 2.5, 5, or 7.5 mg of drug. Clonidine is also available in a combination product containing the diuretic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Toxic dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;No globally applicable minimum toxic dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    has been established. A review of low-dose clonidine poisonings among children details eight children who developed some combination of central nervous system, cardiovascular, or respiratory depression after alleged exposure to just one or two tablets [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, survival has been documented after 1000-fold overdoses in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Topical imidazoles, though structurally similar to clonidine, are more polar than clonidine and less likely to cross the blood-brain barrier. Still, they have been implicated in pediatric poisoning after ingestion of small amounts of drug or after therapeutic use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacological mechanisms through which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    lowers blood pressure and causes sedation are complex and still await full characterization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      stimulates alpha-2 adrenergic receptors and imidazoline receptors which are located primarily in the rostral ventrolateral medulla. This effect leads to decreased sympathetic outflow from the central nervous system and reduced plasma norepinephrine levels [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endothelialium-derived nitric oxide (NO) also plays a role in the antihypertensive effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Further sedative effects may occur from the stimulation of alpha-2 adrenergic receptors in the locus coeruleus, by augmented release of gamma-aminobutyric acid (GABA), and by interaction with opioid and serotonergic receptor systems [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stimulation of alpha-2 adrenergic receptors located in peripheral vascular smooth muscle causes vasoconstriction. This action explains the utility of imidazoline compounds as topically applied vasoconstrictors and the early and transient hypertension that is occasionally seen following",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      overdose [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption, distribution, and elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    vary depending upon the formulation of clonidine and route of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clonidine tablets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics for oral ingestion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    tablets are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bioavailability is 75 to 100 percent.",
"     </li>",
"     <li>",
"      Peak plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      concentrations occur at approximately 2 hours, and absorption is complete by 2.5 hours in hypertensive, fasting adults [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maximal blood pressure reduction occurs between three and eight hours after a routine daily dose [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      in the bloodstream is 20 to 40 percent protein bound and has an apparent volume of distribution of 3.2 to 5.6",
"      <span class=\"nowrap\">",
"       L/kg.",
"      </span>",
"     </li>",
"     <li>",
"      Elimination half-life in therapeutic use ranges from 6 to 24 hours with more than half excreted unchanged in the urine [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clonidine patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    patch formulations are available in doses of 2.5, 5, and 7.5 mg contained in a timed matrix delivery system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      is delivered at a constant rate over seven days.",
"     </li>",
"     <li>",
"      The elimination half life while the patch is adherent varies from 26 to 55 hours.",
"     </li>",
"     <li>",
"      Up to 75 percent of the total dose may remain in a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      patch after seven days of use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning relies on a careful history and physical examination. A rapid overview summarizes the important clinical features and initial management of clonidine poisoning (",
"    <a class=\"graphic graphic_table graphicRef63110 \" href=\"UTD.htm?42/27/43452\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data obtained should include the specific agent, amount ingested, time of ingestion, and any coingestions. Any possible witnesses and emergency medical services (EMS) personnel who may have recovered pill bottles at the scene should be contacted. The patient's pharmacy may provide valuable information regarding prescribed medications, the date of the most recent refill, and the total number of pills dispensed.",
"   </p>",
"   <p>",
"    If the ingestant is unknown, a history of glaucoma or hypertension in an adult patient or household member suggests a possible",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    exposure as does a patch medication prescribed for behavioral disturbance in a pediatric patient or sibling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The circumstances that led to the poisoning should be considered, as suicidal or malicious overdoses may warrant involvement of social services. It is also important to review the medical history for conditions which may predispose patients to the toxic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , such as airway compromise or preexisting cardiac conduction abnormalities.",
"   </p>",
"   <p>",
"    A detailed knowledge of the patient's coingestants and chronic medications is important, as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    exacerbates the hypotension of coingested antihypertensive medications (eg, beta blockers, calcium channel blockers) and the lethargy or coma following ingestion of ethanol, barbiturates, and other sedative hypnotics (eg, benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    ). The clinical approach to the poisoned patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic toxic syndrome, or \"toxidrome,\" associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    consists of central nervous system depression, bradycardia, hypotension, respiratory depression, and small pupil size [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 60 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    exposures that are reported to regional poison control centers result in symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/4\">",
"     4",
"    </a>",
"    ]. However, clinical presentations can vary [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/4,29,30\">",
"     4,29,30",
"    </a>",
"    ]. The relative frequency of findings in children and adults poisoned with clonidine are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef75960 \" href=\"UTD.htm?8/18/8493\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Signs of toxicity are seen within one hour of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    tablet ingestion and new findings rarely appear more than four hours after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    patch exposure through ingestion or self application to the skin may result in signs of toxicity beyond four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A full body search for adherent transdermal patches is an important aspect of the physical examination.",
"   </p>",
"   <p>",
"    Depressed mental status, ranging from lethargy to coma, is the most common finding after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/4,29,30\">",
"     4,29,30",
"    </a>",
"    ]. Miosis, hyporeflexia, and hypotonia often accompany the alteration in mental status and making the differentiation of clonidine poisoning from opioid toxicity difficult (",
"    <a class=\"graphic graphic_table graphicRef56801 \" href=\"UTD.htm?10/12/10443\">",
"     table 3",
"    </a>",
"    ). Transient responsiveness to painful stimuli is more frequently seen in patients poisoned with clonidine than with opioids.",
"   </p>",
"   <p>",
"    Respiratory depression and apnea accompany",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning in a significant number of patients, especially children, and may require immediate airway support [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/4,29,30\">",
"     4,29,30",
"    </a>",
"    ]. Children will often resume breathing upon tactile stimulation.",
"   </p>",
"   <p>",
"    Bradycardia and hypotension are prominent signs of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and related imidazoline toxicity. Sinus bradycardia is the usual rhythm although atrioventricular [AV] block and sinus arrest have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Second-degree AV block or complete AV dissociation are uncommon and should prompt consideration of toxicity from other cardioactive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blockers, or calcium channel blockers (",
"    <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"UTD.htm?28/37/29270\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63951 \" href=\"UTD.htm?10/23/10609\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hypertension occurs transiently in many patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    overdose, particularly after a large ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. In addition, hypertension has been reported in patients with clonidine poisoning who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . Hypertension progressing to hypotension has also been reported after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=see_link\">",
"     guanfacine",
"    </a>",
"    overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/35\">",
"     35",
"    </a>",
"    ]. Hypertensive emergency requiring treatment is very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pallor, hypothermia, and dry mouth may also be seen following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/29,37\">",
"     29,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of coma that deserve consideration when evaluating the patient with suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning (",
"    <a class=\"graphic graphic_table graphicRef65571 \" href=\"UTD.htm?39/19/40254\">",
"     table 4",
"    </a>",
"    ). In the poisoned patient, it is especially important to consider hypoglycemia and potential traumatic brain injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in all poisonings, careful consideration should be given to the potential for coingested toxic agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    exacerbates the lethargy or coma following ingestion of ethanol, barbiturates, and other sedative hypnotics (eg, benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among toxic agents that may cause coma, other centrally acting, though chemically distinct, antihypertensive medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=see_link\">",
"     guanfacine",
"    </a>",
"    , and guanabenz, also decrease sympathetic outflow and mimic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    's toxic effects.",
"   </p>",
"   <p>",
"    The combination of central nervous system depression and pupillary miosis closely resembles the toxic syndrome seen with opioid intoxication, which may be further confused by the variable response of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56801 \" href=\"UTD.htm?10/12/10443\">",
"     table 3",
"    </a>",
"    ). Many other sedative-hypnotic and psychoactive agents may also produce somnolence and bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link\">",
"     \"Opioid intoxication in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative and qualitative testing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    is available from dedicated toxicology reference laboratories with methodology, such as gas chromatography or mass spectroscopy. However, the results usually cannot be obtained in time to be useful for patient management. Thus, specific measurement of clonidine in the urine or other fluids is typically performed for forensic or other nonclinical purposes.",
"   </p>",
"   <p>",
"    Further laboratory evaluation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning varies depending on the circumstances of exposure. A witnessed exploratory ingestion in a toddler or a known therapeutic error in a hospitalized patient may merit little laboratory investigation whereas an unwitnessed suicidal overdose may lead to more extensive testing, especially if clonidine is not the definite cause of symptoms. Other ancillary studies may be indicated in selected patients in whom trauma, infection, or other etiologies besides poisoning are suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following tests in adolescent and adult patients with altered mental function and suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    overdose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bedside glucose determination, to exclude hypoglycemia as the cause of reduced consciousness.",
"     </li>",
"     <li>",
"      Arterial blood gas evaluation or venous blood gas measurement combined with pulse oximetry to assess adequacy of ventilation in patients with serious and persistent respiratory depression.",
"     </li>",
"     <li>",
"      Serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level in patients who ingest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      with suicidal intent.",
"     </li>",
"     <li>",
"      Serum ethanol level, to identify patients at a higher risk for coma and respiratory depression due to coingestion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      and ethanol.",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to evaluate for drug-induced cardiac electrical dysfunction.",
"     </li>",
"     <li>",
"      Chest radiography, if the history or exam suggests the possibility of pulmonary aspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies that may be helpful in selected patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum electrolyte determination, in the setting of likely coingestants, to assess for electrolyte disturbance or metabolic acidosis and to calculate the anion.",
"     </li>",
"     <li>",
"      Serum blood urea nitrogen and creatinine to identify patients with renal insufficiency who may have delayed elimination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      after overdose.",
"     </li>",
"     <li>",
"      Rapid urine pregnancy test in postmenarchal women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a clinical toxicologist is available to provide guidance in managing individual patients. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The management for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and related imidazoline intoxications is the same. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Formulation'",
"    </a>",
"    above.) Almost all clonidine poisoned patients will have good outcomes with attentive supportive care alone. A rapid overview summarizes the important clinical features and initial management of clonidine poisoning (",
"    <a class=\"graphic graphic_table graphicRef63110 \" href=\"UTD.htm?42/27/43452\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    No randomized controlled trials exist to guide specific care. The recommendations for gastrointestinal decontamination and potential antidotal therapy given below are based upon individual reports and case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Basic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management begins with assessment and stabilization of the airway, breathing, and circulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory depression often responds transiently to tactile stimulation of the patient. However, clinicians should proceed with endotracheal intubation and mechanical ventilation if there is any doubt about the patient's ability to breathe adequately on their own or if pulmonary aspiration poses a significant risk.",
"     </li>",
"     <li>",
"      Bradycardia is typically mild, but may respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/29,38\">",
"       29,38",
"      </a>",
"      ]. Isolated hypotension may initially be treated with Trendelenburg positioning and rapid administration of intravenous isotonic crystalloid fluids (normal saline or Ringer's lactate solution).",
"      <br/>",
"      <br/>",
"      Dopamine, or similar pressor agents, may be useful in the minority of patients whose bradycardia or hypotension that does not respond to stimulation, intravenous atropine administration and rapid intravenous infusion of isotonic fluids.",
"     </li>",
"     <li>",
"      Hypertension may be noted early after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      overdose. As hypertension is typically of short duration and is often followed by hypotension, use of antihypertensive therapy is only warranted when there are signs of hypertensive emergency, a rare event after clonidine poisoning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the unlikely event that hypertension must be treated, a short-acting, easily titratable agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      is advised. Beta adrenergic antagonist agents should be avoided as they may lead to unopposed alpha adrenergic action with worsening of hypertension.",
"     </li>",
"     <li>",
"      Hypothermic patients merit external warming. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"       \"Accidental hypothermia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link\">",
"       \"Treatment of hypothermia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     External decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any adherent transdermal patches found on diligent search of the patient's skin during exposure should be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    and related imidazolines bind well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC), the primary means of decontamination in overdose. The recommendation of AC administration following clonidine overdose derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/39\">",
"     39",
"    </a>",
"    ]. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032558#H10032558\">",
"     \"Decontamination of poisoned children\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H26755739#H26755739\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Evidence of efficacy and adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend gastric emptying by gastric lavage or by syrup of ipecac induced emesis in patients who ingest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or related imidazolines based on randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Tablet or liquid preparation",
"    </span>",
"   </p>",
"   <p>",
"    We suggest that patients who present within one to two hours of a known or suspected ingestion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    tablet, related imidazoline tablet, or imidazoline liquid preparation receive AC (1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    maximum dose 50 grams) by mouth or nasogastric tube. Great care must be taken to ensure that the airway is not compromised prior to administration and that pulmonary aspiration risk be minimized. Patients with respiratory depression or coma should first have their airway secured, as needed based on clinical evaluation, prior to AC administration.",
"   </p>",
"   <p>",
"    In patients who present for care more than two hours after ingestion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    tablet, related imidazoline tablet, or imidazoline liquid preparation, we suggest that AC not be given because the likelihood of preventing medication absorption is low and is outweighed by the risk of pulmonary aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Clonidine patch",
"    </span>",
"   </p>",
"   <p>",
"    We suggest the nasogastric administration of whole bowel irrigation (WBI) (500 mL to 1 L of polyethylene glycol per hour) after oral administration of AC (1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    maximum dose 50 grams) in patients who have ingested",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    transdermal patches. In this setting, AC may also prevent delayed absorption of clonidine when administered more than one hour after ingestion. Safe administration of WBI requires attention to the following provisions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should have bowel sounds present and no evidence of gastrointestinal obstruction.",
"     </li>",
"     <li>",
"      Airway adequacy must be assessed and secured, if necessary, prior to the procedure.",
"     </li>",
"     <li>",
"      Nasogastric tube placement must be radiographically confirmed prior to initiation of whole bowel irrigation.",
"     </li>",
"     <li>",
"      The patient should be maintained in an upright position (minimum 45 degree elevation of the head) throughout the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastrointestinal decontamination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Specific treatment measures and antidotal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No true antidote for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or related imidazoline intoxication exists.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    and alpha adrenergic antagonists have been utilized to treat seriously poisoned patients with inconsistent results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Naloxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case reports and case series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    administration has reversed signs of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    poisoning in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/28-30,41\">",
"     28-30,41",
"    </a>",
"    ]. Intravenous doses ranging from 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 10 mg) have been used. Experience with naloxone administration for related imidazolines is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on results from case reports and retrospective case series, we suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoned patients with marked CNS depression and apnea receive intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose: 2 mg; may be repeated every one to two minutes up to 10 mg total dose). This treatment should not delay the timely provision of aggressive supportive care in patients who do not respond. Patients who improve after naloxone administration still warrant hospital admission and intensive monitoring for recurrence of symptoms.",
"   </p>",
"   <p>",
"    Many patients who respond to the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    do not require additional doses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/29\">",
"     29",
"    </a>",
"    ]. However, if altered mental status and respiratory depression recur, we suggest the administration of additional intermittent doses as needed rather than a continuous infusion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    therapy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    overdose has been rarely associated with the onset of acute hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Alpha adrenergic antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonselective alpha adrenergic antagonist, tolazoline, and the specific alpha-2 adrenergic antagonist, yohimbine, have been proposed as potential antidotes to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], but the risk associated with these agents exceeds any expected benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/29,43,45,46\">",
"     29,43,45,46",
"    </a>",
"    ]. Thus, the use of these agents for treatment of clonidine poisoning is strongly discouraged. Selective alpha-1 adrenergic antagonists would be expected to promote hypotension and should also be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications for extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is not amenable to extracorporeal removal (eg, multiple dose AC, hemodialysis, hemoperfusion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further management depends on presence of symptoms and reason for ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients displaying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or related imidazoline toxicity warrant hospital admission and intensive medical care regardless of their response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . These patients typically fully recover within 24 to 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disposition of asymptomatic patients depends on the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    formulation ingested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral imidazoline preparations - Patients who remain asymptomatic at six hours after exploratory or inadvertent ingestion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      tablets, imidazoline tablets, or imidazoline liquids may be discharged home as long as close observation and ability to rapidly return for medical care, if needed, is assured. An extended release formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=see_link\">",
"       guanfacine",
"      </a>",
"      is now marketed, and may warrant longer observation periods.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      patch preparations - Asymptomatic patients who ingest a clonidine transdermal patch should be admitted and closely monitored because signs of poisoning may be delayed for up to 24 hours in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Suicidal overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who ingest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or related imidazolines with intent of self-harm warrant mental health consultation, measurement of serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    levels, and careful evaluation for other coingestants. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients should be evaluated by the mental health provider before discharge from medical care. Psychiatric evaluation should be deferred in symptomatic patients until after they have recovered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADDITIONAL PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is frequently prescribed for behavior problems in children. Clonidine exposure often involves young children who ingest their own medication or that of another child in the household [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22313/abstract/29,47\">",
"     29,47",
"    </a>",
"    ]. Ingestion of as little as one clonidine tablet or one swallow of imidazoline containing eye drops can cause life-threatening toxicity in children.",
"   </p>",
"   <p>",
"    In addition to routine anticipatory guidance regarding poisoning prevention, clinicians should counsel caretakers about measures to prevent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or imidazoline poisonings as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Used transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      patch preparations contain a significant amount of clonidine. These patches should be carefully discarded so that young children cannot find them in the trash. Caretakers should be alerted to the serious toxicity these patches pose if ingested or reapplied to the skin.",
"     </li>",
"     <li>",
"      Topical imidazoline preparations, which are tasteless and highly potent after ingestion, often do not have child-resistant closures and need to be maintained out of reach of children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=see_link&amp;anchor=H376519128#H376519128\">",
"       \"Prevention of poisoning in children\", section on 'Anticipatory guidance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview summarizes the important clinical features and initial management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    poisoning (",
"    <a class=\"graphic graphic_table graphicRef63110 \" href=\"UTD.htm?42/27/43452\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      , an alpha 2 agonist, is a biochemical derivative of imidazoline that causes lethargy, coma, small pupils (miosis), bradycardia, hypotension, transient hypertension, and respiratory depression in overdose. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical Features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ingestion of as little as one",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      tablet or one swallow of imidazoline containing eye drops can cause life-threatening toxicity in children. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Additional pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most signs of toxicity are seen within one hour of ingestion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      tablets and new findings rarely appear more than four hours after exposure. Clonidine patch exposure through ingestion or self application to the skin may develop signs of toxicity beyond four hours. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical Features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      poisoned patients will have good outcomes with attentive supportive care of airway, breathing, and circulation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Basic measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Decontamination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be fully exposed and any adherent transdermal patches should be removed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'External decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who ingest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      tablets or related imidazoline preparations and who present within the one to two hours of known or suspected clonidine ingestion receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) (1",
"      <span class=\"nowrap\">",
"       g/kg,",
"      </span>",
"      maximum dose 50 grams) by mouth or nasogastric tube. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving charcoal. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the likelihood of preventing medication absorption is low and is outweighed by the risk of pulmonary aspiration, we suggest that patients who seek care more than two hours after known or suspected",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      tablet or related imidazoline preparation ingestion not receive AC. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who ingest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      transdermal patches and who present within the first hour receive a single oral dose of AC (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In this setting, AC may also prevent delayed absorption of clonidine when administered more than one hour after ingestion. We suggest that AC be followed by nasogastric whole bowel irrigation with polyethylene glycol&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endotracheal intubation may be necessary in symptomatic patients to avoid aspiration. In addition, gastrointestinal integrity must be assured before initiation of whole bowel irrigation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      emptying the stomach by gastric lavage or syrup of ipecac induced emesis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Specific therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients poisoned with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      or related imidazolines with marked CNS depression and apnea receive intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This treatment should not delay the timely provision of aggressive supportive care in patients who do not respond. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Specific treatment measures and antidotal therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Disposition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We admit the following patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      or related imidazoline ingestion:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All symptomatic patients",
"     </li>",
"     <li>",
"      All patients who ingest transdermal patches",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are suicidal warrant psychiatric evaluation prior to discharge and should also be carefully evaluated for coingestions, including the measurement of an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level",
"     </li>",
"     <li>",
"      Patients who are asymptomatic for six hours after ingestion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      or related imidazoline tablets or liquid, and who are not suicidal, may be discharged home as long as close observation and the ability to return rapidly if care is needed are assured. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/1\">",
"      Lowenstein J. Drugs five years later: clonidine. Ann Intern Med 1980; 92:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/2\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010; 48:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/3\">",
"      Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006; 44:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/4\">",
"      Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med 2002; 156:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/5\">",
"      Nishina K, Mikawa K, Uesugi T, et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. Anesthesiology 2002; 96:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/6\">",
"      Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naloxone. Lancet 1980; 1:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/7\">",
"      Stanley KM, Worrall CL, Lunsford SL, et al. Experience with an adult alcohol withdrawal syndrome practice guideline in internal medicine patients. Pharmacotherapy 2005; 25:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/8\">",
"      Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988; 259:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/9\">",
"      Clayden, JR, Bell, JW, Pellard, P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974; 9:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/10\">",
"      Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/11\">",
"      Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette's syndrome. Lancet 1979; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/12\">",
"      Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/13\">",
"      Schnoes CJ, Kuhn BR, Workman EF, Ellis CR. Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance. Clin Pediatr (Phila) 2006; 45:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/14\">",
"      Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/15\">",
"      Rangan C, Everson G, Cantrell FL. Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings. Pediatr Emerg Care 2008; 24:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/16\">",
"      Spiller HA, Bosse GM, Adamson LA. Retrospective review of Tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol 2004; 42:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/17\">",
"      Lai Becker M, Huntington N, Woolf AD. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics 2009; 123:e305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/18\">",
"      Eddy O, Howell JM. Are one or two dangerous? Clonidine and topical imidazolines exposure in toddlers. J Emerg Med 2003; 25:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/19\">",
"      Romano MJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/20\">",
"      Oliver Rotellar JA, Sedano Monasterio E, Sabate de la Cruz J, Gausi Gene C. Clonidine in thousand-fold overdose. Lancet 1981; 1:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/21\">",
"      Seger DL. Clonidine toxicity revisited. J Toxicol Clin Toxicol 2002; 40:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/22\">",
"      Head GA, Gundlach AL, Musgrave IF. Recent advances in imidazoline receptor research: ligands--localization and isolation--signaling--functional and clinical studies. J Auton Nerv Syst 1998; 72:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/23\">",
"      Talke PO, Caldwell JE, Richardson CA, Heier T. The effects of clonidine on human digital vasculature. Anesth Analg 2000; 91:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/24\">",
"      Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol 1981; 12:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/25\">",
"      Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 1976; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/26\">",
"      Lowenthal DT. Pharmacokinetics of clonidine. J Cardiovasc Pharmacol 1980; 2 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/27\">",
"      MacGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther 1985; 38:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/28\">",
"      Osterhaudt KC. No sympathy for a boy with obtundation. Pediatr Emerg Care 2004; 20:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/29\">",
"      Wiley JF 2nd, Wiley CC, Torrey SB, Henretig FM. Clonidine poisoning in young children. J Pediatr 1990; 116:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/30\">",
"      Spiller HA, Klein-Schwartz W, Colvin JM, et al. Toxic clonidine ingestion in children. J Pediatr 2005; 146:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/31\">",
"      Rapko DA, Rastegar DA. Intentional clonidine patch ingestion by 3 adults in a detoxification unit. Arch Intern Med 2003; 163:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/32\">",
"      Killian CA, Roberge RJ, Krenzelok EP, Stonage CL. \"Cloniderm\" toxicity: another manifestation of clonidine overdose. Pediatr Emerg Care 1997; 13:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/33\">",
"      Williams PL, Krafcik JM, Potter BB, et al. Cardiac toxicity of clonidine. Chest 1977; 72:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/34\">",
"      Osterhoudt KC, Henretig FM. Sinoatrial node arrest following tetrahydrozoline ingestion. J Emerg Med 2004; 27:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/35\">",
"      Minns AB, Clark RF, Schneir A. Guanfacine overdose resulting in initial hypertension and subsequent delayed, persistent orthostatic hypotension. Clin Toxicol (Phila) 2010; 48:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/36\">",
"      Hunyor SN, Bradstock K, Somerville PJ, Lucas N. Clonidine overdose. Br Med J 1975; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     Wiley JF. Clonidine and related imidazoline derivatives. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Burns MJ (Eds), Saunders Elsevier, Philadelphia 2007. p.1001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/38\">",
"      Maggi JC, Iskra MK, Nussbaum E. Severe clonidine overdose in children requiring critical care. Clin Pediatr (Phila) 1986; 25:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/39\">",
"      Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/40\">",
"      Horowitz R, Mazor SS, Aks SE, Leikin JB. Accidental clonidine patch ingestion in a child. Am J Ther 2005; 12:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/41\">",
"      Kappagoda C, Schell DN, Hanson RM, Hutchins P. Clonidine overdose in childhood: implications of increased prescribing. J Paediatr Child Health 1998; 34:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/42\">",
"      Gremse DA, Artman M, Boerth RC. Hypertension associated with naloxone treatment for clonidine poisoning. J Pediatr 1986; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/43\">",
"      Roberge RJ, McGuire SP, Krenzelok EP. Yohimbine as an antidote for clonidine overdose. Am J Emerg Med 1996; 14:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/44\">",
"      Schieber RA, Kaufman ND. Use of tolazoline in massive clonidine poisoning. Am J Dis Child 1981; 135:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/45\">",
"      Olsson JM, Pruitt AW. Management of clonidine ingestion in children. J Pediatr 1983; 103:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/46\">",
"      Shannon M, Neuman MI. Yohimbine. Pediatr Emerg Care 2000; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22313/abstract/47\">",
"      Nichols MH, King WD, James LP. Clonidine poisoning in Jefferson County, Alabama. Ann Emerg Med 1997; 29:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6509 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22313=[""].join("\n");
var outline_f21_50_22313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Formulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Toxic dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clonidine tablets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clonidine patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Basic measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      External decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Tablet or liquid preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Clonidine patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Specific treatment measures and antidotal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Naloxone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Alpha adrenergic antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications for extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Suicidal overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADDITIONAL PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Decontamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/27/43452\" title=\"table 1\">",
"      Clonidine and related imidazoline poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/18/8493\" title=\"table 2\">",
"      Clonidine tox findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/12/10443\" title=\"table 3\">",
"      Manifestations opioid toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/19/40254\" title=\"table 4\">",
"      Causes of coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6509|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/37/29270\" title=\"waveform 1\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?10/23/10609\" title=\"waveform 2\">",
"      ECG third degree AV block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=related_link\">",
"      Prevention of poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=related_link\">",
"      Treatment of hypothermia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_50_22314="Determining eligibility for allogeneic hematopoietic cell transplantation";
var content_f21_50_22314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Determining eligibility for allogeneic hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22314/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22314/contributors\">",
"     H Joachim Deeg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22314/contributors\">",
"     Brenda M Sandmaier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22314/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/50/22314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/50/22314/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/50/22314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H87611135\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is a general term that encompasses a series of procedures in which the patient is treated with chemotherapy, radiation therapy, or both (referred to as the",
"    <span class=\"nowrap\">",
"     &ldquo;preparative/conditioning",
"    </span>",
"    regimen&rdquo;) followed by the infusion of hematopoietic",
"    <span class=\"nowrap\">",
"     stem/progenitor",
"    </span>",
"    cells. HCT can be broadly divided into subtypes based upon the hematopoietic cell donor, the source of hematopoietic progenitor cells, and the preparative regimen. Each of these factors influences efficacy and the short and long-term toxicities associated with the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link&amp;anchor=H83240218#H83240218\">",
"     \"The approach to hematopoietic cell transplantation survivorship\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic HCT (allo-HCT) uses hematopoietic progenitor cells collected from someone other than the individual with the disorder. Allo-HCT is increasingly used to treat a variety of hematologic neoplasms, nonmalignant marrow disorders (acquired and inherited), and inborn errors of metabolism. Eligibility for allo-HCT varies across countries and institutions. Ultimately, decisions regarding transplant eligibility should be made on a case-by-case basis based on a risk-benefit assessment, and the needs and wishes of the patient. Here we discuss eligibility for allo-HCT. Eligibility for autologous HCT, the use of HCT in specific disease settings, and the short- and long-term complications of HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=see_link\">",
"     \"Determining eligibility for autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7277724\">",
"    <span class=\"h1\">",
"     IMPACT OF UNDERLYING DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7278017\">",
"    <span class=\"h2\">",
"     Disease-related indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, allo-HCT was offered to patients with hematologic malignancies who had exhausted other treatment modalities, and eligibility was largely based upon whether the patient was in adequate physical condition to tolerate the anticipated toxicity. Currently, a decision to perform allo-HCT must include an assessment of the underlying disease state and whether allo-HCT is likely to offer superior results when compared with other treatment options. The risks of morbidity and mortality associated with allo-HCT must be compared with those of other treatment approaches.",
"   </p>",
"   <p>",
"    The role of allo-HCT in specific diseases is discussed in more detail separately. In general, allo-HCT may be considered in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute myeloid leukemia &mdash; As post-remission therapy for patients in first or subsequent remission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H14#H14\">",
"       \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Myeloablative allogeneic transplantation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H21584407#H21584407\">",
"       \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Hematopoietic cell transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute lymphoblastic leukemia &mdash; As post-remission therapy for patients in first or subsequent remission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3497?source=see_link&amp;anchor=H4420451#H4420451\">",
"       \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\", section on 'Allogeneic HCT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link&amp;anchor=H11#H11\">",
"       \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Allogeneic transplantation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic lymphocytic leukemia &mdash; Patients refractory to or relapsing after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -containing regimens. Rarely, young patients with high risk disease could be considered for non-myeloablative allo-HCT at first complete or partial remission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"       \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic myeloid leukemia &mdash; As part of the initial management of patients with accelerated phase disease or blast crisis following induction with a tyrosine kinase inhibitor (TKI) and for patients with relapsed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      TKI resistant or intolerant disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"       \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral T cell lymphoma &mdash; Treatment of chemotherapy sensitive relapsed disease or as part of the initial management of high risk disease (eg, adult T cell",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Allogeneic HCT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment and prognosis of adult T cell leukemia-lymphoma\", section on 'Hematopoietic cell transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Follicular lymphoma &mdash; Treatment of chemotherapy sensitive relapsed disease or disease that has progressed to a clinically aggressive histology (eg, diffuse large B cell lymphoma). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse large B cell lymphoma &mdash; Treatment of chemotherapy sensitive relapsed disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Allogeneic HCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonhematologic malignancies &mdash; Treatment of neuroblastoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link&amp;anchor=H1337816#H1337816\">",
"       \"Treatment and prognosis of neuroblastoma\", section on 'Other approaches'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonmalignant inherited and acquired marrow disorders &mdash; Treatment of sickle cell anemia, beta-thalassemia major, refractory Diamond-Blackfan anemia, myelodysplastic syndrome, idiopathic severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, Fanconi anemia, amegakaryocytosis, or congenital thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"       \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link\">",
"       \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=see_link\">",
"       \"Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link\">",
"       \"Hematopoietic cell transplantation in sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link\">",
"       \"Shwachman-Diamond syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &mdash; Treatment of autoimmune diseases and the treatment of children and adults with inborn errors in metabolism and congenital immune deficiencies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"       \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"       \"Adrenoleukodystrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35082?source=see_link\">",
"       \"Complications and management of the mucopolysaccharidoses\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"       \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15176?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID) with JAK3 deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link\">",
"       \"Chronic granulomatous disease: Treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=see_link\">",
"       \"Krabbe disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4724?source=see_link\">",
"       \"NK cell deficiency syndromes: Treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"       \"DiGeorge syndrome: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link\">",
"       \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allo-HCT is also being studied for a variety of disorders (eg, multiple myeloma) within the context of clinical trials. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     clinicaltrials.gov",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, there are no accepted guidelines regarding indications for allo-HCT, and recommendations differ between transplant centers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/1\">",
"     1",
"    </a>",
"    ]. For malignant disorders, disease stage at the time of HCT and cytogenetic abnormalities have consistently been identified as the strongest determinants of relapse after allo-HCT. These factors are closely linked to the underlying diagnosis and prior treatment. Many pre-HCT factors such as patient age, type of disease, genetic determinants, and most comorbid conditions are not modifiable. However, assuming that a suitable donor is available, clinicians have some control over the timing of allo-HCT and thereby the disease stage when allo-HCT is carried out.",
"   </p>",
"   <p>",
"    General issues that complicate recommendations regarding the timing and efficacy of allo-HCT include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have received more cytotoxic therapy before allo-HCT are more likely to be in worse physical condition and less likely to tolerate allo-HCT. As an example, a patient with refractory disease is very likely to have received twice the amount or more of prior therapy (chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation) before allo-HCT than that received by a patient in first remission. Thus, it is difficult to separate the effect of prior therapy from disease status in such patients.",
"     </li>",
"     <li>",
"      There is a general lack of randomized trials comparing allo-HCT with nontransplant strategies. Instead, investigators have often relied on a &ldquo;genetic randomization&rdquo; in which patients are assigned to treatment with or without allo-HCT based upon the presence or absence of an HLA-matched sibling donor. Patients without an HLA-matched sibling are assigned to treatment with either chemotherapy alone or autologous HCT, depending upon the trial design. This strategy does not take into account the availability of alternative donors including HLA-matched unrelated donors.",
"     </li>",
"     <li>",
"      Chemotherapy and radiation therapy programs change over time as new drugs and techniques are developed. Clinicians must figure out how to incorporate data regarding new therapies within a context that has previously shown a benefit from allo-HCT. Patients referred for allo-HCT may have been exposed to chemotherapeutic or biologic agents whose impact on allo-HCT is unknown. Patients who have received these regimens may be more refractory to the effects of allo-HCT than patients exposed to different agents in the past.",
"     </li>",
"     <li>",
"      Nonmyeloablative (NMA) or reduced intensity (RIC) conditioning regimens have allowed for allo-HCT in older patients and patients with comorbidities. As a result, there is a broad spectrum of preparative regimens suitable for various disease categories and patient populations (",
"      <a class=\"graphic graphic_figure graphicRef87814 \" href=\"UTD.htm?26/40/27278\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/2\">",
"       2",
"      </a>",
"      ]. There appears to be a higher relapse rate with",
"      <span class=\"nowrap\">",
"       NMA/RIC",
"      </span>",
"      conditioning in several disease categories [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/3\">",
"       3",
"      </a>",
"      ]. As such, the disease status becomes a central issue when considering",
"      <span class=\"nowrap\">",
"       NMA/RIC",
"      </span>",
"      allo-HCT. Additional therapy may be administered to decrease tumor bulk before allo-HCT to increase the probability of post-HCT success [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The availability of RIC regimens has also allowed for second transplantations to be carried out after failure of a previous (autologous or allogeneic) transplant after a high-dose regimen, a situation where repeat conditioning with high-dose therapy is expected to cause prohibitive toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/4,6,7\">",
"       4,6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ongoing trials are assessing the role of allo-HCT in other settings and tumor types. Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institute of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7278633\">",
"    <span class=\"h2\">",
"     Disease type and status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aggressiveness of the underlying disease and the disease status (eg, complete remission, partial remission) at the time of transplant have a considerable impact on the long-term survival of patients undergoing allogeneic HCT for malignancies. These variables have made the results of studies of transplantation across disease entities difficult to analyze.",
"   </p>",
"   <p>",
"    A disease risk index was created using data from 1539 patients who underwent allogeneic HCT at Dana-Farber Cancer",
"    <span class=\"nowrap\">",
"     Institute/Brigham",
"    </span>",
"    and Women&rsquo;s Hospital from 2000 to 2009, and was validated in an independent cohort of 672 patients who underwent transplant at the Fred Hutchinson Cancer Research Center [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/8\">",
"     8",
"    </a>",
"    ]. Sixteen defined underlying diseases were categorized as low risk (eg, AML with favorable cytogenetics, CLL, CML, indolent B cell NHL), high risk (eg, AML or MDS with adverse cytogenetics, extranodal T cell lymphoma), or intermediate risk (eg, all others). Disease stage was categorized as low risk (eg, complete remission, first partial remission, untreated disease) or high risk (eg, induction failure, active relapse, accelerated or blast phase CML). These two ratings were then combined to define four risk groups with significantly different estimated rates of overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) at four years (",
"    <a class=\"graphic graphic_table graphicRef88591 \" href=\"UTD.htm?22/19/22846\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef88592 \" href=\"UTD.htm?34/18/35109\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3203004\">",
"    <span class=\"h1\">",
"     PRETRANSPLANT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best determine the likelihood that a patient with an indication for allo-HCT is an appropriate candidate for the procedure, a pretransplant assessment must establish the extent of disease and provide information about the individual&rsquo;s comorbidities that are likely to impact outcomes. This assessment varies by institution.",
"   </p>",
"   <p>",
"    It is our practice to perform the following pretransplant assessment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detailed history &mdash; While all elements of the patient&rsquo;s history are pertinent, issues particularly relevant to potential complications include: performance status (",
"      <a class=\"graphic graphic_table graphicRef57945 \" href=\"UTD.htm?3/29/3549\">",
"       table 2",
"      </a>",
"      ), psychological history, prior therapies, transfusion history, drug allergies (especially to antibiotics), and a detailed infection history (especially a history of aspergillus infection or tuberculosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation for infection before hematopoietic cell transplantation\", section on 'Recipient'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical examination with particular attention to the oral cavity (a potential source of infection) and central nervous system. A dental examination and dental radiographs allow for the maximization of dental status prior to transplant.",
"     </li>",
"     <li>",
"      Laboratory studies include HLA testing, complete blood count with differential, chemistries with liver and renal function and electrolytes, and an assessment of prior exposure to various infectious agents (",
"      <a class=\"graphic graphic_table graphicRef71688 \" href=\"UTD.htm?24/46/25323\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"       \"Evaluation for infection before hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chest radiograph, an electrocardiogram, and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"       \"Noninvasive methods for measurement of left ventricular systolic function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary function test, including DLCO. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"       \"Overview of pulmonary function testing in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disease-specific restaging studies &mdash; This assessment usually includes a computed tomography (CT) scan or combined positron emission",
"      <span class=\"nowrap\">",
"       tomography/CT",
"      </span>",
"      scan for patients with lymphoma. Patients with leukemia or lymphoma should undergo a bone marrow biopsy to assess for involvement and a lumbar puncture with cytologic examination in order to evaluate for meningeal involvement. Patients with meningeal involvement usually require intrathecal chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cranial radiation prior to transplantation. Similarly, parenchymal involvement of the central nervous system may increase the risk of cerebral bleeding during the transplantation procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link&amp;anchor=H7#H7\">",
"       \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'After treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"       \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children, men, and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies may be required depending upon signs and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24292817\">",
"    <span class=\"h1\">",
"     IMPACT OF INDIVIDUAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decision to proceed with allo-HCT must take into consideration multiple factors regarding the patient&rsquo;s physical condition. Some studies have evaluated the impact of individual parameters (eg, age, performance status, cardiopulmonary function), while others have created scoring systems to evaluate the effects of multiple parameters. These are described in the following sections. None of these factors represents an absolute contraindication to allo-HCT. Instead, they must be carefully weighed within the context of the clinical scenario. (See",
"    <a class=\"local\" href=\"#H24292859\">",
"     'Determining eligibility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24292824\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incorporation of age cutoffs into eligibility criteria for allo-HCT is controversial. Historically, myeloablative allo-HCT has been limited to patients &le;55 years due to the expected",
"    <strong>",
"    </strong>",
"    toxicity associated with the procedure. The development of transplantation conditioning regimens",
"    <strong>",
"    </strong>",
"    of lower intensity (eg, nonmyeloablative, reduced intensity) has allowed allo-HCT to be carried out with less",
"    <strong>",
"    </strong>",
"    toxicity than observed in the past and has permitted transplantation",
"    <strong>",
"    </strong>",
"    of patients who hitherto had not been considered candidates. While lower intensity regimens appear to be associated with less toxicity, they result in a greater risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/9\">",
"     9",
"    </a>",
"    ]. Many centers continue to use an age cutoff of 55 years for myeloablative allo-HCT, but allow for lower intensity allo-HCT in physically fit patients up to age 75 years.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"    </strong>",
"    median age of transplanted patients has increased continuously",
"    <strong>",
"    </strong>",
"    over the past few decades with reports including patients up to age 75 years. The Center for International Blood and Marrow Transplantation",
"    <strong>",
"    </strong>",
"    Research (CIBMTR) database shows a median patient age of",
"    <strong>",
"    </strong>",
"    25, 39, and 46 years in the 1980s, in the 1990s, and in the first decade of this century, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Transplants performed between 2002 and 2009 included a substantial percentage of patients &gt;50 years (44 percent) and &gt;60 years (20 percent).",
"   </p>",
"   <p>",
"    The factors driving allo-HCT eligibility and the patient&rsquo;s goal of therapy may change with age. In younger patients, decisions regarding HCT are primarily governed by disease risk and donor availability, and allo-HCT aims to add many more years of life. In older patients, the presence of comorbid conditions and the suitability of conditioning regimens play a central role in the decision process and patients may feel more strongly about quality of life (QOL) during whatever time remains. In either case, QOL can be significantly impaired by transplantation-related complications, in particular graft-versus-host disease and its treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a description of studies that have investigated the impact of recipient age on outcomes after HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study from the European Bone Marrow Transplantation (EBMT) group analyzed the impact of age on the outcomes of 1333 older adults (age 50 to 74 years) who underwent myeloablative (38 percent) or reduced intensity allo-HCT from HLA-identical siblings (61 percent) or unrelated donors for the treatment of MDS or secondary AML [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/11\">",
"       11",
"      </a>",
"      ]. Estimated four-year survival for all patients was 31 percent. There was no significant association between age and relapse or non-relapse mortality. Relapse was significantly more likely in patients with advanced disease and those who underwent reduced-intensity conditioning. In contrast, non-relapse mortality was greater in those with advanced stage disease, the use of unrelated donors, and reduced-intensity conditioning regimen.",
"     </li>",
"     <li>",
"      In another analysis from the CIBMTR, 1080 older adults (&gt;40 years) underwent reduced intensity conditioning followed by allo-HCT for MDS or AML in first remission from 1995 to 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/12\">",
"       12",
"      </a>",
"      ]. Among those with AML, estimated two-year survival was 44, 50, 34, and 36 percent among those ages 40 to 54, 55 to 59, 60 to 64, or older than 64 years, respectively. Two-year overall survival was correlated with pre-HCT performance status. Chronologic age did not impact rates of non-relapse mortality, relapse, or graft-versus-host disease (GVHD).",
"     </li>",
"     <li>",
"      An analysis of 372 patients aged 60 to 75 years enrolled in prospective clinical trials of nonmyeloablative allo-HCT reported five-year cumulative incidences of non-relapse mortality and relapse of 27 and 41 percent, respectively, and overall and progression-free survival rates of 35 and 32 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/13\">",
"       13",
"      </a>",
"      ]. There was no statistically significant difference in these outcomes when stratified by age. Greater age was associated with increased bacterial infections and hospitalizations. The incidence of chronic GVHD and the rate of resolution were similar to that seen in younger patients treated with HCT. Two-thirds of survivors had resolution of their GVHD and returned to near-normal physical function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronologic age alone should not be the sole criteria used to determine eligibility for allo-HCT, but may impact the choice of conditioning regimen. Although it is difficult to agree on parameters to define biologic age, age must be taken into consideration in the decision process. Even in the absence of clinically apparent comorbidities, changes in organ function with age may modify drug metabolism or excretion and contribute to differences in outcome compared with younger patients. As an example, increasing age is associated with decreased glomerular filtration rate and is a risk factor for the development of chronic kidney disease after allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Similarly, increasing age is associated with decreased forced expiration volume at one second, which might interfere with airway clearance and infection prevention after HCT. Therefore, it is important to consider age as a predictor of how well (or poorly) a patient is expected to tolerate not only the transplantation regimen but also the management after HCT, in particular GVHD and its treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19386571\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for pulmonary, cardiac, liver, and kidney dysfunction is performed in an attempt to identify patients at increased risk for complications and to help guide therapy. Patients with organ dysfunction prior to allo-HCT are expected to have more complications with the procedure. In addition, knowledge of underlying organ dysfunction can guide therapy decisions to minimize further toxicity. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pulmonary disease",
"      </strong>",
"      &mdash; Historically, a corrected DLCO of 60 percent or greater has been required for allo-HCT eligibility. However, a subset of patients with DLCO less than 60 percent can be transplanted successfully. This is particularly important for patients with autoimmune diseases involving the lungs who are considering HCT. As an example, a study from the Fred Hutchinson Cancer Research center evaluated the impact of pulmonary function as part of the PAM score that also includes transplant donor type, disease risk, and planned transplantation regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/17\">",
"       17",
"      </a>",
"      ]. This analysis showed that the discriminating capacity of PAM was superior to DLCO and that patients with DLCO less than 60 percent could be transplanted. Patients with known pulmonary dysfunction should avoid conditioning regimens, such as BCNU-based regimens and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      plus total body irradiation, which are known to decrease diffusion capacity. (See",
"      <a class=\"local\" href=\"#H3520624\">",
"       'PAM score'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=see_link\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac disease",
"      </strong>",
"      &mdash; While life-threatening cardiac complications are uncommon following allo-HCT, the transplant procedure is associated with sub-acute cardiac injury even in patients with normal cardiac function pretransplant. This cardiac injury is assumed to be of greater impact in patients with less cardiac reserve. Cardiac risk factors should be minimized in all patients prior to transplant (eg, smoking, obesity, hyperlipidemia, hypertension, hyperglycemia). The degree of cardiac dysfunction allowed depends largely upon the underlying disease and conditioning regimen. In general, patients with a left ventricular ejection fraction (LVEF) &lt;40 percent or uncontrolled coronary artery disease or uncontrolled arrhythmias are not considered candidates for allo-HCT. A reduced ejection fraction and a history of congestive heart failure have a strong association with cardiotoxicity following transplant.",
"     </li>",
"     <li>",
"      <strong>",
"       Liver dysfunction",
"      </strong>",
"      &mdash; A substantial percentage of patients with hematologic malignancies have abnormalities on liver function tests. Causes include those seen in patients without malignancy (eg, hepatitis, alcohol abuse, hepatic steatosis) and iron overload due to a large number of previous transfusions. Patients with abnormal liver function tests should undergo a detailed workup for etiology, ideally in consultation with a hepatologist. Patients with increased transaminases are at increased risk of developing veno-occlusive disease (VOD) post-HCT. Other risk factors for VOD post-HCT include a history of VOD and a history of exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"       gemtuzumab ozogamicin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"       \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Renal dysfunction",
"      </strong>",
"      &mdash; The impact of renal dysfunction on transplant eligibility largely depends upon the planned preparative regimen and underlying disease. Adequate renal function is important due to the potential for exposure to many nephrotoxic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , aminoglycosides and amphotericin) following transplant. Patients with renal failure must be approached with caution since many of the clinical trials evaluating conditioning regimens have mainly studied patients with serum creatinine &lt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or Cr CL &gt;50 to 60.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3520542\">",
"    <span class=\"h2\">",
"     Infectious disease status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for infectious diseases before allo-HCT is designed to prevent post-transplant infections by defining specific infection control policies and antimicrobial prophylaxis and therapy, which will be necessary after transplantation. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seropositivity for HIV, hepatitis B, or hepatitis C does not exclude patients from undergoing allo-HCT, but does affect transplant care. Patients with these infections need further evaluation regarding the status of the infection, ideally in consultation with an infectious disease expert. Patients with hepatitis B or hepatitis C are at increased risk of viral reactivation after transplant, even if the infection appears to be resolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link&amp;anchor=H4261285#H4261285\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\", section on 'Allogeneic transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3520363\">",
"    <span class=\"h2\">",
"     Weight and nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient weight is not used as a criterion for transplant eligibility, but may affect drug delivery and dosage considerations. Patients with obesity, anorexia, cachexia, or malnutrition should be evaluated by a dietician to maximize their nutritional status before and during the transplant procedure. Obesity should not exclude patients from undergoing allo-HCT.",
"   </p>",
"   <p>",
"    Several analyses examined the impact of patient weight on transplantation outcome with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. When compared with patients closer to ideal body weight, patients who are severely underweight or obese appear to have inferior outcomes following allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Inferior outcome in underweight patients may be related to aggressive pre-HCT therapy, resulting in a negative nitrogen balance and wasting. Inferior outcomes in overweight patients may be related to general deconditioning and reduced activity; physical constraints regarding the care of obese patients who are too ill to care for themselves; and an increased incidence of infections. In addition, inferior outcomes may reflect differences in the volume of distribution of drugs and the impact of weight on pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24292831\">",
"    <span class=\"h1\">",
"     RISK ASSESSMENT SCORING SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of composite scoring systems are available for estimating mortality risk in patients considering allo-HCT. Of these, the three most commonly used assessments are the European Group for Blood and Marrow Transplantation (EGBMT) risk assessment score for allogeneic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/24\">",
"     24",
"    </a>",
"    ], the Pretransplant Assessment of Mortality (PAM) score [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/25\">",
"     25",
"    </a>",
"    ], and the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potentially important issue is that mortality rates after allo-HCT have decreased since these tools were created. A retrospective single-center study of 1418 patients who underwent allo-HCT from 1993 through 1997 and 1148 patients who were transplanted from 2003 through 2007 reported a significant decrease in non-relapse mortality (odds ratio 0.48, 95% CI 0.40-0.57) and overall mortality (odds ratio 0.59, 95% CI 0.52-0.67) in the patients in the latter group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/28\">",
"     28",
"    </a>",
"    ]. Similar results were reported in a study of 5972 patients younger than age 50 years undergoing myeloablative conditioning and allo-HCT for AML in first or second complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/29\">",
"     29",
"    </a>",
"    ]. This benefit probably reflects shifts in conditioning regimens, preferred stem cell source, graft-versus-host disease prophylaxis, and other supportive measures.",
"   </p>",
"   <p>",
"    There are few studies comparing these risk scores. One study compared the PAM model with the HCT-CI and found that a modified HCT-CI, allowing for risk group stratification different from that used in the original description, was the best predictor of non-relapse mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/30\">",
"     30",
"    </a>",
"    ]. An additional analysis involving data on 286 patients transplanted at a French center found the comorbidity indices to have little discriminating power but acknowledged that many children did not have pulmonary function tests available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While future studies will be needed to validate these scoring systems and other available comorbidity scores [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/26,27,32\">",
"     26,27,32",
"    </a>",
"    ], including the Karnofsky performance status [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/33\">",
"     33",
"    </a>",
"    ], all can serve to help patients better appreciate their mortality risk after allo-HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3520617\">",
"    <span class=\"h2\">",
"     EGBMT score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Group for Blood and Marrow Transplantation (EGBMT) devised a risk score based on five separate characteristics, which predicted treatment-related mortality and five-year overall survival following allo-HCT for patients with chronic myeloid leukemia (CML) (",
"    <a class=\"graphic graphic_table graphicRef67260 \" href=\"UTD.htm?35/31/36348\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/24\">",
"     24",
"    </a>",
"    ]. This risk score was later validated for CML using separate data from the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/34\">",
"     34",
"    </a>",
"    ] and subsequently for predicting survival, treatment-related mortality, and death from relapse for those transplanted for hematologic disease in general (ie, CML, AML, ALL, MDS, myeloma, non-Hodgkin lymphoma, aplastic anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H4#H4\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3520624\">",
"    <span class=\"h2\">",
"     PAM score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators at Seattle constructed a Pretransplantation Assessment of Mortality (PAM) score incorporating the following eight pretransplant clinical variables including disease risk (factors associated with a significantly increased risk of death at two years are shown in parentheses) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient age (&gt;50 years)",
"     </li>",
"     <li>",
"      Donor type (unrelated or mismatched related)",
"     </li>",
"     <li>",
"      Disease risk (all conditions with the exception of CML in chronic phase, refractory anemia, aplastic anemia, Blackfan-Diamond syndrome)",
"     </li>",
"     <li>",
"      Conditioning regimen (all regimens except nonmyeloablative)",
"     </li>",
"     <li>",
"      Serum creatinine (&gt;1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or &gt;106",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum alanine aminotransferase level (&gt;49",
"      <span class=\"nowrap\">",
"       units/L)",
"      </span>",
"     </li>",
"     <li>",
"      FEV1 (&le;80 percent of normal)",
"     </li>",
"     <li>",
"      Carbon monoxide diffusing capacity (&lt;70 percent of normal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By applying weighting factors derived from a multivariate analysis, they obtained a score ranging from 8 to 50, which was found to predict two-year mortality in early and late validation groups as well as three separate groups of patients with CML, AML, or MDS. As an example, the estimated two-year mortality for patients with CML and the following risk scores were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score 9 to 16 &mdash; 14 percent two-year mortality; hazard ratio (HR) 1.0",
"     </li>",
"     <li>",
"      Score 17 to 23 &mdash; 32 percent mortality; HR 2.5, 95% CI 1.8-3.6",
"     </li>",
"     <li>",
"      Score 24 to 30 &mdash; 60 percent mortality; HR 5.8, 95% CI 4.1-8.3",
"     </li>",
"     <li>",
"      Score 30 to 44 &mdash; 83 percent mortality; HR 12.0, 95% CI 7.6-19",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3520631\">",
"    <span class=\"h2\">",
"     HCT-CI score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Charlson Comorbidity Index (CCI) is commonly used to predict the impact of comorbidities on mortality from various medical conditions including solid malignancies. However, many of the comorbidities assessed in the original CCI are exclusion criteria for allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/32\">",
"     32",
"    </a>",
"    ]. As such, a modified hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was created for this patient population (",
"    <a class=\"graphic graphic_table graphicRef59272 \" href=\"UTD.htm?7/48/7950\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This index weighs 17 possible comorbidities for a score ranging from 0 to 29. In a validation cohort of 346 patients undergoing allo-HCT, rates of two-year non-relapse mortality for patients with scores of 0, 1, 2, 3, and 4 or more were 14, 22, 19, 41, and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/26\">",
"     26",
"    </a>",
"    ]. The HCT-CI has also been used to predict non-relapse mortality and overall survival in pediatric patients undergoing a first allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/36\">",
"     36",
"    </a>",
"    ]. The HCT-CI strictly considers only pre-HCT patient characteristics, in particular cardiovascular, gastrointestinal, hepatic, and renal dysfunction along with antecedent solid cancer.",
"   </p>",
"   <p>",
"    Numerous reports have shown increased mortality and lower survival with increasing HCT-CI scores. Patients with scores of 3 or higher generally had significantly inferior survival, often half the probability of patients without comorbidities. A score of 3 could result, for example, from a combination of atrial fibrillation with diabetes mellitus and a body mass index of more than 35 or an active infection in a patient with a creatinine of more than 177 micrometers or a prior diagnosis of breast cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of results in patients with chronic myelomonocytic leukemia, a score of 3 or higher reduced the probability of long-term survival from 54 to less than 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, 391 patients with AML and 186 patients with MDS underwent nonmyeloablative (NMA, 125 patients) or myeloablative (MA, 452 patients) conditioning followed by allo-HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/38\">",
"       38",
"      </a>",
"      ]. Patients receiving NMA conditioning were older and were more likely to have high HCT-CI scores, to receive an unrelated transplant, and to have been heavily pretreated. There were higher relapse rates following NMA conditioning. Estimated rates of two-year survival varied by HCT-CI score, disease risk, and conditioning regimen as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HCT-CI scores of zero to 2 undergoing NMA conditioning with low or high risk disease &mdash; 70 and 57 percent, respectively",
"     </li>",
"     <li>",
"      HCT-CI scores of zero to 2 undergoing MA conditioning with low or high risk disease &mdash; 78 and 50 percent, respectively",
"     </li>",
"     <li>",
"      HCT-CI scores of 3 undergoing NMA conditioning with low or high risk disease &mdash; 41 and 29 percent, respectively",
"     </li>",
"     <li>",
"      HCT-CI scores of 3 undergoing MA condition with low or high risk disease &mdash; 45 and 25 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of 372 patients age 60 to 75 years enrolled on prospective clinical trials of nonmyeloablative allogeneic HCT, HCT-CI predicted survival [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The HCT-CI was validated in a prospective, multicenter study of 1937 patients receiving HCT in Italy from 2008 to 2011 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/39\">",
"       39",
"      </a>",
"      ]. Estimated two-year non-relapse mortality rates were 14.7, 21.3, and 27.3 percent for patients with HCT-CI scores of 0, 1 to 2, and &ge;3, respectively. Corresponding rates of overall survival at two years were 56.4, 54.5, and 41.3 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are important observations that show that the patient&rsquo;s condition, including comorbidities and performance status, which presumably reflects biologic age, is of equal importance to disease status when assessing a patient&rsquo;s suitability for HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3519395\">",
"    <span class=\"h1\">",
"     DONOR AVAILABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of a donor is a critical element contributing to the success of allo-HCT. There are several possible sources for these cells:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An identical twin (syngeneic, HLA identical)",
"     </li>",
"     <li>",
"      A sibling, relative, or unrelated donor (which can be HLA identical, haploidentical, or mismatched)",
"     </li>",
"     <li>",
"      Umbilical cord blood (which can be HLA identical, haploidentical, or mismatched)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General issues involved in donor selection for HCT and the decision as to which donor source to utilize depends to a large degree upon the clinical situation and the approaches employed at the individual transplant center. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24292838\">",
"    <span class=\"h1\">",
"     RACE, SOCIAL, AND ECONOMIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final decision to perform an allo-HCT must take into account the psychosocial and financial support structure available to the patient. A plan must be in place to care for the patient&rsquo;s usual responsibilities and dependents during the prolonged hospital stay.",
"   </p>",
"   <p>",
"    The patient&rsquo;s living situation must be taken into consideration. Patients are immunocompromised following allo-HCT and are therefore at increased risk for infectious complications, especially if exposed to large crowds. As such, patients who are homeless are unlikely to be able to get the needed care post-transplant. Similarly, transportation costs may become significant for patients who do not live near the transplant center. Some centers require that the patient have available or hire a full-time caregiver during the peri-transplant period, and this may be cost prohibitive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective studies have also suggested that low socioeconomic status has a negative impact on the success of HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/41\">",
"     41",
"    </a>",
"    ]. Low socioeconomic status is correlated with a lower likelihood of health insurance, which may be associated with poor health maintenance, and the need to delay HCT. Postponement or delayed referral may be associated with more advanced disease, although such an explanation was not supported by one analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/42\">",
"     42",
"    </a>",
"    ]. Although many patients have health insurance that would cover allo-HCT, even patients with insurance coverage often have a lifetime maximum coverage on insurance contracts, and the cost for allo-HCT and subsequent medical care may exceed that maximum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, patients may incur major out-of-pocket expenses, thereby exhausting their savings, or even being forced to sell their home. Expenses are due not only to direct medical costs, but also the need for the patient&rsquo;s partner or other family members, serving as caregivers, to take a leave from work, thus incurring a loss of income and the frequent need to rent an apartment close to the medical center to allow for appropriate treatment of the patient. Therefore, families must weigh this enormous investment against the probability of long-term success.",
"   </p>",
"   <p>",
"    There are disparities in the use of allo-HCT among patients of different races and ethnicities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/44\">",
"     44",
"    </a>",
"    ]. Studies investigating this association are complicated by the understanding that race is a complex social, cultural, and political construct, rather than a biologic concept [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/45\">",
"     45",
"    </a>",
"    ]. A retrospective analysis, summarizing data from four states, showed that blacks were less likely than whites to undergo HCT for leukemia or lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/46\">",
"     46",
"    </a>",
"    ]. Results of subsequent studies have been mixed, with some confirming this difference and others not showing a difference [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Factors that may contribute to this include health insurance coverage, educational status, and health literacy.",
"   </p>",
"   <p>",
"    In addition, retrospective studies have suggested that black patients may have inferior survival rates following allo-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/41,42,49\">",
"     41,42,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 2221 allo-HCT recipients reported that black race was associated with significantly higher mortality rates than observed in whites (HR = 1.65) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/42\">",
"       42",
"      </a>",
"      ]. Blacks had more severe acute GVHD and higher non-relapse mortality following related and unrelated allo-HCT. A matched cohort analysis showed no correlation of higher mortality with socioeconomic status, suggesting that differences may be the result of currently unidentified genetic polymorphisms.",
"     </li>",
"     <li>",
"      In an analysis of 6207 patients undergoing unrelated allo-HCT, blacks (but not Hispanics or",
"      <span class=\"nowrap\">",
"       Asians/Pacific",
"      </span>",
"      Islanders) had inferior overall survival (relative risk [RR] = 1.47) when compared with whites [",
"      <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, nonrelapse mortality (NRM) was higher in blacks (RR = 1.56) and Hispanics (RR = 1.30). Across all racial groups, patients in the lowest quartile of median income had worse overall survival (RR = 1.15) and higher risk of NRM (RR = 1.21) than patients with higher incomes. This suggested that inferior transplantation outcome in blacks is not fully explained by socioeconomic status; other factors, such as genetic polymorphisms and health behavior, may contribute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potential explanations for apparent differences in outcome according to race include a higher rate of comorbid conditions (eg, hypertension and kidney disease, which are prevalent in blacks) and difficulty in interpreting skin findings (eg, cutaneous GVHD) in patients with dark skin complexion. Studies are needed to address these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24292859\">",
"    <span class=\"h1\">",
"     DETERMINING ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a disease-related indication for allo-HCT should be offered the opportunity to discuss the procedure with a transplantation physician. Eligibility for allo-HCT varies across countries and institutions and there are few strict rules about who is and who is not an appropriate candidate. Instead, clinical judgment should be used for the majority of patients as to whether the long-term and short-term risks with the transplant outweigh the benefits. Risk factors include and are based on performance status, comorbidity, age, compliance, extent and status of disease, as well as the sensitivity of the tumor to standard therapy. We are currently not able to predict who will develop chronic GVHD or other complications, but we must inform patients of those possibilities and their effects on quality of life; risk-averse patients may not want to proceed. All of these factors should be considered when determining appropriateness of allo-HCT for an individual. The final decision on transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient.",
"   </p>",
"   <p>",
"    The following general principles apply (",
"    <a class=\"graphic graphic_table graphicRef87815 \" href=\"UTD.htm?23/30/24043\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General features associated with superior outcomes following allo-HCT include: younger age, disease that is in remission or responsive to therapy with a low risk of disease relapse after HCT, the absence of active infections or other comorbid conditions, the presence of an HLA-matched donor, and a good socioeconomic support system.",
"     </li>",
"     <li>",
"      General features associated with increased risk of morbidity and mortality following allo-HCT include: older age, relapsed or refractory disease or disease with a high risk of relapse after HCT, a history of aggressive chemotherapy, and comorbidities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Criteria for allo-HCT are not absolute and vary by center. In general, patients are eligible for allo-HCT if they meet these criteria (",
"    <a class=\"graphic graphic_table graphicRef88755 \" href=\"UTD.htm?29/24/30091\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A disease-related indication &mdash; An underlying hematologic disease at a stage likely to benefit from allo-HCT. (See",
"      <a class=\"local\" href=\"#H7278017\">",
"       'Disease-related indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional capacity &mdash; An ECOG performance status &le;2 or Karnofsky performance status &ge;70 (",
"      <a class=\"graphic graphic_table graphicRef57945 \" href=\"UTD.htm?3/29/3549\">",
"       table 2",
"      </a>",
"      ) for a myeloablative HCT or &ge;50 for a nonmyeloablative HCT.",
"     </li>",
"     <li>",
"      Renal function &mdash; Serum creatinine &lt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or Cr CL &gt;50. Transplantation of patients with greater renal impairment differs by center. (See",
"      <a class=\"local\" href=\"#H19386571\">",
"       'Comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac reserve &mdash; Left ventricular ejection fraction (LVEF) &gt;35 percent.",
"     </li>",
"     <li>",
"      Pulmonary function &mdash; A corrected DLCO &gt;35 percent.",
"     </li>",
"     <li>",
"      Liver function &mdash; Patients with frank cirrhosis of the liver are excluded from allo-HCT because of excessive mortality and morbidity.",
"     </li>",
"     <li>",
"      Support structure &mdash; Adequate psychosocial and financial support. (See",
"      <a class=\"local\" href=\"#H24292838\">",
"       'Race, social, and economic issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors &mdash; While no specific age cutoff is universally used, many centers limit myeloablative allo-HCT to patients &lt;55 years, and reduced intensity allo-HCT to patients &lt;75 years. Patients must be informed of the potential short- and long-term complications (eg, GVHD) and be willing to accept these risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pre-transplantation, transplantation-associated, and post-transplantation risk factors cannot be separated completely, as pre-transplantation conditions will affect selection of the transplantation protocol, and both may modify post-transplantation events, such as the risk and severity of graft-versus-host disease and infections.",
"   </p>",
"   <p>",
"    The morbidity and mortality associated with allo-HCT has decreased over the past several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This is in part related to efforts directed at optimizing",
"    <strong>",
"    </strong>",
"    patient selection, graft selection, conditioning regimens, and supportive care. We can expect the field to continue to",
"    <strong>",
"    </strong>",
"    evolve, hopefully eliminating some of the problems that currently exist. Two major obstacles that remain are relapse and GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/51,52\">",
"     51,52",
"    </a>",
"    ];",
"    <strong>",
"    </strong>",
"    because of the GVHD-associated graft-versus-tumor (GVT) effect, these",
"    <strong>",
"    </strong>",
"    problems are closely interrelated. As the intensity of transplantation",
"    <strong>",
"    </strong>",
"    conditioning is reduced, we rely increasingly on donor",
"    <strong>",
"    </strong>",
"    cell-mediated GVT effects to prevent relapse. As an example, the relationship between GVHD and GVT was investigated in an analysis of 1092 patients receiving a uniform conditioning regimen consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and low-dose TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/53\">",
"     53",
"    </a>",
"    ]. Most relapses occurred early after HCT while patients were on immunosuppression for prevention of acute GVHD. Chronic GVHD, but not acute GVHD, was associated with increased GVT effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient&rsquo;s underlying comorbidities often dictate the type of conditioning regimen that may be offered. Patients with substantial comorbidities and older patients are not candidates for myeloablative conditioning regimens, but may be candidates for a reduced intensity conditioning (RIC) regimen. Many older adults are not candidates for RIC. However, allo-HCT may be considered for older adults who are biologically younger than their chronologic age if the following are met: they have no significant comorbidities; they have stable social and economic support; their disease is considered &ldquo;responsive&rdquo; to treatment; and the patient fully understands the potential complications and long-term sequelae that may ensue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/50/22314/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even younger patients and patients without significant comorbidities, whose disease has been refractory to various chemotherapeutic regimens, are not good candidates for current transplantation strategies except, possibly, as part of clinical trials that address refractory disease with disease-specific approaches. In such settings, it is not known whether allo-HCT offers a significant advantage over nontransplantation therapy.",
"   </p>",
"   <p>",
"    Patients must have a suitable donor, a good social support system, and a secure financial net. They must be well informed, not only about the transplantation process but also about expected or potential post-HCT events, including GVHD and delayed effects, which may become manifest only years after HCT. Treatment with glucocorticoids in particular can have severe side effects in older persons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24292866\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly used to treat patients with a variety of neoplasms, nonmalignant marrow disorders, autoimmune disorders, and inborn errors of metabolism. There are no accepted guidelines regarding indications for allo-HCT, and recommendations vary among transplant centers. Patients with a potential disease-related indication for allo-HCT should be offered the opportunity to discuss the procedure with a transplantation physician. (See",
"      <a class=\"local\" href=\"#H7278017\">",
"       'Disease-related indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pretransplant assessment must establish the extent of disease and provide information about the individual&rsquo;s comorbidities that are likely to have an impact on transplant-related complications. Importantly, comorbidities often impact the type of conditioning regimen that can be used. The choice of conditioning regimen is intimately linked to not only the expected toxicities, but also the potential efficacy compared with non-transplant therapies. (See",
"      <a class=\"local\" href=\"#H3203004\">",
"       'Pretransplant assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients considering allo-HCT must have adequate functional capacity, cardiopulmonary, liver and renal function, limited comorbidities, and adequate psychosocial and financial support (",
"      <a class=\"graphic graphic_table graphicRef87815 \" href=\"UTD.htm?23/30/24043\">",
"       table 6",
"      </a>",
"      ). The risks of morbidity and mortality associated with allo-HCT must be compared with those of other treatment approaches. Factors that impact the efficacy and toxicity of allo-HCT include the patient&rsquo;s performance status, comorbidity, age, compliance, extent and status of disease, as well as the sensitivity of the tumor to standard therapy (",
"      <a class=\"graphic graphic_table graphicRef88755 \" href=\"UTD.htm?29/24/30091\">",
"       table 7",
"      </a>",
"      ). The final decision on transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. (See",
"      <a class=\"local\" href=\"#H24292859\">",
"       'Determining eligibility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/1\">",
"      Lee SJ, Joffe S, Artz AS, et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008; 26:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/2\">",
"      Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/3\">",
"      Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/4\">",
"      de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/5\">",
"      Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/6\">",
"      Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/7\">",
"      Martino R, Caballero MD, de la Serna J, et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplant 2002; 30:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/8\">",
"      Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/9\">",
"      Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx (Accessed on November 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/11\">",
"      Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/12\">",
"      McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/13\">",
"      Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/14\">",
"      Yee GC, Lennon TP, Gmur DJ, et al. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/15\">",
"      Esposito C, Plati A, Mazzullo T, et al. Renal function and functional reserve in healthy elderly individuals. J Nephrol 2007; 20:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/16\">",
"      Glezerman IG, Jhaveri KD, Watson TH, et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/17\">",
"      Chien JW, Sullivan KM. Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant 2009; 15:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/18\">",
"      Deeg HJ, Seidel K, Bruemmer B, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 1995; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/19\">",
"      Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/20\">",
"      Fleming DR, Rayens MK, Garrison J. Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 1997; 102:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/21\">",
"      Deeg HJ, Seidel K, Sullivan KM. Body weight and outcome of hematopoietic stem cell transplantation. Am J Med 1998; 104:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/22\">",
"      Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/23\">",
"      Yee GC, Lennon TP, Gmur DJ, et al. Effect of obesity on cyclosporine disposition. Transplantation 1988; 45:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/24\">",
"      Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/25\">",
"      Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/26\">",
"      Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/27\">",
"      Kataoka K, Nannya Y, Ueda K, et al. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 2010; 45:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/28\">",
"      Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/29\">",
"      Horan JT, Logan BR, Agovi-Johnson MA, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 2011; 29:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/30\">",
"      Barba P, Pi&ntilde;ana JL, Martino R, et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 2010; 16:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/31\">",
"      Xhaard A, Porcher R, Chien JW, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/32\">",
"      Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/33\">",
"      Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/34\">",
"      Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/35\">",
"      Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115:4715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/36\">",
"      Smith AR, Majhail NS, MacMillan ML, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood 2011; 117:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/37\">",
"      Kerbauy DM, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/38\">",
"      Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/39\">",
"      Raimondi R, Tosetto A, Oneto R, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood 2012; 120:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/40\">",
"      Deschler B, Binek K, Ihorst G, et al. Prognostic factor and quality of life analysis in 160 patients aged &gt; or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/41\">",
"      Baker KS, Davies SM, Majhail NS, et al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/42\">",
"      Mielcarek M, Gooley T, Martin PJ, et al. Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/43\">",
"      Majhail NS, Omondi NA, Denzen E, et al. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2010; 16:1070.",
"     </a>",
"    </li>",
"    <li>",
"     Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care, National Academies Press, Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/45\">",
"      Kreklau EL, Pollok KE, Bailey BJ, et al. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Mol Cancer Ther 2003; 2:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/46\">",
"      Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol 1997; 15:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/47\">",
"      Joshua TV, Rizzo JD, Zhang MJ, Horowitz MM. Access to hematopoietic stem cell transplantation: effect of race and gender [abstract]. Biol Blood Marrow Transplant 2007; 13[suppl 1]:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/48\">",
"      Hwang JP, Lam TP, Cohen DS, et al. Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas. Cancer 2004; 101:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/49\">",
"      Klingemann HG, Deeg HJ, Self S, et al. Is race a risk factor for allogeneic marrow transplantation? Bone Marrow Transplant 1986; 1:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/50\">",
"      Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116:4762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/51\">",
"      Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/52\">",
"      Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104:3501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/53\">",
"      Storb R, Gyurkocza B, Storer BE, et al. Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/50/22314/abstract/54\">",
"      Sun CL, Francisco L, Kawashima T, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010; 116:3129.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16870 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-210.101.131.231-9551285854-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22314=[""].join("\n");
var outline_f21_50_22314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24292866\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87611135\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7277724\">",
"      IMPACT OF UNDERLYING DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7278017\">",
"      Disease-related indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7278633\">",
"      Disease type and status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3203004\">",
"      PRETRANSPLANT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24292817\">",
"      IMPACT OF INDIVIDUAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24292824\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19386571\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3520542\">",
"      Infectious disease status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3520363\">",
"      Weight and nutritional status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24292831\">",
"      RISK ASSESSMENT SCORING SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3520617\">",
"      EGBMT score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3520624\">",
"      PAM score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3520631\">",
"      HCT-CI score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3519395\">",
"      DONOR AVAILABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24292838\">",
"      RACE, SOCIAL, AND ECONOMIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24292859\">",
"      DETERMINING ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24292866\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16870|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/40/27278\" title=\"figure 1\">",
"      Conditioning regimens dose intensities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/18/35109\" title=\"figure 2\">",
"      Outcomes of HCT by risk group",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/19/22846\" title=\"table 1\">",
"      Risk groups allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/29/3549\" title=\"table 2\">",
"      Performance status measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/46/25323\" title=\"table 3\">",
"      Assessment for allo-HCT eligibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36348\" title=\"table 4\">",
"      Risk score CML transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/48/7950\" title=\"table 5\">",
"      HCT-CI and CCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/30/24043\" title=\"table 6\">",
"      Selection of patients allo-HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/24/30091\" title=\"table 7\">",
"      Eligibility criteria allo-HCT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35082?source=related_link\">",
"      Complications and management of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=related_link\">",
"      Determining eligibility for autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=related_link\">",
"      Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=related_link\">",
"      Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=related_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4724?source=related_link\">",
"      NK cell deficiency syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3497?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=related_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17050?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15176?source=related_link\">",
"      Severe combined immunodeficiency (SCID) with JAK3 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=related_link\">",
"      Treatment and prognosis of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_50_22315="Eclampsia outcomes";
var content_f21_50_22315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of maternal and neonatal outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abruption",
"       </td>",
"       <td>",
"        7 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"       <td>",
"        7 to 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema",
"       </td>",
"       <td>",
"        3 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute renal failure",
"       </td>",
"       <td>",
"        5 to 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration pneumonia",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiopulmonary arrest",
"       </td>",
"       <td>",
"        2 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver hematoma",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HELLP syndrome",
"       </td>",
"       <td>",
"        10 to 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal death",
"       </td>",
"       <td>",
"        5.6 to 11.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preterm birth",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sibai, BM. Obstet Gynecol 2005; 105:402.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22315=[""].join("\n");
var outline_f21_50_22315=null;
var title_f21_50_22316="Medical conditions with RPLS";
var content_f21_50_22316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical conditions associated with reversible posterior leukoencephalopathy syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute or chronic renal diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolytic and uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cryoglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wegener's granulomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Immunosuppressive, immunomodulatory, and chemotherapeutic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bevacizumab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cisplatin and other platinum-based agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Combination chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclosporine A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gemcitabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Interferon-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intravenous immunoglobulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ipilimumab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rituximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sirolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tacrolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tyrosine kinase inhibitors (pazopanib), sorafenib, sunitinib&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vincristine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia, hypomagnesmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contrast media exposure (cerebral, coronary angiography)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22316=[""].join("\n");
var outline_f21_50_22316=null;
var title_f21_50_22317="International Prostate Symptom Score";
var content_f21_50_22317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Prostate Symptom Score (IPSS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Questions to be answered",
"       </td>",
"       <td class=\"subtitle1\">",
"        Not at all",
"       </td>",
"       <td class=\"subtitle1\">",
"        Less than 1 time in 5",
"       </td>",
"       <td class=\"subtitle1\">",
"        Less than half the time",
"       </td>",
"       <td class=\"subtitle1\">",
"        About half the time",
"       </td>",
"       <td class=\"subtitle1\">",
"        More than half the time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Almost always",
"       </td>",
"       <td class=\"subtitle1\">",
"        Your score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Over the past month, how often have you had a sensation of not emptying your bladder completely after you finished urinating?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Over the past month, how often have you had to urinate again less than 2 hours after you finished urinating?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Over the past month, how often have you found you stopped and started again several times when you urinated?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Over the past month, how often have you found it difficult to postpone urination?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Over the past month, how often have you had a weak urinary stream?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Over the past month, how often have you had to push or strain to begin urination?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning?",
"       </td>",
"       <td>",
"        0 (none)",
"       </td>",
"       <td>",
"        1 (1 time)",
"       </td>",
"       <td>",
"        2 (2 times)",
"       </td>",
"       <td>",
"        3 (3 times)",
"       </td>",
"       <td>",
"        4 (4 times)",
"       </td>",
"       <td>",
"        5 (5 or more times)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"right\" colspan=\"7\">",
"        <strong>",
"         Sum of numbers (AUA symptom score):",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Total score:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        0 to 7: Mild symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        8 to 19: Moderate symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        20 to 35: Severe symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Quality of life due to urinary symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Delighted",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pleased",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mostly satisfied",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mixed - about equally satisfied and unsatisfied",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mostly dissatisfied",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unhappy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Terrible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Barry, MJ, Fowler, FJ Jr, O'Leary, MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 1992; 148:1549. Copyright &copy; 1992 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22317=[""].join("\n");
var outline_f21_50_22317=null;
var title_f21_50_22318="Control of iron absorption";
var content_f21_50_22318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Control of iron absorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathways of iron absorption and excretion in an intestinal mucosal cell in the normal state, in iron deficiency, and in an iron- loaded state. Normal iron absorption is 1 mg/day with a total daily intake of 10 mg. Iron absorption is appropriately enhanced in iron deficiency, and diminished with loss by cell sloughing into the intestinal lumen with iron overload.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Scientific American Medicine, Scientific American, New York, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22318=[""].join("\n");
var outline_f21_50_22318=null;
var title_f21_50_22319="Schematic anatomic locations accessory pathways";
var content_f21_50_22319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Schematic showing anatomic locations of accessory pathways as they cross the AV junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The atrioventricular (AV) valve plane of the heart is viewed from the cardiac apex. The tricuspid valve is on the left in this figure and the mitral valve on the right; the coronary sinus, which provides the venous drainage of the heart, passes posterior to the mitral valve and empties into the right atrium above the tricuspid valve. All AV bypass tracts cross the AV valve plane; their locations are named with respect to this orientation (eg, an anteroseptal bypass tract crosses the AV valve plane from atrium to ventricle in the region marked \"anteroseptal\" in the figure, at approximately 10 to 11 o'clock with respect to the mitral valve ring).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cosio, FG, Anderson, RH, Becker, A, et al. Living anatomy of the atrioventricular junctions. A guide to electrophysiological Statement from the Cardiac Nomenclature Study Group, Working Group of Arrythmias, European Society of Cardiology, and the Task Force on Cardiac Nomenclature from NASPE. North American Society of Pacing and; Electrophysiology.Eur Heart J 1999; 20:1068. Copyright &copy; 1999 European Society of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_50_22319=[""].join("\n");
var outline_f21_50_22319=null;
